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Abstract 
The rise of the Anthropocene has seen more global pollution than before in history. With 
the explosion of consumer electronics in the last half century, the rise of metal pollution 
from their extraction and disposal results in the unnatural introduction of heavy and rare 
metals into the ecosystem. Organisms have a metal defense protein, metallothionein, 
which has multiple roles in essential metal regulation and protection against toxic metal 
exposure. However, these modern heavy metals prominent in electronics are not found 
biologically and their interactions in the body are generally unknown. Some of these 
metals are employed as therapeutic agents in the treatment of cancers, and as such this 
Thesis describes an investigation of therapeutic agents as models for heavy metal 
pollution to provide insight into the mechanisms of metal metabolism. Using electrospray 
ionization mass spectrometry and spectroscopic techniques, the binding of human 
metallothionein with the exotic metals platinum and rhodium is explored. Platinum and 
rhodium bind readily to human metallothionein, raising concerns for toxicity. 
Keywords 
Metallothionein, metal regulation, metalloprotein, ietalation, metallochaperone, 
glutathione, binding constants, kinetic rate constants, pH-dependence, metal-thiolate 
clusters, cisplatin, metallodrugs, Platinum Group Metals, rhodium, oxidation, drug 
resistance, heavy metal pollution, environmental toxicity, anthropogenic waste, 
xenobiotic metals, electronic waste, Molecular Mechanics, Molecular Dynamics, Time-
Dependent Density Functional Theory, Molecular Orbital Theory, UV-visible Absorption 
Spectroscopy, Circular Dichroism Spectroscopy, Native Electrospray Ionization Mass 
Spectrometry, Denaturant, Non-platinum cancer therapeutics, Non-traditional ietalation. 
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Summary for Lay Audience 
Metals are everywhere. Some metals are required by humans and organisms as nutrients, 
while some can be extremely toxic. These toxic metals can be deadly depending on 
amount of exposure, often causing heavy damage to cells and tissues. Life has adapted to 
light levels of toxic metal exposure with proteins that are involved in metal binding - a 
group of proteins known as Metallothioneins. When exposed to toxic metals, cells will 
increase the production of this protein, metallothionein, to counteract the increased 
exposure. These metallothionein proteins capture the toxic metal and isolate it from 
performing its toxic activity. This response also can occur in some cancer cells, in 
response to metal-based therapy (cisplatin, a platinum-based drug), where the metal in the 
drug triggers the cancer cell to have an aggressively defensive response. At the chemical 
level, metallothionein acts to break apart the drug molecule and isolate the toxic metal for 
safe excretion from the body. Recent research in constructing robust molecular 
frameworks for these drugs to improve cancer treatment efficacy may be able to bypass 
Metallothionein’s defensive nature in these aggressive cancers. Using an extremely 
precise analytical methods known as mass spectrometry that show the changes in the 
exact mass as the protein breaks down the metal from the drug. While metal-based drugs 
are a specific type of toxic metal exposure, there is a fear of the increased impact of 
human activity on ecosystems, climate, and the environment will result in toxic metal 
exposure to all life in ways that has not been done before. These involve toxic metals that 
have never had a biological role and are found in major electronics and consumer goods 
that are now a standard of living. The implications of these cancer drug analyses with 
metallothioneins are extended to address this issue of toxic metal pollution and its effects.  
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*A version of this chapter has been submitted for publication: 
In Comprehensive Coordination Chemistry III, Volume 8: Bio-coordination Chemistry, Elsevier. 
Reproduced with permission from: D. L. Wong and M. J. Stillman.  
Chapter 1  
1 Introduction to Metallothioneins* 
1.1 Metals are Ubiquitous 
Living organisms are exposed to metals everywhere on Earth: from its crust and from its 
bodies of water, and through particulates in the air. Essential, non-essential, and toxic 
metals are consumed from fruits, vegetables and meats, and drinking water. Some of 
these metals are necessary for life and play a critical role in biological processes, while 
others can be extremely harmful. Where one resides geographically is a factor in the 
dietary source of metals. For instance, living near an active volcano may make one more 
exposed to airborne metals that settle in surrounding lands, which then become 
incorporated in the surrounding vegetation. This is also the case of those living downwind 
from coal power electric stations and living adjacent to landfill sites. In contrast, other 
regions of the earth are so metal deficient in the soil that they cannot sustain agriculture. 
Heavily urbanized cities with an abundance of vehicular traffic and industries introduce 
metals through exhaust and waste products. Alarmingly, for example the effects of this 
pollution can also be traced in the correlation of heavy metal content in honey in bee 
farms in close proximity to urban development.1 Human exposure to heavy metals is also 
related to the occupational environment, for instance industrial workers involved in raw 
material processing are more likely to have higher exposure to toxic xenobiotic metals. 
Metal bound proteins isolated from fish2 such as rainbow trout (Salmo gairdneri),3 show 
that polluting aquatic bodies with mineral waste can result in bioaccumulation in the 
tissue. Yet despite the ubiquity of heavy toxic metals, there is clearly a defense 
mechanism in play that protects organisms against such constant, chronic exposures. 
Even in the environmentally conscious minds of the 21st century, the trash from the past 
haunts us.4 Widespread global metal poisoning events from industrial malpractices still 
leave scars (for more information, google search terms like “Itai-itai Disease,” or 
“Ontario Minamata Disease”). While as a whole, the human population is moving 
towards “green” technology, waste generation from infrastructure materials and consumer 
goods is still a major issue. In the current technological age, our love for super computers 
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that fit in our hands demands greater quantities of rare metals. The mining, refining, and 
production of materials containing these metals can be devastating on the environment.4-6 
The end of product life cycles also leaves much metal behind in landfill sites. Some of 
these metals being discarded have never been biologically present or played any role in 
physiological chemistry yet is now well known that this pollution is being distributed 
globally. As a result, all life across the globe will eventually be exposed to a host of 
xenobiotic metals that are unknown to human and organismal physiology. To understand 
the effects of this non-traditional metal exposure, we first must understand the metal 
regulation mechanisms that Life has in play. 
 
Figure 1-1 Dose-Response Curve (Bertrand Diagram) 
Dose-response curve that shows the physiological effect (positive or negative) from 
exposure to metals under essential, (green line), therapeutic (blue line), and toxic 
conditions (red line).  
Figure 1-1 shows a dose-response curve (more antiquatedly known as a Bertrand 
Diagram, named by Bert L. Vallee).7 Its schematic description illustrates the 
physiological effects as the exposure to a metal increases from zero. For all organisms, 
there is a minimum requirement for the intake of essential metals (green line, examples of 
which include Fe(II), Mg(II), and Zn(II)) that keep the biological machinery functioning 
optimally. Not achieving that minimum results in a state is described as “Deficient” with 
negative physiological effects. Like much in Life, moderation is key – saturating a system 
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with metals will damage the delicate physiological chemistry when there is no mechanism 
with which it can respond. There are some metals that are always toxic and play no 
known physiological role, where any amount is detrimental (red line). Small exposures to 
these metals may be tolerated due to inherent resistance mechanisms, but if the exposure 
exceeds these levels, death results (for instance, arsenic was used as a classic 
Shakespearean poison). In rare cases, a metal ion or a metal complex can act 
therapeutically (blue line) but only in a narrow dosage window can the benefits outweigh 
the detrimental effects. Often, these metals used for such specific applications will cause 
negative side effects with long term use. This is the case with cisplatin, a platinum based 
anti-cancer agent that can cause severe renal damage with long term use.8 
1.1.1 Zn(II) is Essential, Cd(II) is Toxic 
Zn(II) is an abundant d-block metal that is essential in humans in its Zn(II) cationic 
oxidation state for physiological chemistry. It differs from most d-block metals as it 
remains in a fixed 2+ oxidation state, but its role is no less exciting. Based on its 
remarkable Lewis acidity and almost rigid tetrahedral geometry in structural roles, it has 
been reported that Zn(II) is a required cofactor in thousands of essential metal-dependent 
enzymes.9  
Isomorphous to Zn(II) but deadly, Cd(II) is a poisonous metal with toxic effects that 
result from its similarity to Zn(II) and Ca(II). Cd(II) exists naturally alongside Zn(II) and 
it is absorbed biotically via the same mechanisms as biological Zn(II). However, any 
amount of Cd(II) is toxic, with a long biological half-life of several decades in humans.10 
Cd(II) can replace native Zn(II) in enzymes, can cause brittleness in bones, and causes 
renal damage during excretion.11 
Human cellular physiology can tolerate small amounts of Cd(II), which is good 
considering many plants and the animals that feed on them can draw minute amounts 
from the soil. This raises the question: how do our cells manage to sort essential metals 
from those that are toxic?  
The focus of this thesis is the metal-binding protein, metallothionein (MT), whose major 
role has been identified as the metal chaperone for Zn(II) and Cu(I), and a source of 
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cellular Zn(II) for metal-dependent enzymes. Metallothioneins (MTs) are a large family 
of small cysteine rich proteins that are found in all Life. It is through the multitude of its 
cysteine residues (30% of the residue content) that it can sequester metals. MTs have 
been found to be involved in a large variety of biochemical mechanisms and response 
pathways. MT has an unusual structure due to its small size and flexibility. With the 
general mantra that protein structure begets function, this makes MT’s function difficult 
to define. The structural details of holo- and apo-MT are described further below. 
What is the role of MTs in Life? Since its discovery in 1957,12 many original research 
papers have had trouble strictly defining MT’s role in Life; that is, its designed purpose. 
In the Proceedings of the second international meeting on metallothionein and other low 
molecular weight metal-binding proteins, Vallee, one of the original discoverers of 
equine MT, describes metallothionein as a “sphinx’s riddle”.13 That enigma is multiplied 
by the broad genetic diversity of metallothioneins across all of Life, and questions its 
evolutionary development. The multiple possible roles of MT presented a two-sided coin 
in terms of how to approach its study. In vivo observation of MT activity in wildlife lets 
us see the native structure in its natural role, and its response to differing environments. In 
vitro observation lets us see what chemistry MT is capable of, depending on the external 
factor, like metal poisoning or drug resistance. 
1.1.1.1 Homeostasis and Regulation of Physiological Zn(II) 
MTs are believed to be key players in d-block metal regulation through trafficking and 
storage, primarily of Zn(II) and Cu(I), and cellular levels are controlled through MT 
induction.14-16 However, there is basal level of MT expression, even in Zn(II) deficient 
situations.17-19 MT’s ability to chelate multiple intermediate and soft metals and to donate 
these ions individually to enzymes is strong evidence of this role in vivo. The stepwise 
binding coefficient of each preceding metallation event selects the first metal for 
donation, as the last bound.20 Factors that control stepwise metallation include the solvent 
accessibility of the bound metal, which MT domain the metal is bound to, and whether 
the metal ion binding site involves terminal or bridged cysteine coordination.  
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Udom et al. showed that Zn(II) MT could reconstitute apo-enzymes that had lost their 
essential metal cofactor and reactivate them to full activity.21 Maret and Vallee showed 
that MT interacts via Zn(II) mediation between itself and the DNA binding domain of the 
transcription factor Gal4.22 This Zn(II) transfer likely occurs via protein-protein 
interactions between MT and the receiving peptide, as MT has been shown to transfer  
metals between other MT molecules in this fashion.23, 24 When we consider that Zn(II) 
makes up cofactors in every chemical class of enzymes, and is essential for gene 
expression, the regulation of this metal in the cell is vital.25  
The concepts of the magnitude of the binding constant strength in relation to the chelate 
effect theory apply here. Metallothioneins are essentially multiligand chelators that 
metallate in stepwise fashion. The rate kn with which the first metal binds is statistically 
greater than the next kn+1 such that the last metal bound (7
th for M(II)) is the slowest to 
bind. When describing this in terms of binding constants, the stepwise reaction with the 
greatest KF is most favourable and most stable, from which we can identify the 
cooperative cluster formation, from its greater KF. The last metals to bind are, therefore, 
the weakest bound, and most likely to dissociate first (lowest KF, highest KD).
20 It is clear 
that these most labile metals are those that are involved in metal donation to enzymes and 
biological targets. Corresponding NMR studies show that the most labile metals are 
bound to the more solvent accessible cysteines, which may explain their lability.26  
Figure 1-2 illustrates how the 7 stepwise binding constants for Zn1-7MT overlap the 
binding constant of apo carbonic anhydrase (CA), with the last two Zn(II) ions bound to 
MT shared or donated to apo-CA. Competition studies showed that the MT does not 
donate a Zn(II) ion to the apo-CA until after the fifth metal has bound to the MT. This 
indicates that the last two metals to bind for fully metallated Zn7MT are the most labile 
and available for donation.27 
The most effective technique for analyzing the binding constants of the individual 
metallation steps is by using the resolving power of native electrospray ionisation mass 
spectrometry (ESI-MS), discussed further in this Chapter.  
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Figure 1-2 Donation of Zn(II) in Zn-MT to apo carbonic anhydrase 
Zn(II)5-7MT, the most labile ions in terms of the stepwise binding constants, are the first 
metals donated to carbonic anhydrase. This figure is adapted from T. B. J. Pinter and M. 
J. Stillman (2015). 28 
1.1.1.2 Cadmium and Heavy Metal Toxicity 
Without a doubt, the initial discovery of MT as a Cd-binding protein presented a bias 
towards its perceived role in heavy metal detoxification. MTs are excellent at 
accumulating toxic heavy metals. Soft heavy metals like Hg(II) and Cd(II) bind to MT in 
vivo, which induces the synthesis of new MT protein. Accumulation of MT in response to 
elevated metal ion concentrations, combined with its association with these ions, indicates 
a role in the sequestration of any excess metal ion.29 Importantly, heavy, toxic metal ions 
including, but not limited to, Hg(II), Cd(II), Pb(II), As(III), Pt(II), Pd(II), Rh (I,II), only 
are present in the body as a result of external intake. These soft heavy metals have no 
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known biological role. Man-made industrial practices as described above have literally 
dug up these metals and through consumerism, introduced these metals into the 
ecosystem of the Earth’s surface, with the nightmare scenario being a catastrophic 
pollution event (for example, Aznalcóllar Disaster, Donana Park, Spain30). These 
electron-rich d-block metals displace natively bound essential metals (e.g. Zn(II), Cu(I)), 
destroying enzymatic activity, or disrupting biological structures, often irreversibly. The 
presence of these metal ions can also establish a pro-oxidant environment, where redox 
reactions and resulting reactive oxygen species can affect cellular and genetic structures.31 
The induction of MT synthesis has been correlated to external Cd(II) and Cu(I) tolerance 
in both a variety of cultured cells and animal studies.32 Heavy metals like Hg(II) and 
Mn(II) are known to accumulate in thiol rich fractions of cells in marine fish.3 Use of 
trace metal analysis of fish to understand the extent of pollution in a marine source is 
based on the idea of bioaccumulation. During the life of a fish, metals accumulate within 
their body and are neither metabolized nor excreted. Biomagnification is a related 
principle that extends bioaccumulation through the predators of the food chain; those at 
the top of the food chain consume not only the metals of those within the fish of the rung 
below, but also the fish that was consumed by that fish, and the fish below that, etc.  
Animal studies show that after exposure, Cd(II) binds to albumin in the blood plasma, and 
is transported to the liver.11 Initially, Cd(II) levels rise in the liver as a result. The arrival 
of Cd(II) in the liver signals MT synthesis, which chelates the Cd(II) to form Cd-bound 
MT (Cd-MT), which in turn, circulates the body via blood plasma towards the kidneys.10 
In mammals, the small molecular weight (MW) of Cd-MT allows it to be filtered by the 
proximal tube of the glomerulus, excreted though the renal system and exits the body in 
urine. Unfortunately, this process is not rapid. Cd-MT can be reabsorbed by the tubular 
cells, and subsequently release relatively large concentrations of Cd(II) upon Cd-MT 
degradation, leading to renal damage. Friberg et al. reported that the half-life of Cd(II) in 
the blood on the order of hundreds of days, and several years to decades in the kidneys.11 
High levels of Cd-MT in the urine are markers for toxicity, as was established in Japan 
following the mass “Itai-Itai Disease” outbreak from Cd(II) poisoning  caused by 
malpractices of Mitsui Mining & Smelting Co.  Itai-Itai disease is one of the Four Major 
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Pollution Diseases of Japan.33 Industrial waste from the smelting plant entered the Jinzu 
River Basin, where downstream citizens relied on the river ecosystem to provide fish, 
fresh water, and irrigation for rice crops. Over time, crippling physiological effects 
related to the poisoned ecosystem became evident in the affected population. Side effects 
included brittle bones, and severe renal damage with Cd-MT prevalent as a urinary 
marker for the affliction.34 
More recently, similar damage to other ecosystems occurred both in Japan23 and Canada 
24 from industrial mercury waste,35, 36  which became incorporated in the marine 
ecosystem including fish that were essential to the local diet. This caused the severe 
neurological effects of Minamata disease in the affected population. 
1.2 Metallothioneins are Ubiquitous 
The metallothionein family is remarkable in that it appears that every phylum in Life has 
an MT or MT-like protein involved in metal regulation. About one-third of its short, ~61 
amino acid sequence comes from phylogenetically conserved cysteine regions. These 
cysteines, often in the sequence as –C-C-, -C-X-C- or -C-X-X-C- repeat regions, have 
soft, reactive thiolates involved in metal binding, but do not form disulfide bonds 
natively. MTs are present in all mammalian tissues, with more pronounced expression in 
the liver, kidney, brain, and during fetal development.37 These proteins exist in the 
cytosol and in the nucleus, as well as in extracellular fluids like bile, plasma, and urine.38 
MTs are unorthodox in their high metal loading capabilities, and their promiscuous 
nature: one protein molecule is capable of multiple and variable stoichiometric metal 
binding.13 Class 1 MTs do not form a single, specific metal –loaded species, unless 
through strictly controlled metal exposure. We see this heterogeneous binding property in 
the simultaneous binding of Zn(II), Cu(I), and Cd(II) in a single protein molecule. 
Because of these wildly adaptive behaviors, the biological role of MT was a subject of 
great debate in the years following its discovery.39 Was it involved in detoxification? 
Could MT reactivate apo-enzymes? Why could MT be induced by such a variety of 
external agents? 
9 
 
The discovery of other low MW, cysteine rich proteins demonstrated their evolutionary 
necessity, but through natural divergence, the purpose and functions have become 
optimized by their amino acid structure. These sulfur rich metal binding proteins are 
given the family name of, “metallothioneins,” and are divided among 3 class types, based 
on their similarities of their cysteine homologies.  
Class 1 MT: polypeptide with a highly conserved sequence: cysteine residues are 
congruent with those in the equine renal cortex sequence (e.g. mammalian, vertebrate) 
Class 2 MT: polypeptide that is also rich in cysteine residues, though not entirely in the 
same location as equine renal cortex. (e.g. fungi, plant, invertebrate) 
Class 3 MT atypical, non-translationally synthesized metal thiolate polypeptides e.g. 
cadystins, phytochelatins 
  
Figure 1-3 Mammalian MT isoforms  
Representative single amino acid code sequences of mammalian MTs. Conserved cysteine 
motifs highlighted with black. Sequences obtained from the UniProt Database, with the 
respective protein ID in parenthesis. 
Within each class, there are 4 major isoforms characterized by their cysteine topology 
(e.g. MT1, MT2, MT3, MT4, Figure 1-3, Figure 1-4), that represents a protein category 
within a species’ MT gene expression. A representative sequence of mammalian MTs 
representing each isoform is shown in Figure 1-4. These isoforms themselves may have 
sub-isoforms (e.g. MT1A,-1B, -1C etc.). These sub-isoforms exhibit single residue 
variation in their amino acid sequence that affects the charge of the overall protein. This 
leads to the question of whether sequence-specific MT in higher level eukaryotes 
expressing these multiple MT genes have their own have specific metal binding 
properties. The majority of the studies described in this Thesis concern Class 1 MTs, with 
the experiments performed utilizing recombinant human metallothionein 1a. 
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1.2.1 Human Metallothioneins 
Human metallothioneins are understandably the most relatable of the vertebrate MTs. 
Humans MTs are divided into four main subtypes, and each display slightly varied 
characteristics. 
 
Figure 1-4 Human MT1 and MT2 protein sequence 
Single amino acid code sequences of human MT isoforms 1-4 displaying MT1 with its 
multiple sub-isoforms. Cysteine residues are highlighted in black. Sequences obtained 
from the UniProt Database, with the respective protein ID preceding the isoform. 
MT1 and MT2 are the major isoforms present in all species but are highly expressed in 
the liver and kidneys. These isoforms are generally found in vivo bound to Zn(II) and 
some Cd(II). While MT2 is expressed homogenously, MT1 can exist in several 
subisoforms as shown in Figure 1-4. MT 3 is expressed in the brain and is known to 
favour Cu(I)/Zn(II) binding. This particular isoform has been linked to mitigation of 
protein misfolding and aggregation in neural cells, leading to neurodegenerative diseases. 
MT 4 is expressed in squamous epithelial cells, which line the outside of organs to afford 
external protection. 
Along with their metal binding properties, MTs are associated with oxidative stress 
remediation. Compared to glutathione, another prominent cellular antioxidant, MT is 
shown to have a twenty times greater protective power against peroxide radical 
damage.40, 41 This makes MT an indirect player in many roles of cellular regulation, and 
protection against generic cellular damage, sparking interest especially in MTs role in 
diseases, aging, and drug resistance. 
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1.3 Structural Elements of Metallothioneins 
Protein structure defines its function. This is a dogma that is difficult to apply to the 
flexible nature of MT. The structural properties of MTs are enigmatically elusive; the 
most easily observable form being the fully metallated MTs. Complete metallation forms 
the two characteristic metal-thiolate clusters; an observable feature that can be readily 
identified using a number of instrumental techniques, once it has completely formed. 
Even with full metallation, crystallization of MT has proven hard. In many proteins, their 
secondary structural features provide stability such that crystals can be isolated and 
structurally analyzed, but with MT this is not the case. To our knowledge, just one X-ray 
diffraction study is reported for mammalian MT, that is, for Cd,Zn-MT1 from rat liver.42 
The structural parameters were greatly extended by 1H NMR studies subsequent to this 
report.43 The presence of a two domain structure in mammalian MT was established from 
111/113Cd NMR studies pioneered by the Armitage group, starting in 1980. The 1H NMR 
and X-ray diffraction results were discussed together in a single paper giving great detail 
to the protein structure and linker region.43 
MT is a cytoplasmic protein and relies heavily on the solution environment for the native 
structure it adopts. MT in vivo is not fully metallated. Cd7MT and Zn7MT are not easily 
found, unless under extreme Cd(II) or Zn(II) exposure. Conversely, the metal-free apo-
protein, or partially metallated protein long eluded isolation, until Maret and workers 
reported the use of Förster Resonance Energy Transfer (FRET) imaging to establish the 
presence of free thiols in MT.44-46 This new discovery led to a significant paradigm shift: 
what was originally believed to be fully holo (fully metallated) was now known to exist in 
a partially metallated state. Therefore, metallation of MT is a post-translational 
modification.47 The MT structure is significantly more dynamic and variegated than 
traditional elucidation techniques could determine.  
1.3.1 Metal-Induced Structure 
The formation of the many metal-thiolate bonds in MT is the driving force for its 
subsequent folding and structural order. MT has few hydrophobic residues, implying that 
the major intramolecular forces at play are electrostatics, hydrogen bonding, and the key 
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element: formation of the metal-thiolate bond in tetrahedral beads,48 as we continue in our 
discussion below. The stepwise metallation sequence itself, has revealed most unusual 
binding site properties for a protein, in that the metal induced folding depends on the 
metal loading status. Early spectroscopic studies involving MT metal binding focused on 
finding the stoichiometry at which the observed signal for metallation became saturated. 
This provided in essence, a “frozen” state that could be examined for its properties. Thus 
the idea of “magic numbers” based on the stoichiometry of signal saturation was 
popularized for defining the metal binding properties of MT.49 These golden numbers 
were identified with the metals that had been found in MTs of living organisms, including 
Zn(II), Cd(II), Cu(I), and Hg(II). These metals were studied extensively for their possible 
role in MT’s function. For the purpose of this Chapter we will refer to these as the 
classical metals. As we will see further in the Chapter, metals that do not belong in this 
category or are encased in coordination complexes do not follow these magic numbers. 
These metals are never found physiologically. Their metal binding chemistries are 
governed by the flexibility of the MT protein, and the geometry of the incoming metal 
complex. We will describe these metals as non-traditional, when we discuss their 
metallation of MTs further below. 
1.3.2 Non-Traditional Metallation of Metallothioneins 
All cells have a basal level of MT expression. Increased protein production can be 
induced by external pressures, such as oxidation, or the presence of heavy metals as 
described above. In certain cancer types, MT expression has been correlated to developed 
resistance against therapeutic action. MT can break down metal complexes to their metal 
ion. Platinum based drugs and other cytotoxic agents face this drug resistance, which has 
been associated with an increase in gene expression or protein production of MT, 
particularly in cancerous cells. The combination of the abhorrent and uncontrolled growth 
of cancerous cells plus the ability to increase production of this multi-protective peptide 
provides a formidable defense against chemotherapeutic agents. As we will discuss 
further, the acidic conditions of a cancerous cell50 promotes the protective effect of MT, 
particularly against the electron rich transition metals being used in these medicines.  
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Because of their propensity to bind soft d10 metals (e.g. the aforementioned Cu(I), Zn(II), 
Cd(II), Pt(II) etc.), MTs are suspected of playing a role in the developed resistance to 
cisplatin and as such, the protein’s ability to possibly bind any metal has been of interest 
when considering therapeutic agents that can withstand this resistance.  
As we will see in Chapter 2, the general metallation mechanism in vivo involves 
tetrahedral cysteine M(II) coordination, with the onset of clusters at high metal loading or 
a lower pH environment. We can see a variety of different coordination behaviors with 
M(I), e.g. Cu(I) can bind MT with a variety of metal stoichiometries (6, 12, 20), and each 
of these may involve different coordination modes. With 6 mol. eq. of Cu(I), a Cu6S9 
cluster forms. With 12-13 mol. eq., a combination of a Cu6 and Cu7 cluster forms. In both 
cases, trigonal coordination was assigned. However, at 20 eq.of Cu(I), the metal 
conformation requires digonal cysteine thiolate coordination. The reaction with Cu(I) 
shows the great degree of flexibility that MT binding can take on, and that in vitro, we 
can push the envelope of possible binding modes to explore what could happen. The 
flexible nature of hydrogen bonding in MT allows for a variety of unexpected interactions 
to occur. For example, N and O donors are known to be involved in binding some metals 
and may tune the soft/hard nature of the chelating MT. 
In the following section we describe the mechanism of this metal sequestration, how the 
structures adopted from the metallation relates to MT function, and how the resulting 
protein depends on the conditions involved.  
1.4 Techniques Used in this Thesis 
1.4.1 Expression and Purification of Recombinant Human 
Metallothionein 1a 
Model species are “models” because they have rapid production times and can be 
observed easily. What grows faster than bacteria? Recombinant expression involves 
employing bacterial machinery to over express translation of a desired protein, in our case 
MT. This technique is ideal for plant and human MTs, as Escherichia coli can grow in 
large quantities with short life cycles and faster growth periods, without the need for 
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animal decapitation. The technique used in this Thesis was developed by Peter Kille and 
Ian Watt at Cardiff university.51 The general procedure is summarized as:  
Complementary DNA (cDNA) of the metallothionein mRNA is cloned into a plasmid. 
Typical plasmids will also include coding for proteins “tags” or short amino acid 
sequences that can assist in protein purification that are later removed. Other important 
elements of the plasmid include a transcriptase, a resistance marker to aid in cell 
selection, and an inducible repressor (such as the Lac I repressor) to induce expression. 
Once these plasmids are prepared, they are transformed, or transferred into the host E. 
coli cells.  
These cells now carry a resistance to the antibiotic defined in its plasmid sequence, and 
we can take advantage of antibiotics to ensure the growth of only the transformed cells. A 
small preparation is made on LB Agar plates with the antibiotic kanamycin, according to 
the protocol in Figure 1-5(Left). These cells are inoculated in a liquid LB Broth culture 
(prepared according to the protocol in Figure 1-5(Right) and grown until they reach a “lag 
phase” (the bacterial growth plateau), at which point the maximum number of viable cells 
is present. In the case of the Lac I repressor, Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) turns on this repressor and is added externally to initiate MT expression. 
A difficulty with metalloprotein overexpression is the maintenance of structure upon 
synthesis, as once formed, proteins are vulnerable to protease and other regulatory 
actions. To properly isolate large quantities of the induced protein, extra metal is added to 
the medium to prevent protein degradation by the bacterial proteases. The cells are then 
harvested usually by centrifugation and can be kept frozen in a glycerol solution prior to 
purification.  
To purify the protein from the bacteria, the cells must be lysed with high pressure. 
Generally, with the addition of that protein tag, described earlier, the desired protein can 
be isolated using a chromatographic column that complements the protein tag properties. 
The extra residues are then removed with a protease reaction. In the case of the MT 
produced in the Stillman Group, the 15 amino acid S-tag is attached to the N-terminus.52 
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The recombinant human MT1A used in the experiments described in this Thesis were all 
prepared using the following method: 
Preparation of Recombinant Human Metallothionein I: Recombinant human 
metallothionein I (rh-MT1) was expressed in BL21(DE3) E. coli cells that were 
transformed using a pET-29a plasmid containing an S-tag for protein stability during the 
purification. The cells were grown in LB broth with 0.5 mL 50 mg/mL kanamycin. MT 
expression was induced with IPTG and metallated with CdSO4 (Figure 1-5). Cells were 
lysed using a cell disruption system (Constant Systems, UK), and then centrifuged to 
separate the MT- containing supernatant from unwanted cellular components. Further 
purification was performed using High Performance Liquid Chromatography (HPLC, 
Dionex UltiMate 3000, Thermo Fischer Scientific). Elution through a 5 mL HiTrap SP 
HP ion exchange column was achieved using 10 mM tris(hydroxymethyl)aminomethane 
(Tris-HCl) at pH 7.4 (Fisher) was monitored by UV-visible absorption (Cary UV 50 Bio, 
Varian, Toronto) at the characteristic Cd-MT wavelengths of 300-200 nm. Fractions that 
contained metallated MT were collected, and the S-tag removed using a Thrombin 
CleanCleave™ Kit (Sigma Aldrich). The thrombin resin beads were recovered, 
regenerated, and stored for later use. The purified MT protein was evacuated and purged 
with Argon prior to storage in -80°C, with individual experimental preparations as further 
described in each Chapter.  
 
16 
 
Figure 1-5 LB agar and LB broth preparation 
LB agar (Left) and LB broth (Right) preparation instructions for the preparation of 
kanamycin-resistant, human MT expressing E. coli cells. 
1.4.2 Spectroscopic Methods 
Spectroscopic analysis of metallothioneins has been generally restricted to UV-visible 
absorption, Circular Dichroism (CD), and proton and metal Nuclear Magnetic Resonance 
(NMR) techniques. This is because the nd10 metals that traditionally are used in vitro and 
are recovered from MTs in vivo, exhibit only ligand-to-metal-charge-transfer (LMCT) in 
the absorption spectrum and the peptide, with its absence of aromatic amino acids, 
exhibits a very restricted band envelope below 220 nm. In addition, the lack of native 
secondary or tertiary structure for the apo-MT means that the CD spectrum in the absence 
of metals, is also uninformative. In a sense, this absence of spectroscopic signatures for 
the apo-protein has allowed the metallation reaction to be followed readily from changes 
in the absorption spectrum centred on the LMCT band of the specific metal, for example, 
at 250 nm for Cd-MT. In parallel with the increase in absorption, and red shifted from the 
apo-MT edge at 220 nm, is the development of CD spectral properties related to the 
metal-induced folding of the peptide backbone. This technique is used especially in 
Chapters 4 and 5. 
1.4.2.1  Absorption Spectroscopy  
Bioinorganic complexes can exhibit spectral properties arising from charge transfer 
absorption bands that are characteristic of certain bonds, such as the one for S→ Cd 
described above.53 Comparing isosbestic changes in absorption patterns during metal 
titrations provides important information on metal binding stoichiometries of MT.54 Care 
must be taken to avoid the interference of buffers and metals to exclude side reactions; 
and significantly, to avoid oxidative conditions due to the sulfur rich nature of MTs.  
1.4.2.2 Circular Dichroism Spectroscopy 
The absorption of circularly polarized light of the CD experiment is modified by the 
presence of chiral environments. The structural properties of α helices and β pleated 
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sheets commonly found in proteins exhibit specific CD spectral signatures. These spectral 
features can be used to analyze the consequences of structural modifications in proteins. 
The MT peptide, however, does not adopt well-formed secondary or tertiary structural 
elements, and as a result, the CD spectrum for apo-MT is devoid of these spectral 
signatures. However, metal binding to apo-MT imparts metal-induced structural 
properties, which results in strong CD spectral envelopes in the LMCT region. These CD 
envelopes arise from metal-induced chiral environments, and are stoichiometrically 
dependent, allowing the quantitation of the metal-induced structural properties of the 
metallated MT.48 These spectroscopic properties are useful for monitoring structural 
changes during metal titrations. Good examples have been reported for titrations of MT 
with Ag(I), Au(I), Cu(I), Pt(II), Cd(II), and Co(II).55 
Prior to the common use of native ESI-MS, the changes in the CD spectral envelopes 
provided by far the greatest detail about the structural properties of the MT peptide. This 
is because for there to be significant changes in the CD spectrum there had only to be an 
absorption band related to the metal that was sensitive to a major influence of the 
coordination geometry on the structure of the metallated MT.53, 56 The focus on the use of 
CD spectroscopy was specifically important for the metallation of MT because of the 
number of metals that bind in almost identical environments, meaning that the absorption 
chromophore does not distinguish between each metal. It is not possible to resolve 
changes that takes place as a function of the metal bound. This issue became most 
apparent when the use of native ESI-MS was common and metallation titrations became 
available, showing a wide distribution of species during titration for each mol. eq. added 
except for saturation.27 
1.4.3 Electrospray Ionization Mass Spectrometry (ESI-MS) 
Mass spectrometers ionize species in a solution and separate those ions based on their 
mass. All mass spectrometers Figure 1-6A) have the following components: (a) sample 
inlet ionization source, (b) ion optics, (c) mass analyzer and ion detector, (d) data 
analyzer, and (e) vacuum pump system.57 There are many methods of ionization possible, 
but the method most useful for metalloprotein studies uses direct sample solution infusion 
into an electrospray ionization atmospheric interface. The sample solution is passed 
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through a fine, highly charged capillary, which results in charged molecules in solution 
either from the ionization of the solvent or from a redox reaction directly with the 
molecule. The central feature of the ESI-MS approach is that the wet droplets of protein 
must rapidly dry to form the ionized protein efficiently Figure 1-6(B). High temperature 
N2 gas evaporates the solvent until nothing remains but the charged molecular ion. There 
are two common mass analyzers: (i) quadrupole and (ii) time-of-flight (TOF).58 Recently, 
a third mass analyzer based on the quantized ion trap has become an emerging player 
(Orbitrap ™).59 For a wider range of mass speciation in metalloproteins and with greater 
resolution, the TOF is most useful, because it has a wider and almost linear range of 
detection allowing a greater variety of metallated species to be analyzed. The charged 
particles are accelerated through a time-of-flight mass analyzer; all ions are given the 
same kinetic energy but are then separated by their different distributions of mass. The 
charge distribution of the protein species leaving the atmospheric interface is not singular; 
rather a multiplet of charged species exists. The range of the multiplet can be from two or 
three charges to up to 25 components. It is now generally accepted that the charge 
distribution depends on the surface area that will contain the charged ions, which, for 
positive, protonated, species will be diagnostic for the extent of the instantaneous folding 
or unfolding of the protein under the solution conditions.60, 61 This multiplet consists 
therefore, of several m/z species where m is the mass of the protein plus the number of 
protons and z is the total charge introduced by the number of protons bound. The 
deconvolution of the series of multiplet masses, knowing their charge, can be determined 
mathematically to give the parent protein mass. This is illustrated in Figure 1-7. The 
structural power of this requirement is that as the surface area increases (for e.g. with a 
denaturant or by unfolding) the multiplet number increases. This provides a fine measure 
of the degree of folding under any solution conditions that exceeds the typical 
quantitation of folding provided by the CD experiment described earlier. The specific 
structures involved though, have not been associated to date, with the different multiplets 
observed. I will describe the value of this experimental technique below when I discuss 
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the structural properties of apo-MT. 
 
Figure 1-6 An ESI-TOF-MS and its ionization mechanism 
A) Schematic of a basic ESI-MS instrument. B) As the analyte solution droplets move 
through the charged capillary, the surface tension of the solution becomes overcome by 
the repulsive force of the charged particles, known as a “Coulombic explosion.”62 
An analytical method like this can precisely describe the composition of a protein 
mixture, showing the masses of all the individual components. Data from native ESI-MS 
experiments can be used to account for the species in an averaged spectroscopic signal by 
defining the individual contributions. ESI-MS methods have been used widely in drug-
protein interaction studies, enzymatic reactions, and elucidative applications.  
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Figure 1-7 Charge state and deconvoluted mass spectra 
Apo α-MT fragment at pH 2. Screenshot of the acquired spectrum window in the Bruker 
DataAnalysis 4.2 software with the m/z spectra shown top with major charge states +5, 
+4, +3, +2, labelled, with the bottom showing the deconvoluted spectrum showing the 
mass in Da of the species resolved from the m/z spectra. 
1.4.3.1 Electrospray Ionization Mass Spectrometry (ESI-MS) in MT 
studies 
Fenselau’s group was a leader in the realm of ESI-MS analysis of metallothioneins. At 
the time in the early 1990’s, mass spectrometry was being recognized as a high resolution 
technique for analysing protein complexes.63 Fenselau and coworkers used ESI-MS to 
identify the many partially metallated species of MT that accompany metal titration, 
while showing the ease of use especially in the case of direct solution infusion. Their 
work highlighted the delicacies of the pH environment in metallation, suggesting the pH 
dependence of cooperativity that is now widely understood,64 while also demonstrating 
the power of ESI-MS in drug—protein complex analysis.65 They pioneered work in 
cysteine alkylation studies using therapeutic alkylating agents to probe the structure of 
MT, which we will expand on further in this section. With Fenselau and others now 
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illustrating the ease with which ESI-MS can be used to analyze solution samples, 
Lobinski introduced the idea of coupling techniques for high resolution metal binding 
analysis.66 Since ESI-MS allows for direction infusion of the sample, attaching a high 
performance liquid chromatography (HPLC) system with an acidification column prior to 
ESI analysis allowed for the absolute identification of rabbit liver MT isoforms and 
subisoforms, that could previously only be postulated through chromatographic 
separation. ESI-MS then took off as the best way to quantify metallation of MTs, and was 
used to compare different MT species,67 compare polymorphisms in plant MTs,68 and to 
further question the cluster formation properties of MTs.69 
Structural studies with MS using Cysteine Modification by Alkylation 
Because of its cysteine rich structure, MT is prone to react with alkylating agents. This 
was postulated as a method of drug induced resistance by Fenselau, who used alkylating 
therapeutic agents like chlorambucil, melphalan, and dexamethasone to probe the cysteine 
structure.64, 65, 70-72 These alkylating methods were also used to demonstrate the effects of 
alkylation on metal ion flux between enzymes, as these therapeutic agents reacted in 
small stoichiometric ratios without dissociating seven divalent metals, but that 
modification did increase rates of Zn(II) donation to apo CA, suggesting that the 
modification had distorted the native structure.65 Depending on the size and charge 
density of the alkylating agent, differential binding patterns could be resolved, and used 
to infer structural information.65 For instance, the smaller alkylating agents penetrate and 
bind free cysteines differentially based on their solvent exposed surface area. This is 
combined with ESI-MS to show that the structure of the protein may define the 
metallation mechanism (cluster vs. bead, described in Chapter 2) that dominates 
metallation. These alkylating reactions show that not only are the cysteine residues buried 
within the protein structure, but also that they are differentially accessible by solvent. It 
supported the idea that not all 7 binding sites can be considered equal, emphasising that 
the pseudo first order generalizations of these early MT studies were not adequate 
assumptions.  
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Figure 1-8 Various cysteine alkylating agents 
Reactions of various small alkylating agents with free thiols. (A) the reaction of para-
benzoquinone. (B) the reaction of n-ethyl maleimide. (C) the reaction of iodoacetamide. 
(D) the reaction with 5,5'-Disulfanediylbis(2-nitrobenzoic acid). 
As we have seen in the variety of metallation reactions that MT can partake in, the 
richness of its cysteine thiols imparts great reactivity. These thiolates can act as 
nucleophiles in substitution reactions. For instance Ellman’s Reagent (5,5'-
disulfanediylbis(2-nitrobenzoic acid), DTNB, Figure 1-8(D)), has been historically used 
to quantify thiols in solution, with stoichiometric reaction depicted in the Figure 1-8 
above.73 Iodoacetamide (IAM, Figure 1-8(C)) is used as well, but it benefits from a small 
spatial size, allowing it to fully penetrate most protein structures. Para-benzoquinone 
(pBQ, Figure 1-8(A)) is a useful agent that is easy to prepare but is photo-reactive and 
works best below neutral pH. This is a difficulty when trying to analyze proteins at 
neutral, physiological pH. N-ethyl maleimide (NEM, Figure 1-8(B)) can work under 
those conditions, albeit it is not as small and penetrating as IAM. Depending on the 
conditions used, the alkylation is so favourable that it can displace native bound metals. 
Regardless, both pBQ and NEM (Figure 1-8A, B) differentially bind MT and provide 
information about the solution structure under controlled conditions. Their differential 
mass spectrometric profiles of species distribution can give clues about the shape of the 
protein solvent surface. This technique and its related principles are used to analyze the 
native structure of apo-MT in Chapter 2, and to probe Rh-bound MT in Chapter 5. 
1.4.3.2 ESI-MS for Quantitative Analysis of Stepwise Metallation 
The binding constants of each metallation event depict the metal donation properties of 
MT. With the advent of ESI-MS, quantitative studies involving metal titrations into MT 
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could be equilibrated and measured with ESI-MS to find the resulting equilibrium 
constants K, from the relative intensities of the products.  
Kinetic rate constant determination 
Another advantage with ESI-MS is the ability to monitor reactions in real time up to 
hours (or however long the sample solution lasts at a particular flow rate). With MT 
however, the metallation is generally rapid and complete before the dead time of the 
instrument. As such, the kinetic analysis of metallation to MTs was mostly constrained to 
inferring results from competition reactions.  
Ngu et al. took advantage of the differential rates of metallation depending on metal type, 
using arsenic metallation of MT.74 As(III) is known to bind in vitro to MT with a 
maximum stoichiometry of As6MT. This binding is slow enough that it can be monitored 
using ESI-MS and was used as a model for the metallation by more naturally found Zn(II) 
and Cd(II). The highly detailed time-dependent, temperature-resolved results show that 
the each metallation event is faster than its subsequent metallation event (k1> k2 and so 
on). This is true for both the whole protein and the metallation of the individual domains, 
shown in Figure 1-9. 
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Figure 1-9 Decreasing rate constants shown in the stepwise metallation of βαMT and its 
individual domains. 
Comparison of the rate constants calculated from the time-resolved ESI-MS 
measurements for As3+-metallation of βhMT, αhMT, and βαhMT, the trend in rate 
constant values for six equivalent sites where k1 = 28.8 M
-1s-1 and the rate constants 
reported for βhMT-S-tag and αhMTS-tag.1 The red dashed line represents rate constant 
data for the βhΜΤ redrawn with the value of n shifted by three to illustrate the similarity 
to the rate constant trend for the final three As3+ binding to βαhMT. Reproduced from 
Ngu et al.74 Copyright 2008 American Chemical Society.  
Equilibrium Constant determination 
The early studies of MT were focused on observed optical signals, but now the focus 
resides on numerically assigning properties to MTs to distinguish isoforms and their 
specific functions. Historically, the metallation reaction of MT can be described as a 
bimolecular reaction with metals binding at a single rate with a single binding constant.  
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Mn + MT = Mn+1MT 
MT + 7M = M7MT 
This simplification of the metallation mechanism was to compensate for the lack of detail 
in the instrumental method. Often the metallation reaction was complete within the dead 
time of the instrument, resulting in an apparent cooperative reaction. Because metals like 
Cd(II), Zn(II), and Cu(I) bind so rapidly, the individual steps cannot be visualized. 
However, the lability of Zn(II) and Cu(I) bound to MT is linked to the thermodynamic 
stability of the bond and this defines MT’s metal donation properties. As the metallation 
reaction progresses, the last metals to bind have the weakest binding affinity. If the 
binding affinity of the last metallation reaction of MT is close to the binding constant for 
a protein’s Zn(II) binding site, metal donation to the apoenzyme occurs. Otherwise, the 
MT harvests Zn(II) from sites with lower KF than it. As such, these numerical values are 
requisite for understanding MT’s metallation and metal donation processes.20, 28  
Kenzyme > K(Zn7MT) = MT donates Zn to enzyme 
Knon-specific Zn site < KZn(0-7)MT = MT harvests Zn 
1.4.4 Computational Studies of Metallothionein  
Because protein structures are not limited to the rigid dimensions defined by their crystal 
structure, the dynamic nature of proteins is hard to visualize. Computer simulations and 
molecular dynamics (MD) can predict what might happen to a truly dynamic protein 
system on small timescales (fs to ps). In the case of MT, studies on the fluxional apo 
structure showed the position of the cysteines in the native structure prior to metallation, 
as a model for the de novo synthesized protein. By doing so with MD, we can also watch 
the energy of the system until it reaches a minimum, resting state. A combination of 
molecular mechanics (MM) and MD were used by Rigby et al. to watch the effect on 
protein folding that each M(II) metallation event imparted on the structure. This showed 
the metal dependent folding mechanism emphasized the importance of the native apo 
structure. The study showed that initially, cysteines were partially solvent exposed, and as 
metallation progressed, the metal cysteine bonds coalesced into the protein center. When 
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the reverse (demetallation) was performed, the cysteines moved to the exterior of the 
protein chain.75 This structural rearrangement is evident in the models of Rh2MT in 
Chapter 5. The early ESI-MS work by Fenselau identified alkylating agents that reacted 
readily and selectively with MT. To determine the position of the cysteine residues 
involved in the selective alkylation, the eight most solvent accessible cysteines were 
simulated bound to drug molecules and the energies and distances were compared, 
identifying Cys 33 and Cys 48 as the most favourable for complexation,70 giving 
information on metal binding sites. 
The challenge with applying computational chemistry to metallothioneins actually begins 
when metallating the protein. The complexity of transition metals is still computationally 
expensive compared to simple MM, MD, or Newtonian based calculations. In order to 
consider the electronic effects of orbitals, Time Dependent Density Functional theory is 
used to apply models for forces that are present with the diffuse electronic orbitals of d-
block metals. This is because the inclusion of the d and higher orbitals introduces electron 
movements that are not included in the MM theory and creates complications when 
calculating structures. A way to deal with this is by both defining a fixed geometry and 
assuming it, or separating the sections involved in the calculations. However this greatly 
limits the affordable calculations that can be performed. Returning to the concept of 
models and modelling reactions, the binding of glutathione, a small peptide with a 
cysteine thiolate, is used to mimic a single thiolate binding event in the metallation of 
MT, as is discussed in Chapter 6. 
1.5 Scope  
To understand the possible binding mechanisms of xenobiotic metals in vivo, it is 
necessary to first understand what we have now defined as traditional metal binding to 
MT. 
In Chapter 2, I provide an overview of the metallation of M(II) to MTs by exploring 
millisecond timescale reactions of Cd(II) binding to apo-MT. Particularly, the partially 
metallated forms are of interest as they are the most probabilistic form of the protein in 
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vivo, and as they are known to exist in multiple conformations, either terminally bound or 
in complex metal thiolate networks involving bridging cysteines between the metals. 
With the onset of xenobiotic metal pollution and metal-based therapy (e.g., platinum 
group metals), it is necessary to consider how these foreign metals bind to MT in vivo. It 
is often the clustering pattern of metals in MTs that give structural features, but in the 
case of these non-physiologically relevant metals, binding is anything but characteristic. 
It is through these reactions with xenobiotic metals that the flexible nature of MT metal 
chelation can be tested, as the world is approaching exposure to heavy metal pollution 
unimaginable before.  
Currently, the best model of the physiological effects of non-natural metals comes from 
metal-therapeutics testing. These tests involve strictly controlled exposure and well 
documented effects. By testing the metal defense protein MT with these xenobiotic 
complexes, we understand our own physiological metal defense and the mechanism 
behind developed drug resistance.  
In Chapter 3, using cisplatin, I unravel the rapid initial reaction pathway for MT with 
cisplatin, that is believed to be involved in developing cisplatin resistance. The results 
show the step by step destruction of cisplatin, and ligand displacement by the MT’s 
cysteine thiolates. 
Following the studies with cisplatin, in Chapters 4 and 5, we explore a platinum 
alternative, dirhodium(II) tetraacetate, in a model study with the β domain fragment of 
MT followed by a study with the whole protein. Through this reaction we see the 
sequential destructive chemistry clearly with the loss of all 4 acetate ligands, but in this 
complexation geometry, the metal-metal bond remains intact. This bond strength is 
analyzed with molecular modelling studies employing GSH and Rh2(OAc)4, using TD-
DFT methods in Chapter 6, to observe the electronic interactions and to investigate the 
origin of the spectroscopic signal. 
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Finally, in Chapter 7, we summarise the findings of this Thesis exploring non-traditional 
metallation of metallothioneins, by introducing some examples of xenobiotic metals in 
therapeutic use, and reviewing their reactions with metallothioneins.  
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Chapter 2  
2 Understanding Cd2+ Binding Mechanisms and its 
Relation to the Intrinsically Disordered Structure of 
Metallothioneins* 
The 20-cysteine mammalian metallothioneins are considered to be central to the 
homeostatic control of the essential metals Zn(II) and Cu(I) and, as part of their partially 
metal-loaded status, play a role in reversing oxidative stress.1 Native apo-MT does not 
adopt a well-known structural motif, being described as a random-coil or intrinsically-
disordered. Conclusions reached from a combination of ESI-mass spectral charge states, 
As(III) metallation of apo-MT at low pH, from molecular dynamic calculations and from 
metallation of the α-domain fragment, suggest that in fact the native apo-MT adopts a 
structure that is highly efficient towards metallation at physiological pH. The results in 
this Chapter show that the initial (M<5) Cd(II) metallation at physiological pH takes 
place to rapidly form structures based on isolated Cd(SCYS)4 units, beads. At pH 5, 
cysteine bridged Cd4(SCYS)11 clusters form. The ESI-mass spectral profile of cysteine 
modified apo-MT at physiological pH shows that it is folded, whereas in the presence of 3 
M guanidinium hydrochloride, the apo-MT is unfolded. Stopped-flow kinetic studies of 
the Cd(II) metallation show that the reaction is much slower for the denatured vs. the 
native apo-MT for formation of either beads or clusters. Metallation is slower for the 
formation of clusters than the formation of beads. These results are the first to quantify 
the presence of structure in native apo-MT in terms of the critical metallation properties. 
The implications of this study suggest that disruption of apo-MT structure due to ageing 
or other agents will negatively impact the metallation process for essential metals. 
2.1 The Native Structure of Metallothionein 
Essential metals are critical to Life’s processes. Metals that disrupt these processes are 
considered toxic. Therefore, Life requires control of metal ions for necessary function, 
employing regulatory control agents like metallothioneins (MT). MTs are a family of 
cysteine-rich, low molecular weight proteins that coordinate, and, therefore, isolate a 
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variety of free metal ions. Despite the critical involvement of MTs in Zn(II) and Cu(I) 
homeostasis, their stepwise metallation mechanisms are poorly understood. Since MT’s 
discovery in 1957, as a Cd-containing protein,2 much research has focused on the metal 
saturated, two-domain structure of Cd7MT and Zn7MT. When it was reported that MT 
natively exists predominantly in either the reduced apo (metal free, no S-S) state, or the 
partially metallated states,3-5 interest was spurred about the metallation mechanism and 
the true structure of native MT in vivo.4, 6-14 
Information about the apo-MT structure has remained mysteriously vague. Labelled as 
“random coil,” “globular,” or “intrinsically disordered,” the structure of partially 
metallated MTs have been historically difficult to elucidate due to the lack of secondary 
structures, little to no aromatic residues, extreme sensitivity to oxidation, and dependence 
on solution phase interactions. MT is unique in that progressive metallation imparts a 
major increase in the ordered structure.15 Initially, at physiological pH, the divalent metal 
ions bind tetrahedrally to terminal cysteinyl thiolates as isolated beads, which with further 
metallation, progress to the formation of metal-thiolate clusters, involving metal-bridging 
cysteine thiols.16 The traditional, two-domain, dumbbell-like structure is formed only 
upon full metallation with 7 divalent metals at physiological pH.  
Extensive advances have been made in studying partially metallated and metal-free MTs, 
including in vivo fluorescence detection,5, 17 molecular dynamic simulations,18, 19 collision 
induced denaturation,20 and mass spectrometric methods.14, 21 The work in this Chapter 
builds on recent investigations involving denaturation,22 cysteine modification12 and mass 
spectrometry,6, 23-25 in conjunction with stopped-flow kinetic analysis to provide new 
detail about the first metallation steps that take place as a function of the structural status 
of the apo-MT. The structures adopted initially by de novo apo-MT are critical to the 
subsequent metallation steps and define the complete metallation pathway. These early 
metallation steps are vital to the function of MTs in vivo.  
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Figure 2-1 The many structures of metallothionein. 
(A) Conceptual structures for (i) the Cd4 cluster in the α domain, (ii) the fully metallated 
structure, and (iii) 5 terminally-bound (beaded) Cd(II) displaying no domain structure 
based on MM3 molecular models and (B) sequence and connectivity diagrams of fully 
metallated βαMT and the two partially metallated pathways. Calculations and image 
from N. C. Korkola, reproduced with permission from the Royal Society of Chemistry. 26 
The confirmation of the presence of apo-MT in vivo has cemented the fact that 
metallation is a post-translational modification. The connectivities of bridging cysteines 
take place across the domain, Figure 2-1B (i) and (ii), and, as a result, these metal-bonds 
can only be formed once the protein is fully synthesized. Therefore, the initial states of 
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metallation are of great interest for the purpose of determining the properties and 
influence of the structure adopted by metal free MTs. 
From studies reported specifically over the last two years by Irvine et al.,8, 16 two distinct, 
pH dependent, metal binding pathways or mechanisms are at play. Initially, and 
especially for M≤3, the formation of “beads” involving terminally bound cysteines is 
dominant, especially for Zn(II) above pH 6 and Cd(II) above pH 7. The native MT 
protein structure under the beaded pathway can accommodate a maximum of 5 M(II), 
with the 20 cysteines tetrahedrally coordinating each metal, Figure 2-1(iii). MT adopts a 
“single domain” type globular structure, where the lack of bridging cysteines results in no 
true binding domain as described previously.16, 27, 28 Figure 2-1shows these two major 
conformations that MTs flexibly adopt at specific points during metallation. The ball-and-
stick models are displayed Figure 2-1A and the peptide sequence inFigure 2-1B, and 
Figure 2-1(i) show the structure of the Cd4S11 cluster that forms favourably in the α-
domain.  
At metallation levels of M = “magic number 4” 1, 11, 12, 20, 29, 30 and higher, the pathway 
adopted involves cooperative coalescence to a metal-thiolate cluster. This is now a 
thermodynamically stable, M4Scys11 cluster formed in the C-terminal α domain,
31 and 
increases the stability of the MT peptide against protease digestion. The conditions for 
selecting the dominant pathway are pH, temperature, and metal concentration and the 
selection is element dependent. The effects of the dominating pathway can be seen in the 
speciation of the metallated products using ESI-MS methods. 
The rapid stepwise metallation of MTs has been difficult to observe. Due to the 
spectroscopically silent nature of native Zn(II)MT, Cd(II) is used as a spectroscopic probe 
because of its S → Cd(II) ligand to metal charge transfer (LMCT) that is at 250 nm; this 
is well clear of protein-based absorbance because of the absence of aromatic residues. 
Initial kinetic reports of MT metallation focused on rates of demetallation, or rates of 
metallation of the C-terminal α-domain of this protein.14, 31 The α-domain is an 11-
cysteine fragment that contains the M4S11, thermodynamically stable, adamantine-like, 
metal-thiolate cluster. The β-domain (“β-MT”) is a smaller, 9 cysteine peptide fragment 
that forms a cluster when saturated (M3S9) but is more labile than the α-fragment. The α 
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domain has been studied previously by our group, with results that show that the 
metallation kinetics are influenced by the apo-MT structure, and is flexible enough to 
accommodate 5 M(II) in forced conditions.7 While studying the isolated domains gives 
valuable information regarding individual cysteine coordination,31 it is now understood 
that the isolated domains behave differently than the intact protein.17, 27, 32, 33  
In this Chapter, the rates of the metallation by Cd(II) of the native βαMT protein in 
solution are reported and discussed to understand how changes in the apo structure 
influence the metal-binding pathways. The rate of the early steps in the Cd(II) metallation 
of apo-βαMT depends on the folded state of the MT, and the metallation structure that 
results. By using denaturing agents at physiological pH, and at pH values that favour 
either beaded (pH ~8) or cluster formation (pH ~5), stopped-flow kinetic methods provide 
the binding rate for the Cd(II) metallation. The extent of folding under these conditions is 
obtained from the ESI-mass spectral data using cysteine modification methods. The 
results show that the metallation rate at physiological pH is 10 times faster than at pH 5 
for both the folded and the denatured protein. Metallation involving cluster formation is 
slower than bead formation. These results indicate that at physiological pH, MT is a 
highly efficient scavenger of Cd(II) and can employ its 20 cysteines with flexible binding. 
The metallation properties for partially metallated Cd-MTs at both pH extremes, which 
would mimic the pathways adopted specifically for zinc binding, are described below. By 
selecting conditions that are known to favour either of the two pathways, and confirmed 
using ESI-MS, the rates of metallation of the beaded pathway vs. the cluster pathway can 
be compared. The outcomes of these experiments provide evidence that at physiological 
pH, apo-MT adopts a specific native structure that is optimized for metallation. 
2.2 Experimental Methods 
2.2.1 Solution Preparation 
Ammonium formate (J.T. Baker) and tris(hydroxymethyl)aminomethane-HCl (Tris-HCl) 
(Sigma-Aldrich) buffers were prepared by dissolving solid crystals into DI water to make 
a final concentration of 10 mM. The solution was then pH adjusted to 2.80, 5, 6, 7, 7.4, 
7.5, or 8 using HCl and NH4OH. KCl (Fisher) was added to the ammonium formate 
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buffer used in stopped flow studies to final concentration of 200 mM to maintain a 
constant ionic strength. 
50 mg/mL Kanamycin (Teknova), 1 M isopropyl β-D-1-thiogalactopyranoside (IPTG) 
(Fisher), and 1 M CdSO4 (J.T. Baker) for cell growth were prepared by dissolving the 
appropriate amount of solid reagent in DI water. 10 mM solutions of N-ethylmaleimide 
(NEM) (Eastman) and Cd(OAc)2 (Acros) were made by mixing solid crystals into the 
ammonium formate buffer of the desired pH for the experiment. KCl was added to the 
Cd(OAc)2 solution used in stopped flow studies to a concentration of 200 mM. 8 M 
guanidinium chloride (GdmCl) was prepared by mixing solid GdmCl crystals (Omnipur) 
and KCl to make 200 mM in the case of stopped flow experiments with ammonium 
formate buffer. The mixture was gently heated until all the solid crystals had dissolved. 
The solution was allowed to cool and was then pH adjusted to the desired pH of 5, 6, 7, 
7.4, 7.5, and 8 using HCl and NH4OH. CdOAc2 solutions at concentrations of 5, 10, 12.5, 
15, 20, and 25 μM for use in stopped flow reactions were prepared by diluting the stock 
10 mM Cd(OAc)2 solution with the appropriate amount of ammonium formate buffer and 
GdmCl at the desired pH of 5, 6, 7, 7.4, 7.5, or 8 for a final denaturant concentration of 4 
M.  
Preparation of apo-MT with pH adjustment 
A 1-2 mL solution of Cd7MT was thawed under a vacuum and demetallated by buffer 
exchange using a pH 2.80 ammonium formate buffer, and then raised using ammonium 
formate buffer of the desired sample pH of 5, 6, 7, 7.4, 7.5, or 8. 
Mass spectrometric (MS) studies of the apo-MT structure were carried out using samples 
prepared with a Millipore centrifuge filter tube with a cut-off of 3kDa. The MT and low 
pH buffer were centrifuged at 4000 rpm for 30 minutes twice. The 10 mM ammonium 
formate buffer at pH 7.4 was then added along with a drop of concentrated ammonium 
hydroxide. The buffer exchange was performed under the same conditions as the 
demetallation 3-4 times. The pH of the flow-through was tested after each spin. For MS 
studies of the partial metallation of MT, the protein was demetallated using a PD-10 (GE 
Healthcare) size exclusion column with pH 2.80 ammonium formate buffer. The protein 
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was centrifuged once at 4000 rpm for 30 minutes and then run down another column at 
pH 5 or 8 to raise the pH. The MT was then centrifuged again for 30 minutes at the same 
speed as before. For stopped-flow studies, the MT was demetallated using the PD-10 
column with the pH 2.80 ammonium formate buffer. It was then put down another PD-10 
column with the buffer of pH 5, 6, 7, 7.5, or 8. The pH of the resulting protein solution 
was tested. 
The concentration of the apo-MT was determined by metallating a small portion of the 
sample with excess Cd(OAc)2 and measuring the absorbance of the S → Cd(II) LMCT 
band at 250 nm. Beer’s law was used to calculate the concentration using the molar 
extinction coefficient of fully metallated βαMT of ε = 89000 cm-1. 
For MS studies of the apo protein, the apo-MT sample was split into 2 vials. One of the 
vials was denatured by adding 8 M GdmCl to make a final concentration of 3 M. The 
other was left in its native state. The appropriate amount of 10 mM NEM solution was 
added to both samples to equal 10 molar equivalents compared to the MT concentration. 
The denatured solution was buffer exchanged by dialysis in 10 mM ammonium formate 
buffer at pH 7.4 for 2 hours to remove the GdmCl, as its signal would dominate the mass 
spectrum. Since the NEM was now covalently bound to the cysteine residues, the buffer 
exchange does not affect the distribution of the modifications. 
For the MS studies of the stepwise metallation of MT, the protein samples at pH 5 and pH 
8 were metallated with the appropriate amount of Cd(OAc)2 to give approximately 0.5, 
1.5, 4, 5, and 6 molar equivalents of Cd(II) per protein for the solutions at pH 5, and 1, 
2.5, and 5 molar equivalents for the pH 8 samples. The exact equivalents of Cd(II) added 
were calculated using the average of all the species present in the spectra. 
For stopped-flow kinetics studies, the protein samples were diluted with 10 mM 
ammonium formate buffer adjusted to pH 5, 6, 7, 7.5, or 8 and 8 M GdmCl to result in a 
final solution of 5 μM MT with either 0, 1, 2, or 4 M of GdmCl. KCl was added to give a 
final concentration of 200 mM KCl to keep the ionic strength of the solution constant. It 
is important to note that the rate of metallation of native apo-MT was compared to the 
rate in the presence of 5 M chloride ions and in the presence of sucrose matching the 
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viscosity of 5 M GdmCl. This was to confirm that the presence of the chloride ions in 
GdmCl did not interfere with the cadmium and the viscosity of the GdmCl did not affect 
the rate of metallation. 
2.2.2 Mass Spectral Studies 
Mass spectra were collected on a MicroTOF ESI mass spectrometer (Bruker, Toronto). 
The parameters were as follows: Capillary: 4200 V, end plate offset: 500 V, dry gas: 8.0 
L/min, dry temperature: 100˚C, capillary exit: 180.0 V, Skimmer 1: 22.0 V, hexapole 1: 
22.5 V, hexapole RF: 600.0 V, skimmer 2: 22.0 V, lens 1 transfer: 88.0 μs, lens 1 pre-
pulse storage: 23.0 μs, mass range: 500-4000 m/z, flow rate: 10 μL/min. The spectra were 
averaged over 2 minutes. 
2.2.3 Stopped Flow Studies 
An SFM-300 instrument (BioLogic, France), Figure 2-2, was used to rapidly mix and 
transfer the reagents to a cuvette with a 10 mm path length and 1 mm aperture. The 
reaction was observed with a MOS 250 spectrophotometer and the resulting kinetic traces 
were recorded using BioKine software. This reaction was performed at 10 ˚C. 
Apo-MT, ammonium formate buffer of the desired pH, and Cd(OAc)2 were loaded into 
syringes 1, 2, and 3, respectively. First, 500 μL of buffer was shot at a flow rate of 5 mL/s 
to clean the cuvette and to confirm the baseline level. Then, 160 μL each of apo-MT and 
Cd(OAc)2 were shot at a flow rate of 8 mL/s. These were mixed and reached the cuvette 
with a dead time of 1.9 ms. After 20 ms mixing time, the hard stop was closed and the 
reagents were allowed to react in the cuvette. The reaction was monitored through the 
LMCT band at 250 nm and recorded every 500 μs for a total of 2 s. This process was 
repeated at least three times to give an average of multiple traces. The standard deviation 
over multiple kinetic traces for each set of experimental conditions was 10 %. 
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Figure 2-2 A schematic of the SFM apparatus.  
The three syringes are shown with their respective reagents along with their path to the 
mixing chamber and then the cuvette. The lowest achievable dead time from the mixer to 
the cuvette is approximately 2 ms. Image from N. C. Korkola, reproduced with permission 
from the Royal Society of Chemistry. 26 
2.2.4 Fitting of the Kinetic Traces  
The data were not transformed from absorbance to concentration units due to the multi-
product nature of the final solution. The partially metallated MT form a distribution of 
species, each of which would have its own specific molar extinction coefficient. These 
coefficient values have not been determined for the individual species, and is further 
clouded by the averaging of the absorption signal. Therefore, Beer’s Law could not be 
used to determine the concentration of the product. It should be noted that the rate 
constants reported by this method are only relative, as the concentration must be known 
to find the absolute values.  
The fitting program GEPASI version 3.3034 was used to fit the experimental kinetic traces 
and find the relative rate constants. The metallation reaction was treated as a single 
bimolecular step as shown below. Although the acquired traces in reality consisted of 
multiple overlapping bimolecular reactions, it was not possible to resolve these as the 
overall reaction was close to the dead time of the instrument. The simplified single 
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bimolecular reaction that encompasses all the metallation steps resulted in an appropriate 
fit for this complicated kinetic mechanism. 
Apo-MT + (1-5) Cd2+ → Cd1-5MT 
Two different methods were used in combination to fit the traces. The Nelder and Mead 
(Simplex) method was used until the sum of squares reached a constant value and then 
the Levenberg-Marquardt was used until the final solution was found. 
2.2.5 Molecular Modelling 
The clustered, beaded, and fully metallated MT structures were modelled using Scigress 
6.0 (Fujitsu, Poland).35 The sequence shown in Figure 2-1 (B) was input into the software. 
The geometry of the MT was optimized to the lowest energy level using the MM3 
procedure. The lowest energy conformation was then found by running the MD (MM3) 
procedure to create multiple random conformations over a time of 5000 ps. The procedure 
was run under low temperature conditions of 5 K to simulate the hydrogen-bonded native 
protein and high temperature conditions of 1000 K to mimic the denatured conformation. 
The dielectric was set at 78, the van der Waals cut-off distance at 9 Å, and the van der 
Waals interaction update rate at 50. The output frequency was 200 steps and the refresh 
rate was 100 steps. 
2.3 Results 
2.3.1 Denaturation of MT with Guanidinium Hydrochloride 
The extent of unfolding of the apo-MT in the presence of the 3 M reversible denaturant 
GdmCl was probed by adding N-ethyl maleimide (NEM) to covalently and irreversibly 
modify solvent exposed cysteine residues. The denaturant was then removed, and the 
resulting modified protein was examined using ESI-MS at pH 7.4. Figure 2-3, A shows 
that the speciation profile of NEM binding to the apo-MT displays preferred modification 
under physiological pH in the absence of denaturant. This spectral profile drastically 
changes in the presence of 3 M GdmCl, Figure 2-3, B, where the alkylated species has a 
Normal distribution profile. 
44 
 
 
Figure 2-3 Native and denatured MT modified by NEM 
Deconvoluted ESI mass spectra of (A) native apo-MT at pH 7.4 and (B) apo-MT 
denatured with 3 M GdmCl at pH 7.4, both modified with 10 molar equivalents of NEM. 
MT in the native environment (A) shows a cooperative modification pattern, while the 
denatured protein (B) shows a modification distribution resembling a Normal curve. Data 
and image from N. C. Korkola, reproduced with permission from the Royal Society of 
Chemistry. 26 
The series of stopped flow kinetic absorbance traces number Figure S1-5 are used to 
create the plots of Figure 2-4. 
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Figure S1. The kinetics traces of the binding of 2.5 eq. of Cd to apo-MT at pH 5 in the 
presence of increasing amounts of GdmCl at concentrations of A) 0 M, B) 1 M, C) 2 M, 
and D) 4 M. Data and image from N. C. Korkola, reproduced with permission from the 
Royal Society of Chemistry. 26 
 
Figure S2. The kinetics traces of the binding of 2.5 eq. of Cd to apo-MT in the presence of 
4 M GdmCl at pH A) 5, B) 6, C) 7, D) 7.5, and E) 8. Data and image from N. C. Korkola, 
reproduced with permission from the Royal Society of Chemistry. 26 
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Figure S3. The kinetics traces of the binding of apo-MT to A) 1, B) 2.5, and C) 5 
equivalents of cadmium at pH 5 and in the presence of (i) 0 M and (ii) 4 M of GdmCl. 
Data and image from N. C. Korkola, reproduced with permission from the Royal Society 
of Chemistry. 26 
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Figure S4. The kinetics traces of the binding of apo-MT to A) 1, B) 2, C) 2.5, D) 3, E) 4, 
and F) 5 equivalents of cadmium at pH 8 and in the presence of (i) 0 M and (ii) 4 M of 
GdmCl. Data and image from N. C. Korkola in reference, 26 reproduced with permission 
from the Royal Society of Chemistry. 
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Figure S5. The kinetics traces of the binding of 2.5 eq. of Cd to apo-MT at pH 5 and with 
no denaturant at temperatures of A) 10.1 ˚C, B) 15.3 ˚C, and C) 18.1 ˚C. Data and image 
from N. C. Korkola, reproduced with permission from the Royal Society of Chemistry. 26 
2.3.2 Relative kobs Decreases with Increasing Denaturant at pH 5 
and Fixed Metal Status 
Figure S1 shows the change in absorbance at 250 nm for the reaction of apo-MT with a 
fixed 2.5 mol. eq. of Cd(OAc)2 and increasing concentrations of GdmCl, at pH 5. The 
relative kobs values are shown in Figure 2-4. The rate of metallation decreases as a 
function of increasing denaturant concentration. 
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Figure 2-4 Plot of the observed rate constant as a function of GdmCl concentration. 
Apo-MT was reacted with 2.5 mol. eq. of Cd(OAc)2with increasing concentration of 
denaturant, at pH 5. At this pH, the resulting product would be the [Cd4S11]
3- cluster. The 
rate of metallation slows down as MT unfolds. Data and image from N. C. Korkola, 
reproduced with permission from the Royal Society of Chemistry. 26 
2.3.3 The Cd(II) Metallation Rate is pH Dependent 
The pH dependence of metallation was determined using stopped flow kinetic methods 
for the reaction of the apo-MT with 2.5 mol. eq. of Cd(OAc)2, with no denaturant present. 
The choice of 2.5 mol. eq. was because the dominating metallation pathway (beads or 
clusters) is readily apparent in the mass spectral data with this level of partial metallation. 
The metallation of apo-MT by Cd(II) is rapid at physiological pH (3633 x106 mol-1 s-1), 
but the rate decreases sharply as the pH is lowered (354 x106 mol-1 s-1), as seen in Figure 
2-5. 
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Figure 2-5 Relationship between observed rate constant k of the reaction of native apo-
MT 
Apo-MT was reacted with 2.5 mol. eq. Cd(II) at pH 5, 6, 7, 7.5, and 8, in the presence of 
4 M GdmCl. The product at each pH can be determined from Figure 2-6 and Figure 2-7. 
At pH 5 the resulting product would be the [Cd4S11]
3- cluster. At pH 8 the resulting 
product would be a series of [Cd1S4]
2- beads. Data and image from N. C. Korkola, 
reproduced with permission from the Royal Society of Chemistry. 26 
The mass spectral data shown in Figure 2-6 and Figure 2-7detail the speciation profiles at 
the extremes of the pH range used in Figure 2-5 above. The two metallation pathways 
manifest in different patterns of species abundance. The spectra taken at both pH 5 and 8, 
with 1, 2.5, and 5 mol. eq. of Cd(II) added show differing speciation at the 2.5 and 5 mol. 
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Figure 2-6 ESI mass spectra for the Cd(II) titration of apo-MT at pH 5 
Deconvoluted ESI mass spectra at pH 5 of the partially metallated MT species using (A) 
0, (B) 0.74, (C) 1.77, (D) 4.11, (E) 5.10, and (F) 5.84 mol. eq. of cadmium. The Cd4 
cluster is favoured at low equivalence and the fully metallated Cd7 species is favoured 
upon adding higher amounts of cadmium. Data and image from N. C. Korkola, 
reproduced with permission from the Royal Society of Chemistry. 26. 
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Figure 2-7 ESI mass spectra for the Cd(II) titration of apo-MT at pH 8 
Deconvoluted ESI mass spectra at pH 8 of the partially metallated MT species using (A) 
0, (B) 0.89, (C) 2.42, and (D) 4.86 mol. eq. of cadmium. The species display a Normal 
distribution pattern centered around the molar equivalents of cadmium added. Data and 
image from N. C. Korkola, reproduced with permission from the Royal Society of 
Chemistry. 26. 
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eq. point, where at pH 5, a strong preference for the clustered Cd4MT species is observed, 
Figure 2-6. In the case of the pH 8 (Figure 2-7) metallation pathway, a Normal 
distribution is observed, indicating the statistical formation of beaded products.  
To test if the presence of denaturant affected either the cluster pathway (pH 5) or the 
beaded pathway (pH 8), or both, the metallation rates were measured for apo-MT binding 
to 2.5 mol. eq. Cd(OAc)2 under 0 M (no denaturant) and 4 M GdmCl conditions. Figure 
2-8 shows the results for four unique conditions: A) pH 5 and no denaturant, B) pH 5 with 
4 M GdmCl, C) pH 8 with no denaturant, and D) pH 8 with 4 M GdmCl. The rate 
constants kobs for A-D are: 354, 325, 3633, and 2150 (10
6 M-1 s-1) respectively, which are 
shown comparatively in Figure 2-9. 
 
Figure 2-8 Kinetic absorption traces of MT metallation 
Kinetic traces of the metallation of 2.5 mol. eq. of cadmium to apo-MT under conditions 
of (A) pH 5 and no denaturant, (B) pH 5 and 4 M of GdmCl, (C) pH 8 and no denaturant, 
and (D) pH 8 and 4 M of GdmCl. The traces show that the beaded pathway at pH 8 
proceeds much faster than the clustered pathway at pH 5 and that denaturant slows down 
both pathways Data and image from N. C. Korkola, reproduced with permission from the 
Royal Society of Chemistry. 26 
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Figure 2-9 Comparison of rate constants  
Bar graph representation showing the observed rate constants of the metallation with 
2.5mol. equivalents of cadmium (A) pH 5 and no denaturant, (B) pH 5 and 4 M of 
GdmCl, (C) pH 8 and no denaturant, and (D) pH 8 and 4 M of GdmCl. The effect of the 
denaturant is much less pronounced than that of the pH environment. Data and image 
from N. C. Korkola, reproduced with permission from the Royal Society of Chemistry. 26 
2.3.4 Relative kobs Decreases with Increasing Metallation  
Figure 2-10 shows the relative kobs values of the reaction of a fixed concentration of apo-
MT with increasing Cd(II) mol. eq. at pH 5 (Figure 2-10A) and pH 8 (Figure 2-10B). In 
both cases, in the absence of denaturant (black dashed line), the relative kobs rate 
decreases as a function of the increase in the number of Cd(II) bound. In the presence of 
denaturant (4 M GdmCl, red dotted line), the overall rates at both pHs are reduced. At pH 
5, there is an approximately 50% reduction in the rate, but continues to follow a 
decreasing trend with metallation. At pH 8 on the other hand, the denaturant dramatically 
reduces the metallation rate.  
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Figure 2-10 Cadmium equivalence vs. observed metallation rate k 
Plots showing the relationship between the observed rate constant and mol. equiv. of 
cadmium added at (A) pH 5 and (B) pH 8, both with denaturant (red dotted line) and 
without denaturant (black dashed line). The observed rate slows down as MT binds 
increasing numbers of cadmium ions. Data and image from N. C. Korkola, reproduced 
with permission from the Royal Society of Chemistry. 26 
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Figure 2-11 Arrhenius plot for Cd(II) metallation of MT 
Arrhenius plot displaying the dependence of the observed rate constant on temperature. 
The natural logarithm of the observed rate constant has a linear relationship to the 
inverse temperature: y=-2791.4x+15.71, R2=0.9375. Data and image from N. C. 
Korkola, reproduced with permission from the Royal Society of Chemistry. 26 
2.3.5 Metallation is Temperature Dependent 
The relative kobs for the metallation of apo-MT with 2.5 mol. eq. of Cd(OAc)2 at pH 5 
were determined at 10.1, 15.3, and 18.1 °C, with the resulting Arrhenius plot shown in 
Figure 2-11. The reaction rate slows as the temperature decreases, with a calculated 
activation energy EA of 232 kJ/mol with an Arrhenius constant of 16. The rate of reaction 
at 25 ˚C and above was too fast for the instrumentation. 
57 
 
2.4 Discussion 
2.4.1 Does Native Apo-MT have a Folded Structure? 
Defining the structure of apo-MT is difficult. It is clear that metallation results in metal-
induced folding, such that the metal-saturated product (M(II)) exists with two, well-
defined binding domains.36 However, these domains do not exist in the absence of the 
metal, unlike most metalloproteins. Circular dichroism spectroscopy can typically be used 
to assess the degree or extent of 2° structure in a protein, from the characteristic CD 
spectral profiles between 190 and 230 nm. However, no such spectral properties exist in 
apo-MTs because of the absence of any defined folding. Mass spectrometry offers an 
alternative and to some extent, a more precise measure of the degree of denaturation 
associated with unfolding from the charge state manifold. Generally, when employing 
mass spectrometry to probe changes in the protein structure as a function of an external 
event, one examines the charge state envelope, its central number, and its spread to assess 
the change in protein-solvent accessibility. With metallothioneins, their limited size 
reduces the magnitude of changes in the charge state distribution, making this a less 
precise method of tracking protein structure, compared to, for example, myoglobin 
(~17000 Da). For greater sensitivity, cysteine alkylating agents, for example NEM or 
pBQ as described in Chapter 1, provide detailed evidence of solvent accessible cysteines 
as a function of increasing denaturant concentrations.6, 23 The use of GdmCl as a 
denaturant allows protein denaturation without affecting the pH of the solution. 
The data in Figure 2-3 showed that the apo-MT structure is dramatically and significantly 
affected by the presence of denaturant. The two profiles have been described previously 
in terms of the structural origins that would result in cysteine modification profiles with 
such differences. The explanation that fits the experimental environment was described 
first by Irvine et al. in 2014 for the structures of apo-α-MT fragment.7 Considering the 
reaction as having simply run out of the NEM, the spectrum obtained is a snapshot of the 
reaction, frozen by the lack of sufficient modifier. NEM covalently alkylates with the free 
cysteinyl thiols in the MT protein to form a mass change readily discernible in the mass 
spectrum. Irvine et al. have demonstrated that the more unfolded or solvent accessible the 
protein is, the more Normal the distribution of the resulting modified species.24, 37 If the 
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protein were folded with only a certain set of cysteines being solvent accessible, this 
would be visualized in the ESI mass spectrum as a strong preference for a certain number 
of alkylations. For the experimental conditions required in the rest of this Chapter, the 
data show that 3 M GdmCl effectively unfolds apo-MT without altering the pH of the 
solution, allowing elucidation of pH dependent metallation pathways, as is described 
below.  
2.4.2 Metallation Slows in the Presence of Denaturant 
Both heat and acidity have been shown to be effective denaturants of MT.7, 8, 22, 23  
 
Scheme 2-1 Guanidinium chloride CH6ClN3 
However, due to the pH dependence of MT’s chelation properties, GdmCl (Scheme 2-1) 
was chosen so that the pH would not be affected by addition of denaturant. GdmCl is a 
chaotropic agent that denatures by disrupting hydrogen bonding.38 The MT sequence 
contains few hydrophobic residues, suggesting that hydrogen bonds and electrostatic 
interactions are solely responsible for the overall stabilization of the protein in the metal 
free state.18 Previously reported molecular dynamics results showed that the hydrogen 
bond network in metal-saturated MT is largely retained upon complete demetallation, but 
increases upon stepwise, sequential, demetallation because the structure becomes more 
folded. 15, 18 
Figure 2-4 shows that even with the cluster structure, that the unfolded peptide metallates 
more slowly. This result is coincident with previous results reported for just the apo α-MT 
metallated with excess Cd(II) in 2015 by Irvine et al.7 pH 5 was chosen specifically for 
the series of experiments described in Figure 2-4 as it ensures the dominance of the 
Cd4S11 cluster. 
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2.4.3 pH Changes the Dominant Metal Binding Pathway: Cluster 
Formation at pH 5 is Slower than Bead Formation at pH 8 
Irvine et al. have demonstrated the pH dependence for Zn(II) and Cd(II) metallation, and 
that the pathway adopted at different pHs can be confirmed by observing the metallated 
species in the ESI-mass spectrum.16 Acidic conditions promote the cluster pathway for 
both metals, as shown in the low pH MS data for Cd(II), Figure 2-6. At physiological pH, 
both Cd(II)and Zn(II) bind in a beaded fashion up to 5 M(II) ions bound, as shown in the 
MS data for Cd(II) metallation, Figure 2-7. Figure 2-7 clearly shows the expected 
stepwise progression of the speciation as a function of Cd(II) mol. eq. There is no 
preference at this pH for the Cd4S11 clusters. The rate of metallation was obtained as 
function of pH. However, Cd(II) switches to the cluster pathway at a much higher pH 
compared to Zn(II). Zn(II) generally follows the tetrahedral terminal bead pathway over 
this pH range, with the cluster pathway only playing a role at a pH <5.1.16 In the case of 
Cd(II), cluster pathways can begin to dominate at a pH <7, which indicates the major 
influence a small change in pH can have on metal binding structures. This is pertinent to 
the discussion of metal anticancer therapeutics in the acidic condition of the tumor cell, 
which would promote MT to form stable metal-thiolate clusters, impeding drug delivery 
and efficacy.39  
In Figure 2-5, the pH range 5-8 encompasses a change in metallation product for the 2.5 
mol. eq. of Cd(II) of clusters at pH 5 and beads at pH 8. Because the trend in rate constant 
follows almost exactly the trend in % terminal binding as a function of pH reported by 
Irvine et al.,16 cluster formation (pH 5) is dramatically slower than bead formation (pH 8). 
The mass spectral data shown in Figure 2-6 and Figure 2-7, indicate that for the solutions 
used in the stopped-flow in Figure 2-8A and B, the metallation products are dominated by 
Cd4S11 cluster formation in the α domain. For Figure 2-8C and D The increase from pH 5 
to pH 8 increased the observed metallation rate tenfold in both cases, with the pH 8, 
native apo-MT, beaded metallation pathway, remaining the most rapid of the four 
conditions, Figure 2-9. It should be noted that in Figure 2-8, the plateaus of the kinetic 
traces do not all end at the same y-value. This is due to instrument variability, caused by 
measuring at 250 nm which is close to the detection limit. Normalizing the curves to end 
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at the appropriate y-values according to Beer’s Law results in the same trends presented 
here. 
2.4.4 Why is Terminal Cysteine Coordination Faster than Cluster 
Formation? 
The formation of terminally bound metal beads is shown to be fast in Figure 2-5. This 
could be because although there is no defined structure for the cysteines: (i) the ESI mass 
spectral modification data, Figure 2-3, (ii) the modification data provided by Irvine et 
al.,6, 23 and (iii) the previous molecular dynamics results, together support a structure for 
the apo-MT that involves non-specific folding optimized for metallation. Beaded 
metallation requires the concerted binding of 4 cysteine thiols at a time to M(II). The 
folded apo-MT structure orients the cysteines in close proximity such that the beads are 
formed rapidly. The cysteines that are most solvent exposed and have the most reduced 
energy upon metallation may well be metallated first.12, 18, 19, 40, 41 
In the case of cluster formation, this is a highly organized process with very specific 
cysteines involved in bridging arrangements resulting in the most energy minimized 
structure. The kinetic data show that this large-scale organization occurs at a slower rate 
than that of the beaded pathway, presumably due to the requirement of such precise 
cysteine coordination.  
2.4.5 Rate as a Function of Metal Loading 
kobs decreases with sequential metallation, with the initial metals having the highest 
values. The last binding sites to be occupied are the slowest, as a reflection of a decrease 
in available sites. This is reflected widely across all metal species, as previously shown 
with time-dependent ESI-mass spectral data with Cd(II),16 As(III),42 and Cu(I).43 A 
sequential increase in Kf is generally associated with the formation of a stable cluster, if 
M>1, as has been shown in the titration of Cu(I)1-20MT,
43 As1-6MT,
11, 12, 36 and notably 
with Cd4S11 and Co4S11 clusters in the α domain. 
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2.4.6 Temperature Dependence of Metallation 
Petering et al.41 and Stillman et al.30 have reported the temperature dependence of the 
metal lability in metallothioneins. The interprotein exchange of Zn(II) between carbonic 
anhydrase is much more rapid at 37 ° C than at 25 °C.41 The intraprotein exchange of 
Cd(II)and Zn(II) between domains can be followed readily with circular dichroism 
spectroscopy at temperature extremes.30 The initial metallation reactions studied in this 
paper are also temperature dependent, as shown in Figure 2-11. There is an upper limit, as 
shown by Irvine et al, who used heat assisted denaturation at 94°C to demonstrate 
temperature dependent denaturation.22 
2.4.7 Metallation of Unfolded Apo-MT is Slower than Native Folded 
MT 
The results of Figure 2-4, Figure 2-5, Figure 2-8, and Figure 2-9 show that the disruption 
of the apo-MT structure affects the rate of both the bead and cluster formation. pH 
influences the dominant pathway, but each pathway does have an optimal structure 
required for efficient metallation. Other structure impeding agents present in the cellular 
environment may cause similar disruption to the metallation process. Being particularly 
sensitive to sulphur oxidation, oxidized MT manifests in the formation of disulphide 
bridges, which will greatly disrupt the delicate and highly specific metal-thiolate 
organization of the native MT.  
Does the apparent lack of formal structure for the native apo-MT have an impact on 
metallation rates? The use of a well-studied denaturant together with well understood 
structural metal-thiolate products (beads up to 5 Cd(II) at neutral pH and up, cluster 
formation below pH 6) meant that the single variable being tested was the extent of 
folding of the apo-MT. The data in Figure 2-8 and Figure 2-9 clearly answer this 
question. The metallation rate for Cd(II) is always faster in the absence of a denaturant. 
At physiological pH (choosing pH 8 to eliminate cluster formation) the folded apo-MT 
(absent denaturant), metallated over 50% faster than the unfolded (with denaturant). This 
same trend is the case at pH 5. 
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On a similar vein, these results demonstrate the effect of misfolding on the efficient 
function of a native protein. A common source of protein damage occurs as a result of 
oxidation. MT plays a role in both the protection and repair of oxidative damage.44-46 
Oxidation and protein misfolding are thought to be one of the causes of cellular ageing, 
with a build-up of misfolded proteins and metal ions aggregating in the lysosome.47 There 
is increasing evidence that MT plays a protective role in metal aggregation limitation, 
such as in the reduction of amyloid plaques in neurodegenerative diseases.48-50 With its 
multitude of reduced cysteine residues, MT can repair oxidative damage through the 
formation of disulphide bonds. This oxidation would greatly reduce MTs metal binding 
efficacy and place the cell at risk for dysfunctional regulation. A build-up of these 
misfolded products could result in differentiating cell conditions, such as decrease in pH, 
thus altering the activity of MT metallation to promote stable cluster formation.  
MTs are well known for their stable metal-thiolate clusters, that protect the MT from 
oxidation and protease digestion.51, 52 From an evolutionary standpoint, MTs adaptive role 
in metallation and oxidative protection makes it a key player against ageing. Its ubiquity 
across all phyla cements this idea. Species specific amino acids may also impart fine-
tuned structural influences to optimize efficiency in particular organisms, for which the 
reader is courteously directed to selected references comparing plant and mammalian 
MTs.53-55 
2.5 Conclusions 
The metallation of MT is a post-translational modification that is dependent on the 
cellular environment, particularly pH and metal loading status. In lower pH environments, 
such as hypoxic or tumorous cells, clustering pathways would predominate, especially in 
the presence of toxic Cd(II). This is relevant towards developed metallodrug resistance 
that some cancer types exhibit: MT of these cancerous cells is capable under these 
conditions of binding soft metals in a stable metal-thiolate cluster, minimizing cellular 
damage. At physiological pH, the evidence from the experiments reported in this Chapter, 
suggest that apo-MT adopts a compact folded structure, with cysteines oriented for facile 
metallation, indicated by the higher metallation rate. Folded apo-MT forms these very 
specific structures during the stepwise metallation process. Further studies are needed to 
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investigate how these structures change when the protein has been damaged as a result of 
misfolding or binding to a foreign or xenobiotic metal. 
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Chapter 3 
3 Capturing Platinum in Cisplatin: Kinetic Reactions with 
Recombinant Human apo-Metallothionein 1a* 
3.1 Introduction 
The prolonged use of cis-diamminedichloroplatinum(II) (cisplatin), a powerful 
chemotherapeutic, can incur chemoresistance in cancers during treatment, reducing the 
chance of therapeutic success. Metallothioneins (MTs) are suspected of metallodrug 
interference via ligand removal and metal sequestration. The mechanistic details and 
reactions rates kobs for the systematic deconstruction of cisplatin by apo-human MT are 
reported and analyzed from mass spectral data. 
In order to understand pre-target resistance in metallo-chemotherapeutics it is necessary 
to investigate the mechanisms responsible for metal-protein binding reactions. Cisplatin, a 
popular and extremely effective anti-cancer drug, is the focus of worldwide 
interdisciplinary investigations into emerging chemoresistance and metabolic toxicology 
in cancers. This present paper focuses on monitoring the abrupt and disruptive reaction 
involving a major cellular thiol source, metallothionein, with cisplatin. MT is implicated 
as a metal sink that may be also involved in nephrotoxicity. Time–dependent, solution-
phase, ESI-MS was used to monitor the destruction of the cisplatin molecule. Kinetic 
analysis provided the reaction rates for the individual steps from the initial binding of the 
complete molecule, through extrusion of the ligands, and final accumulation of isolated 
Pt(II) bound to metallothionein. 
3.1.1 Cisplatin: A Standard Treatment for Cancer 
Since its discovery by Rosenberg in 1978, cis-diamminedichloroplatinum(II) (more 
commonly known as cisplatin) has been used as a potent anti-cancer agent for the 
treatment of testicular, ovarian, head and neck, bladder, colorectal, and lung cancers.1-4 
As a metallodrug, cisplatin can act upon several biochemical pathways to trigger cell 
death. For instance, with its soft, transition metal core, cisplatin is capable of readily 
binding the free thiols of glutathione and metallothioneins, reducing the cell’s facility to 
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respond to oxidative stress.1, 2, 5-9 Binding to glutathione (GSH) can instigate efflux from 
the cell via MRP1 and MRP2, removing this thiol source from the cell.10-12 Similarly, by 
binding to free thiols near the active site of enzymes, cisplatin can disrupt cell function.13, 
14 However, its most well-known method of action is through the creation of DNA 
adducts triggering mitochondrial apoptosis and cell death.  
 
Scheme 3-1 Cisplatin and the aquation reaction involved in its initial entrance to the 
body. Reproduced from D. L. Wong and M. J. Stillman with permission from the Royal 
Society of Chemistry. 15 
Upon administration in the body, cisplatin becomes an active form through aquation 
reactions where the chloride ligands are spontaneously exchanged with water, as 
described in Scheme 3-1, above.16, 17 This results in a complex that reacts readily with 
endogenous nucleophilic groups, like the free thiols mentioned above, or, in particular, 
the guanine N7 site on purines in DNA.2, 18 Multiple reactions can occur for each Pt(II) 
core of the cisplatin, resulting in inter- and intra- strand crosslinking of DNA, disrupting 
transcription and translation. It should be noted that in fact, very little (1%) of the 
intracellular cisplatin binds to nuclear DNA.19 Clearly, DNA damage is not the only 
cytotoxic pathway at play, as cisplatin also exerts toxic effects on enucleated cells.20 
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3.1.2 Metallothionein and Drug Resistance  
While initially effective in many cancer types, chemoresistance to cisplatin can develop 
with prolonged treatment.21, 22 Increased expression of cellular thiols GSH and MT have 
both been implicated in these resistance mechanisms but they are believed to be 
independently induced.23 Kelley et al. remarked that there was a noticeable increase in 
cellular MT levels in several cancer lines treated with cisplatin and antineoplastic agents 
melphalan, and chlorambucil.24 It has also been suggested that MT is an obstacle in the 
treatment of the ovarian cancer A2780CR cell lines that are cisplatin resistant. Work from 
Surowiak et al. suggests that nuclear MT expression levels increase with cisplatin 
treatment, which may be correlated with the diminished overall clinical response.22 The 
direct correlation between cellular MT and chemoresistance is not clear cut for all cancer 
types, as shown by Woo et al, nuclear and cellular MT levels vary greatly across cancer 
types, and this subcellular compartmentalization of MT plays a role in its metal 
response.23 While the relationship between MT expression and developed cisplatin 
resistance is unclear, the correlation between the two has been suggested as a possible 
biomarker for resistance. As such, the connection between the two has been the focus of 
gene expression and metallomics studies.25 
As described extensively in Chapters 1 and 2, MTs are a family of ubiquitous, low 
molecular weight (6-8 kDa), cysteine-rich, metal binding proteins that most notably play 
a role in Zn(II) and Cu(I) homeostasis, heavy metal detoxification, and response to 
oxidative stress.7, 26-30 MTs are capable of creating a variety of metal-thiolate cluster 
structures using 20 cysteine thiolates.29-33 The involvement of MTs in cisplatin resistance 
is suggested to be due to their property of binding a wide array of soft, d-block, 
xenobiotic metals, such as Cd(II), Hg(II), As(III), and Pb(II), as well as those of 
therapeutic interest, like Bi(III), Au(I), Ag(I), and Pt(II), among others.27, 28, 34-37, MTs act 
to sequester toxic metals for excretion, which in the case of cisplatin, can lead to renal 
side effects associated with treatment.38  
MT binding with cisplatin has been studied intensely due to its association with 
developed cisplatin resistance. Reactions showing remetallation of Zn-MT and Cd-MT by 
Pt(II) demonstrate the strong affinity of the cysteine thiol for the Pt(II).6, 39-47 MT 1 and 
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MT 2 are capable of binding up to 7 Pt(II), mimicking the stoichiometry of the two-
domain binding structure of native Zn7-MT and Cd7-MT.
48 The Stillman group has 
previously demonstrated low temperature (77 K) emissive properties of Pt-bound MT,35 a 
property of metal-thiolate cluster formation. 
Extensive kinetic analysis of the metallation of metallothionein by cisplatin has been 
performed by Hagrman et al. involving spectroscopic methods.6 Mimicking chemical 
conditions of the cell, their study involved monitoring in vitro the loss of cisplatin over 
the course of full metallation of metallothionein. As expected, the Pt-MT product has 
none of the ancillary ligands of the original cisplatin molecule. Hagrman et al. note that 
there is a delay in the observed signal, indicating that initial reactions may be occurring 
that are not detectable under the conditions used.6 A limitation of optical techniques is the 
averaging of all the signals, which masks the individual mechanistic details in these early 
stages of the reaction.  
3.1.3 Biological Significance 
Many of the in vitro methods described above utilize widely available rabbit liver or rat 
liver metallothioneins, which often come in mixtures of isoforms, metallated with Zn(II) 
or Cd(II), or as a mixed metal species. Using recombinant human metallothionein 
expressed in Escherichia coli provides isoform-pure recombinant human MT 1a. MT 
regulation is influenced by the presence of xenobiotic metals, like Bi(III), Au(I) and 
Pt(II), and as such, apo-MT will be synthesized by the cell in response to the presence of 
these metals.33, 36, 49 Indeed, several reports now confirm the presence of apo-MT in vivo 
in large quantities.50-53 This perspective indicates that the metallation of MTs is a post-
translational modification. Therefore, the properties of the reaction between apo-MT1a 
and cisplatin are investigated using the high species resolution of ESI-MS. The time-
dependence of this early reaction involving the deconstruction of the cisplatin complex 
can be monitored at this resolution. This provides insight on the interactions between MT 
and complex chemotherapeutic complexes, as opposed to the free ion metallation studies 
of MT performed previously. The benefit of applying ESI-MS is the availability of high-
resolution snapshots of solution-phase intermediates throughout the course of the 
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reaction. With this, the initial reaction that Hagrman et al. and Pattanaik et al. suggest 
exist but have not yet characterized the speciation involved can be identified.6, 46  
The following Chapters involving the aggressive reaction of human MT with 
dirhodium(II) tetraacetate raised the question whether MTs might react similarly with the 
most important and effective metal-based anticancer drug, cisplatin. In the reaction with 
the dirhodium(II) tetraacetate, the MT bound the complete molecule and in a stepwise 
fashion competed for the possible binding sites with its numerous cysteinyl thiols until 
only the [Rh-Rh]4+ core remained encapsulated by the protein. The high resolution 
capabilities of ESI-mass spectral data displayed each of the stepwise species formed 
during the reaction, showing the systematic destruction of the dirhodium(II) 
tetraacetate.54A similar destructive effect was demonstrated by MT upon antimetastatic 
Ru(II)-arene complexes.55  
The experiments reported in this Chapter leverage the exquisite power of the ESI-MS 
technique to interrogate the products formed initially between MT and cisplatin. In this 
manner, the early mechanistic details will become clear, allowing the determination of the 
structural aspects of cisplatin that lead to MT deactivation. The goal of this work is to 
determine the identity of the initial Pt-based species that bind to the MT, and then to 
elucidate the subsequent reaction pathways of the Pt-based species while debilitatingly 
immobilized in the MT. Unlike previous reports, the mechanism explored in this work 
involves the metallation by each individual cisplatin molecule to form the Pt-MT product. 
To avoid the complexity of a distribution of metallated species in partially-metallated 
MTs, 31, 56, 57 The apo-MT with its 20 uncoordinated cysteines was chosen as a model for 
the uncoordinated cysteines in partially metallated MT. The results may be used to guide 
design of metallodrug structures that are resistant to this MT-thiolate destructive 
chemistry.  
3.2 Experimental Methods 
Recombinant human metallothionein 1a were produced and purified according to 
previously described methods with the sequence 
GSMGKAAAACSCATGGSCTCTGSCKCKECKCNSCKKSCCSCCPMSCAKCAQGC
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VCKGASEKCSCCKKAAAA.56, 58, 59 This recombinant sequence has mutations (T27N 
and I51V) compared with the native human MT1a for purposes of overexpression in E. 
coli. The metallation properties of this recombinant isoform (MT1a) has been shown in 
spectroscopic studies from the Stillman Group to behave similarly to mammalian MTs, 
for example, rabbit liver MT2A.60, 61 The purified Cd-bound MT1a was demetallated by 
acidification (pH<2) and the resulting free Cd(II) in solution were removed by centrifugal 
filtration (Amicon Ultra-4 3000 Da MWCO). Protein concentration was calculated by 
remetallating a measured aliquot with CdSO4 and determining the Amax at the 250 nm 
shoulder characteristic of the LMCT of Cd-S bonds (ε = 89,000 L mol-1 cm-1).  
Solutions of cisplatin (Sigma) were prepared in DI water well ahead of time to allow for 
aquation. Aliquots containing cisplatin equivalent to ~ 3 mol. eq. of the apo-MT were 
added to the apo-MT solution (20 mM ammonium formate buffer, Fluka, pH 7.0) 
immediately prior to mass spectral data acquisition using a MicroTOF II (Bruker 
Daltonics, Toronto). All solutions were at room temperature and thoroughly deaerated 
using vacuum evacuation followed by Ar saturation. NaI was used as the calibrant. 
Spectra were collected in positive ion mode, as a function of time following mixing. The 
settings used are described in Chapter 1. 
The averaged spectra and data analysis were carried out using the Bruker Data Analysis 
4.2 program. The resulting spectral data were normalized, and the dominant species 
identified by mass. The identified species and their abundance data were grouped and 
input into GEPASI,62, 63 a biochemical kinetics simulator, as the reactions defined in 
Scheme 2 in the Results and Discussion section. The four reaction rate constants, k1-4, 
were defined as irreversible mass action, and the k’s and concentrations were limited by 
user-defined parameters.  
3.3 Results and Discussion 
The time-dependent deconvoluted mass spectral data recorded during the reaction of 
cisplatin with apo-metallothionein 1a experimental data are shown in Figure 3-1, and in 
block form Figure 3-2. In the Apo panel of Figure 3-2, the black bar represents the Apo-
MT abundance at the beginning of the reaction. By one minute (A) each of the species 
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found at the end of the reaction can be discerned. The speciation is grouped in terms of 
MT involved in Pt1 complexes (red, “Pt1 Group”), Pt2 complexes (blue, “Pt2 Group”), Pt3 
complex (green), and Pt4 complex (pink). The mass spectral data are rich in detail about 
the many species involved in the initial binding of cisplatin to the MT. There are two 
ways of describing the data shown in Figure 3-2: (i) Either by the time-dependence of the 
individual groups, based on the number of Pt(II) bound to the protein (x = 1-4), (ii) or 
based on the appearance of species at each time point (A – F). The kinetic analysis, to be 
described below, is based on the 4 groups, but not the individual speciation within the 
groups. At this point, the focus is directed to describing the change in speciation for each 
individual platinum bound (Figure 3-1 A-F). 
 
Figure 3-1 ESI mass spectra following the reaction of cisplatin with apo-MT1a. 
The apo-MT peak is highlighted by the red dashed line. Platinated species are coloured 
according to the number of Pt(II) atoms contained, with its associated partially ligated 
(PtxL-MT) or fully ligated ((CDDP)x-MT) species sharing the same colour. MT bound to 
Pt1 represented with green dashed lines. MT bound to Pt2 represented with blue dashed 
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lines. MT bound to Pt3 represented with yellow dashed lines. MT bound to Pt4 
represented with pink dashed lines. Reproduced from D. L. Wong and M. J. Stillman with 
permission from the Royal Society of Chemistry. 15 
 
Figure 3-2 ESI mass spectra following the reaction of cisplatin with apo-MT1a in bar 
graph representation. 
The apo-MT peak is highlighted by the black bar. Platinated species are coloured 
according to the number of Pt(II) atoms contained, with its associated partially ligated 
(L-Pt-MT) or fully ligated (CDDP-MT) species sharing the same colour. MT bound to Pt1 
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represented with red. MT bound to Pt2 represented with blue. MT bound to Pt3 
represented with green. MT bound to Pt4 represented with pink. Reproduced from D. L. 
Wong and M. J. Stillman with permission from the Royal Society of Chemistry. 15 
 
Figure 3-3 Detailed ESI mass spectral data of CDDP1MT and CDDP2MT 
Detailed comparison of mass spectral data for the “Pt1 Group” (Red, left) and “Pt2 
Group” (Blue, Right). The selected panels are from the frames shown in Figure 3-1A-F. 
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The overall cisplatin molecule deconstruction is observed from the overall decrease of the 
“CDDP” species and the overall increase of the “Pt” species. Reproduced from D. L. 
Wong and M. J. Stillman with permission from the Royal Society of Chemistry. 15. 
In Figure 3-2A, within the red Pt1 group, the whole CDDP is bound to the MT, and over 
time to F, it loses its ligands, forming Pt1, which is seen in greater detail in Figure 3-3A. 
The intermediate in this pathway reaction can be seen as the peak labelled LPt1-MT, 
where the ligand (L) can be either (2 NH3) or Cl
1-, but this cannot be distinguished 
because of the overlap in the masses of these species. However, due to the nature of the 
ESI-MS experiment, L is most likely to be NH3 from the ammonium formate buffer, and 
due to the favourable loss of the Cl1- as shown in Scheme 3-1. Returning to Figure 3-2A, 
the Pt2 species (blue) can be formed from both CDDP1Pt1-MT and CDDP2 species. 
However, by F, the Pt2MT dominates, again illustrated more clearly in Figure 3-3. 
Returning once more to Figure 3-2A, under the concentration conditions at this stage of 
the initial reaction, only the Pt3Mt and Pt4MT species are observed, but these species 
grow in abundance as the reaction proceeds, to F. To summarize the time-dependence of 
the data, there is clear evidence that two complete CDDP molecules bind to MT, and that 
these two molecules degrade to the sequestered metal core. In F, the dominant species are 
Pt1MT, Pt2MT, Pt3MT, and Pt4MT. The Ptx-MT species without any ligands are the final 
products of each metallation event. The coexistence of Pt1-4MT is not an unusual 
observation for mechanisms that are not cooperatively driven. 31, 57, 58, 64, 65  
Each of the individual species can be seen at the 3-4 minute point, Figure 3-2D. i) β, 
Pt1MT, appearing as expected at 7062.7 Da, α, Apo-MT at 6868.8 Da. This mass 
difference corresponds to the mass of cisplatin molecule. ii) γ, L-Pt1MT at 7096.8 Da, iii) 
δ, CDDP1-MT 7167.8 Da, iv) ε, Pt2MT at 7258.7 Da, v) ζ, L-Pt(Pt)MT 7290.8 vi) η, 
CDDP1Pt1MT at 7363.7, vii) θ, Pt3MT 7453.7, viii) ι, CDDP2MT at 7470.7, and ix) κ, 
Pt4MT 7648.5 Da. MT species of Pt > 4 could not be distinguished from noise. The M4S11 
stoichiometry is a well-known structure involving metal-thiolate cluster formation that 
occurs in other divalent metals.27, 57, 66-68 
Figure 3-3 show the time-dependent change in the Pt1 group (A, red) and Pt2 group (B, 
blue) taken from panels A-F in Figure 3-2. In Figure 3-3A, the initially bound CDDP 
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degrades to L-Pt1MT and then to Pt1MT. In the Pt2 group there are two reactants that can 
form the Pt2MT species: CDDP1Pt1MT and CDDP2MT. Both of these are seen at 7363.7 
and 7470.7 Da, respectively. The time-dependence data again show that the encapsulated 
core, Pt2MT, is the product.  
 
Figure 3-4 Experimental speciation abundance over time 
Abundance speciation data over time taken from the experimental mass spectral data. 
Apo-MT species are represented with black. The holoMT species (red) represents the sum 
of PtxMT species (blue), ligated Pt species LPtxMT (green), and MT species with a whole 
cisplatin molecule bound, CDDPxMT (cyan). Reproduced from D. L. Wong and M. J. 
Stillman with permission from the Royal Society of Chemistry. 15 
The time-dependence of the mass-spectral data is used to quantify the reaction 
mechanism shown in Equation 3-1. The resolving power of ESI-mass spectrometer allows 
monitoring this reaction in higher detail than has been possible previously. In particular, 
the time-resolved spectra shows the emergence and subsequent loss of the intermediate 
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species, as well as the composition of the intermediates that reach a steady state. 
However, the 9 species present make the kinetic analysis extremely challenging. In Figure 
3-4, the metal-free species, Apo-MT (Black), decreases over the course of the reaction, as 
it begins to sequester the cisplatin in solution. All the resulting metallated species are 
summed and reported in Figure 3-4 as Holo-MT (Red). Holo-MT represents the sum of 
all the many sub-species that form as cisplatin is deconstructed while bound within the 
MT. The specific components are i) the majority final products Ptx-MT where x=1-4, 
contains the sequestered and deactivated platinum core that is no longer a functional 
chemotherapeutic (Figure 3-4: Blue); and ii) the ligated species, LPtxMT (Figure 3-4: 
Green) and CDDPxMT (Figure 3-4: Cyan) are intermediate species in much lower 
abundance than those of Ptx-MT, and achieve a steady state over the course of the 
reaction. 
 
Equation 3-1 Bimolecular reaction equations for the metallation of MT by CDDP 
Simplified reaction pathway. Products grouped according to its Pt stoichiometry, with the 
reaction rates k representing the summation of the overall observed rate of the individual 
species. Reproduced from D. L. Wong and M. J. Stillman with permission from the Royal 
Society of Chemistry. 15 
An unusual observation during the metallation reaction of MT with cisplatin (Figure 3-2) 
was that the observed mass corresponds to the dichlorinated cisplatin. This was 
unexpected given the time allowed for aquation to occur. However, the observation of the 
chloride ion in the cisplatin molecule that is bound within the MT clearly delineates the 
starting point of the subsequent deconstruction of the cisplatin. For instance, 
distinguishing between the amine groups and water ligands in the aquated cisplatin would 
be difficult by MS due to protein band broadening, but the loss of the chloride ligands is 
clearly observed with the resulting significant mass difference. While this chlorinated 
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speciation is not likely the physiologically observed form of cisplatin, its appearance in 
these mass spectra provides information that can be used in the development of the 
deconstruction reaction pathway.  
 
Figure 3-5 Experimental and simulated relative speciation abundance  
Experimental data (markers, labelled (E) in legend) and the fitted time dependent 
reaction (smooth lines, labelled (S) in the legend) of speciation abundance. The top 
spectra show the Apo-MT and HoloMT speciation, where HoloMT represents the sum of 
the respective metallated species shown in the bottom spectra. Reproduced from D. L. 
Wong and M. J. Stillman with permission from the Royal Society of Chemistry. 15 
81 
 
The presence of so many individual intermediate species can make kinetic analysis 
difficult by standard fitting methods. Using GEPASI, a biochemical pathway simulator, 
the observed kinetic rates can be simulated by fitting each of the metallation rate laws for 
cisplatin binding to MT to the experimental data.62, 63 For the experimental data, we use 
the time dependence of the abundance of each species in the ESI mass spectral data. To 
simplify the overall process, reactions involving the CDDP-MT, CDDP-Pt-MT, and L-Pt-
MT intermediate species were grouped based on their total Pt:MT stoichiometry (eg: 
Pt1MT, Pt2MT, Pt3MT, Pt4MT) (Equation 3-1), as described for Figure 3-2. The observed 
rate constants were then derived from the experimental data for each group (Table 3-1). 
The four consecutive rate law equations modelled the experimental data using the initial 
concentrations. Taking into account the errors in experimental MS abundancies, the fitted 
k values are quite reasonable, with % standard deviations below 22%. The errors for the 
formation for Pt4MT are large because the abundancies are low as it is the final step in the 
mechanism. The analysis also shows that the reaction is still in progress at the 600 s time 
point. 
Figure 3-5, top, summarizes the fitting results. Apo-MT reacts rapidly with cisplatin to 
form HoloMT, with more than 50% of the metallation occurring in the first 100 s. Figure 
3-5, bottom, shows the individual components of the HoloMT that were fitted with the k 
values shown in Table 3-1. These four k values are the rate constants for the steps by 
which individual PtxMT (x = 1-4) form. They encompass ligand substitution by the MT 
cysteine thiolates until only the Pt(II) core is left. 
Table 3-1 Fitted reaction rate k values from experimental mass spectral data. Reproduced 
from D. L. Wong and M. J. Stillman with permission from the Royal Society of Chemistry. 
15 
Parameter Value (/10-6) Std. Deviation 
k1 34 6% 
k2 23 6% 
k3 14 11% 
k4 28 21% 
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The kinetic analysis provides details of the initial pathways by which metallothionein 
interacts with the incoming cisplatin. The complexity of the reaction, indicated by the 
similarity in the rate constants, arises from multiple overlapping consecutive pathways, as 
noted in previous studies.6, 46 However, the ESI-MS data provides the time-dependent 
concentration of each of these initial species. The kinetic analysis provides the 
quantitative data to support the speciation sequence in the binding of cisplatin to MT to 
form eventually the PtMT product. The first example of a complete analysis of the 
metallation mechanism of MT was reported for As(III) binding using time- and 
temperature-dependent MS data.34 The results of presented in this Thesis allows the 
concentration of any of the 10 cisplatin-MT intermediate species to be calculated at any 
time following mixing, starting with only the initial concentrations of Apo-MT and 
cisplatin. It is interesting to note that Hagrman et al. reported a similar magnitude k value 
for their overall reaction of apo-metallothionein with cisplatin.6  
These ESI-mass spectral methods can be employed in the investigation of 
pharmacodynamics of drug metabolism in other biological or clinical applications. With 
respect to the interaction of MT with cisplatin as discussed above, it is important to 
comment on the toxic effects of the metabolism and excretion of cisplatin through the 
proximal renal tubules. It is now commonplace to induce metallothionein in the kidneys 
using Bi(III) to reduce the tubular damage from the excretion of cisplatin metabolites.69 
For instance, with relevance to Pt-based chemotherapeutics, platinum analogues including 
carboplatin and oxaliplatin, employ alternative ligand structures to deter chemoresistance 
mechanisms and toxic metabolite formation to reduce these symptoms.  
3.4 Conclusion 
This destructive property of MT towards transition metal complexes reported here with 
cisplatin emphasize the role of MT as a major player in pre-target resistance. The role of 
MT in metal metabolism and excretion coupled with the strength of binding to Pt(II), 
demonstrates the route in which renal damage occurs is likely similar to that of Cd-MT 
described in Chapter 1. Evidence of long term platinum persistence in individuals treated 
with platinum anticancer treatments,70 indicates that the metabolism of Pt(II) is a long 
process and chronic exposure would exacerbate this effect. When considering that the 
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heightened reactivity of MT and related thiols with trans-diamminedichloroplatinate(II) 
(transplatin) makes it unable to exact cytotoxic effects, it is clear that the character of the 
ligand on the metal greatly influences treatment success. The importance of the design of 
a thiol-resistant drug necessary to negate this resistance pathway. High resolution ESI-MS 
is a means to quantify metabolic products following metallodrug administration, and 
provides a sophisticated approach for identifying specific metabolic pathways. 
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Chapter 4 
4 Destructive Interactions of Dirhodium(II) Tetraacetate 
with  Metallothionein rh1a* 
4.1 Introduction  
Metallodrugs have a long and successful history in curing many different classes of 
disease; for example, cisplatin for testicular cancer, sodium aurothiomalate for 
rheumatoid arthritis, Li salts for psychological disorders, and Bi salts for gastrointestinal 
distress.1, 2 Challenges in the development of new metallopharmaceuticals include 
overcoming the cellular metal defences protecting the target. Metal-chelating gate-keeper 
proteins can result in dramatically decreased drug efficacy. The experiments in this 
Chapter report that one such gate-keeping protein, metallothionein, both binds dirhodium 
acetate, a potential anticancer metallodrug, and sequentially strips off the acetate ligands 
reducing the complex to just a thiolate-coordinated dirhodium core. This reaction may 
indicate a possible mechanism for a cellular metallodrug resistance pathway.  
Metallothioneins (MTs) are sulfur rich proteins that bind a variety of metals including 
toxic metals and those of medicinal interest. Current metallodrug designs aim to 
overcome these defences, for example using non-platinum compounds, like the robust 
series of half-sandwich arene Ru(II) anti-cancer compounds.3-5 While the over-expression 
of the cysteine-rich MT has been correlated to drug resistance,6, 7 there is very little direct, 
quantitative evidence of the mechanism that may be involved in the proposed 
interactions. In addition, there have been no reports of the subsequent fate of the 
metallodrug following its interaction with MT. Studies with cisplatin have provided some 
insight into the rates of metal ion isolation as seen in the previous Chapter,8, 9 but much 
more detailed information on the mechanism of destruction of the metal complex by the 
MT through ligand exchange is needed. Using dirhodium(II) tetraacetate as a model 
complex this ligand exchange can be observed with four identical ligands, while featuring 
a central metal-metal bond. 
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4.1.1 Dirhodium(II) Tetraacetate as a Model Chemotherapeutic 
Complex 
Metal-metal bonded dirhodium carboxylate complexes have gained interest as an 
alternative to classical platinum anti-cancer compounds.10 Dirhodium complexes are 18 
electron systems when the two axial positions are capped by solvent, with octahedral 
coordination of the rhodium metals. Ground work studies have shown high in vivo 
antitumor activity of Rh2(O2CR)4 (R = Me, Et, Pr) against L1210 tumors, Ehrlich ascites, 
and the sarcoma 180 and P388 tumor lines,11 as well as the ability to bind DNA and 
inhibit protein synthesis in a manner akin to cisplatin.12 Current research has extended the 
applications of rhodium compounds to medical imaging and protein labelling, but the 
significant antitumor characteristics of these rhodium complexes remain of great 
interest.13-16 However, the dirhodium carboxylates are particularly sensitive to sulfur 
coordination from cysteines in biomolecular targets.17, 18 This is significant because MT 
may stand in the way as a formidable defence for cancerous cells due to the tendency of 
cysteine coordination of any incoming metal. Herein, preliminary studies involving the 
remarkable and systematic deconstruction of dirhodium(II) tetraacetate (Rh2(OAc)4), a 
compound with anti-tumor activity, by the β-domain fragment of human metallothionein 
1a, are reported and discussed. 
4.1.2 Electrospray Ionization Mass Spectrometry (ESI-MS)  
ESI-MS is a powerful technique that allows for the quantitative visualization of a reaction 
as it progresses. In particular, mass spectrometry is especially effective in monitoring 
drug-protein binding reactions, as it is able to provide information regarding intermediate 
species as they develop in real time. 19, 20 ESI mass spectral data can be used in the 
characterization of species formed in a reaction by providing kinetic and stoichiometric 
details. When combined with UV-visible absorption and circular dichroism spectroscopic 
information, binding sites and changes of protein structure as a result of metal binding 
can be determined. These techniques provide a simple, yet information-rich method for 
assessing the viability of a preliminary study. While in vivo studies may be suited for 
determining mobility and target binding site information in a cell, the high detail of the in 
vitro studies shown here provide the mechanistic insight required to understand the 
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protective function that MT may perform in such drug resistant cancer forms. In this 
study, ESI-MS, UV-visible absorption and circular dichroism spectroscopy, together with 
molecular dynamics calculations were employed to monitor the binding reaction of 
Rh2(OAc)4 with apo-β-MT.  
4.2 Experimental Methods  
Preparation of recombinant human Metallothionein1a 
Preparation of isolated MT domain fragments followed previously reported methods. 21 
The amino acid sequence for the isolated domain used in this study was based on the 
recombinant human MT1a 38-residue β-MT domain fragment sequence 
(MGKAAAACSC ATGGSCTCTG SCKCKECKCN SCKKAAAA). Each of the 
corresponding DNA sequences was inserted as an N-terminal S-tag fusion protein into 
pET29a plasmids and individually expressed in E. coli BL21(DE3) with cadmium-
supplemented growth medium, as described in Chapter 1. The protein was expressed and 
purified as the cadmium saturated form for stability. All purified protein solutions were 
evacuated and saturated with argon to impede cysteine oxidation. 
Preparation of apo-β-Metallothionein 
Cadmium was removed from the purified, isolated MT domains by acidifying the protein 
solutions to pH 2.7. The protein was desalted and buffer exchanged with argon-saturated 
deionized water, returned to neutral pH, and concentrated using Millipore Amicon Ultra-4 
centrifuge filter units (3 kDa MWCO). Protein concentrations of the final, pH-adjusted 
apo-β-MT solutions were determined by cadmium remetallation of small fractions of each 
protein monitored using UV-visible absorption (Cary 50, Varian Canada): ε250 values of 
Cd3-β-MT is 36000 M
-1 cm-1.22 Protein solutions were diluted to a final concentration of 
10 µM.  
Preparation of Rh2(OAc)4 solutions 
Stock solutions of 500 µM dirhodium(II) tetraacetate (Sigma-Aldrich) were freshly 
prepared in deionized water, evacuated and argon saturated. The MT cysteine 
concentration was determined and two-fold excess of Rh2(OAc)4 was added to the MT 
solution and mixed immediately prior to MS acquisition. The room-temperature UV-
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visible and circular dichroism (CD) spectra of the solutions were also measured following 
Rh2(OAc)4 saturation.  
Electrospray Ionization Mass Spectrometry, UV- Visible and Circular Dichroism 
Absorption 
A Bruker Micro-TOF II instrument (Bruker Daltonics, Toronto, ON) operated in positive 
ion mode was used to collect the data. NaI was used as an external calibrant. The settings 
are the same as those described in Chapter 1. The spectra were collected continuously 
over 1 hr and time slices were deconvoluted using the Maximum Entropy algorithm of the 
Bruker Compass DataAnalysis software package.  
A Cary 50 (Varian, Canada) was used to collect UV-visible absorption data from the 
visible region. A Jasco J810 spectropolarimeter was used to collect CD spectral data. The 
following scan parameters were used: step scan; range, 800-200 nm; data pitch, 1 nm; 
bandwidth, 0.5 nm; response, 1 s.  
Molecular Dynamics Calculations  
A minimized structure of the 38-residue Cd3-β-MT1a domain fragment was used 
(Scigress 6.0.0 MM3/MD method with augmented force field; Fujitsu Poland) to test if 
the Rh2
4+ core could be reasonably coordinated by 8 of the 9 cys of the β-MT1a. The 
three Cd2+ ions were deleted from the original structure and the Rh2
4+ core inserted using 
cysteine thiolate connections that were in close proximity to the 8 x/y ligand positions on 
the Rh2
4+ core. The alignment of the core was locked to stop rotation about the Rh-Rh 
bond. The molecular dynamics calculation was carried out for 200 ps at an average 
temperature of 355 K with 2 fs steps using a dielectric of 78.5. The initial structure 
relaxed immediately then was stable. 
4.3 Results 
ESI mass spectra were recorded continuously over 60 min following the mixing of 
(Rh2(OAc)4) with apo-β-MT in water. Six representative mass spectra extracted at 
different times from the 60 minute collection are shown in Figure 4-1. The spectral data 
were averaged over 15 seconds meaning that the average data point time is 7.5 s from the 
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start of the averaging in each spectrum resulting in data at 7.5, 37.5, 52.5, 67.5, 95.0 and 
127.5 s.  
Apo-β-MT is recognizable at a mass of ~3751 Da (track A), with the metallated species 
resulting in a series of higher mass species (tracks D-H). The metallated Rh2-β-MT has a 
mass of ~3952 Da (track D), with each Rh replacing four of the cysteine thiol protons, 
which, we propose, results in an octahedral geometry for each Rh(II) in the dirhodium 
core, retaining its Rh-Rh bond. The remarkable feature of this binding reaction is that the 
data show, in sequence, the systematic removal of each of the four acetate groups, whose 
mass initially starts at ~4193 Da (track H) and with each acetate removal being noted at 
peaks M = ~4136 (track G), 4081 (track F), and 4016 Da (track E), respectively. The 
released acetates in solution likely form surface adducts to positively charged amino acids 
(such as lysine) in the remaining MT, with these adducted species identified by a mass 
difference of 59 Da, and in proportional amount to the formation of Rh2-β-MT. There was 
no other source of acetate in the solution. The time-dependent data indicate that loss of 
the acetates is faster than the initial interaction because the partially-ligated Rh-MT 
complexes with 2, 3 or 4 acetates are in very low proportional concentration (tracks F-H) 
compared with the mono-acetate and Rh2
4+ core (track D). The overall binding rate can be 
seen from the decline in apo-β-MT abundance. As the Rh2
4+ core binds to the MT, the 
remaining apo-β-MT diminishes so that by 127.5 s almost none remains (tracks A-C). 
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Figure 4-1 Deconvoluted time-dependent ESI-mass spectra recorded following the 
mixing of apo-β-MT with excess Rh2(OAc)4 at pH 7.3. 
The vertical axis shows the normalized intensity; the horizontal axis shows the mass in 
Da. Data were averaged for 15 seconds starting at 0, 30, 45, 60, 90 and 120 s from a 
data set collected over 60 minutes. The apo-β-MT is marked in track A, the final product 
with the Rh2
4+ bound is marked by track D. Track identifiers: A) Apo-β-MT; mass 3751. 
B) Apo(OAc)1-β-MT; 3811. C) Apo(OAc)2-β-MT; 3875. D) Rh2-β-MT; 3951. E) 
Rh2(OAc)1-β-MT; 4013. F) Rh2(OAc)2-β-MT; 4075. G) Rh2(OAc)3-β-MT; 4136. H) 
Rh2(OAc)4-β-MT; 4192. Reproduced from D. L. Wong and M. J. Stillman, with 
permission from the Royal Society of Chemistry. 23 
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Figure 4-2 Absorption and CD spectra of the reaction of Rh2(OAc)4 and β-MT 
UV-visible absorption spectra (A) and circular dichroism spectra (B) of a 55 µM 
Rh2(OAc)4 solution in water with 0.5 and 1.0 mol. eq. of apo-β-MT added. Figure 4-2A. 
Spectral assignments: λA = 350 nm; σ (H2O) → σ*(Rh2). λB = 455 nm; π* (Rh2) → σ*(Rh-
O). λC = 580 nm; π* (Rh2) → σ*(Rh2). λD = 350 nm; σ (S) → σ*(Rh2). Figure 4-2B. 
Spectral assignments: λ1 = 255 nm, a new band appearing upon Rh2(OAc)4 binding. 
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Reproduced from D. L. Wong and M. J. Stillman, with permission from the Royal Society 
of Chemistry.23 
The UV-visible absorption spectra recorded with 0.5 and 1 mol. eq. of Rh2(OAc)4 added 
to the apo-β-MT showed appearance of bands near 3250 nm associated with a change in 
color from blue to yellow (Figure 4-2A). The Rh-Rh metal-metal bond was indicated by 
the band near 580 nm that only slightly blue shifted, as reported by others regarding 
rhodium axial coordination by solvents.18 
The circular dichroism spectra show a new band forming near 255 nm that only appears 
as a result of the protein binding to the Rh2(OAc)4 (Figure 4-2B). 
The ESI-mass spectral data together with the absorption spectral data, support our 
proposal that the Rh2(OAc)4 complex is bound as the Rh2
4+ core after each of the acetate 
bridging ligands is released and replaced by pairs of cysteinyl thiolates from the MT. In 
this mechanism, the thiolates displace the acetates stepwise, allowing the Rh-Rh bond to 
survive. However, the proposal does require a test of whether the Rh2
4+ core could exist 
within the peptide using a reasonable folding motif achievable from the 9 cysteines of the 
apo-β-MT fragment. To test this, an energy minimized structure of Cd3β-MT1a was used 
to establish a typical host volume.24 Using the Rh2(OAc)4 complex structure as a starting 
point, the deleted 3 Cd2+ ions in the protein binding site and inserted the Rh2
4+ core 
aligned by the acetates. The alignment was locked as the MM3 system has no information 
about the electronic structure of the Rh2
4+ metal-metal bond requirement. The 8 
coordination points for the 8 x/y aligned thiolate ligands are defined in the electronic 
structure as being eclipsed. There are two further z-axis coordination points frequently 
used by solvents.18 The cysteinyl thiolate alignments following deletion of the three Cd2+ 
ions were used to guide bond formation to the Rh2
4+ core. The MD calculation trajectory 
showed that the peptide backbone realigned within 10 ps, indicating that the Rh2
4+ core 
required very little rearrangement to use the volume previously occupied by the 3 Cd2+ 
ions. Figure 4-3 shows the space filling representation and the ribbon alignment of the 
orientation at 200 ps. No significant change in the energy was observed for over 170 ps. 
The ribbon (Figure 4-3, right) shows that the peptide encapsulates the Rh2
4+ core. 
Emission data from Cu+ binding studies to metallothioneins support the proposal that 
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when the MT peptide binds using all the cysteines in a cluster that there is little access to 
the solvent,25 so water was not included in the binding region. The ribbon depiction of the 
peptide orientation in Cd3-β-MT was virtually the same as shown in Figure 4-3, 
confirming that replacement of the three Cd2+ ions by the Rh2
4+ core did not require major 
reorientation of the cysteines. The structure in Figure 4-3 is a hypothetical model 
designed to indicate the possible conformational changes necessary for the 38-amino acid, 
9 cysteine apo-β-MT to bind the Rh2
4+ core.  
 
Figure 4-3 Molecular Dynamics structure for Rh2-bound β-MT. 
Results of a molecular dynamics calculation where the Rh2
4+ core was inserted into the 
apo-β-MT1a binding site. The calculation was carried out for 200 ps at an average 
temperature of 355 K with a dielectric constant set to the 78.5 of water. The yellow 
spheres are cysteinyl thiolates while the white spheres (right) are the two Rh2+ ions. The 
intention of this calculation was to examine if the Rh2
4+ core could bind using 8 cys S 
without major change to the normal conformation. Reproduced from D. L. Wong and M. 
J. Stillman, with permission from the Royal Society of Chemistry. 23 
4.4 Conclusion 
This Chapter introduces investigations of the simplest dirhodium carboxylate, 
dirhodium(II) tetraacetate (Rh2(OAc)4), and its deconstruction in vitro by the human 
MT1a β-domain fragment of the metal-defence protein, MT. Metallothioneins have a 
well-documented chemistry of scavenging toxic metals that enter the cell. Our group and 
others have suggested that this property can contribute to greatly reduced efficacies for 
metal-based drugs. In the reaction described in this Chapter, the four metal-coordinated 
acetates are replaced stepwise by the more aggressive cysteinyl thiolates of the 
metallothionein. The protein wraps around the rhodium complex, maintaining the Rh-Rh 
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bond, bringing the cysteinyl thiolates closer to the interior core. To further investigate this 
metallation mechanism, studies continue with the full length, two-domain MT, in the 
following Chapter. 
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Chapter 5 
5 Metallothionein: an Aggressive Scavenger– The 
Metabolism of Rhodium(II) Tetraacetate (Rh2(OAc)4)* 
5.1 Heavy Metal Pollution from Anthropogenic Sources 
With the turn of the millennium, sales of consumer products produced with xenobiotic 
metallic elements have increased globally. Examples of these metals are: Ti, Pb, Ni, and 
Sn in cosmetics,1-6 Sn, Ni, and rare earth elements in electronic cigarettes,7-9 Cd in 
batteries, Hg in lamps, As in older microchips, and Platinum Group Metals (PGM’s, Pd, 
Pt, Rh, Ru, Os, Ir) in jewelry , and widely in the automotive industry.10-13 In addition, 
occupational exposure and environmental pollution can occur as a direct result of metal 
mining and refining.14, 15 These metals have no known physiological role, and with 
multiple routes of exposure, pose an unknown and largely unavoidable risk to human 
health. In the case of metallotherapeutics incorporating a range of rare metals (e.g. Au, 
Ag, Pt, Pd, Rh, and others), humans are directly exposed to acute concentrations. This 
increase in mobilization of these rare metals results in widespread human exposure, 
spreading from concentrated points and diffusing across the globe.  
The physiological response to these rare metals relies on the body’s own protective 
response mechanisms to metals. Because of their nucleophilicity and metal scavenging 
ability, biological thiols like metallothioneins (MTs) and glutathione are involved in toxic 
metal resistance, whether directly or due to a downstream response triggered by metal 
exposure. Reports of these platinum group metals in urban environments and prevalence 
and accumulation in marine life near industrial runoff indicates the impending 
omnipresence and perturbance to daily life.16, 17 This may be reflected in the increased 
expression of MTs and the documented accumulation of PGMs initiated in a wide variety 
of marine, shellfish, seaweed and plant MTs, to changes in mineral environment. This 
metal accumulation in organisms can be used as a natural marker for environmental 
toxicity.18-22 Regardless, while the introduction of such foreign metals trigger an apparent 
defensive response, renal toxicity can still occur (e.g. Cd in MT, Itai-Itai disease). The 
long-term storage of Cd by MT in the kidneys raises the question about whether these 
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xenobiotic metals will follow this pathway and bioaccumulate. For instance, platinum 
levels persist in the blood of women many years after their anticancer treatment.23  
As a consequence of this growing threat, it is important to understand the reaction of MTs 
with metals that humans and the natural world are now becoming increasingly exposed to. 
5.2 Exposure to Xenobiotic Metals from Therapeutics 
Since the discovery of platinum based anti-cancer drugs, developed chemoresistance in 
certain cancer types has been associated with increased expression of MT.24-27 MTs can 
interfere with a chemotherapeutic agent before it can reach its desired target, or act in 
converse to its desired cytotoxic effect. Cellular thiols like glutathione and MT are 
correlated to expression in resistant cancers, although their direct causation to resistance 
is unclear. MT expression levels are affected by a variety of stress inducers18, 25, 27-37 
including metal therapeutics, e.g. Au and Ag nanoparticles,38-40 and Pd, Pt, and Rh 
particles airborne through mining and industrial exposure.15 Cisplatin resistance and its 
relationship with MT’s aggressive metal binding behavior is the focus of much 
research.41-46 MTs are rich in highly reactive cysteine thiolates, which are suspected of 
being involved in the interference of platinum drugs. The many stress inducers of MT 
may easily cause upregulation of the protein following a dosage of platinum drugs. This 
trend has been identified by looking at MT mRNA expression and cellular MT levels in a 
variety of cisplatin resistant cell lines compared to their parent lines.24, 38, 45, 46 In 
medicine, new metallocomplexes show promising results in clinical trials, many of them 
consisting of PGMs and related metals.47 This present study focuses on this new realm of 
“non-traditional metallation” to draw attention to the mechanism behind the metallation 
of xenobiotic metals to mammalian metallothioneins. 
In this study, the global issue is the specific exposure of humans to a xenobiotic metal 
complex, where the clearest examples come from well-defined cytotoxic agents. The anti-
tumor agent and common chemical catalyst dirhodium(II) tetraacetate (Rh2(OAc)4) and 
its binding reactions to MT is the focus of the study described here. 
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5.3 Cytotoxic Dirhodium(II) Tetraacetate as a Model 
Metal Complex  
The discovery of cisplatin in 1978 opened exploration of the cytotoxicity of metal-based 
complexes for cancer treatment.48-50As described in Chapter 4, dirhodium(II) carboxylates 
are one of the classes of complexes of interest for their therapeutic and cytotoxic 
activity.51-53 Similar to cisplatin, these dimeric compounds also cause disruption of DNA 
replication and transcription, as well as creating DNA adducts and crosslinking.54-58 Most 
notably, these anti-tumor dirhodium complexes irreversibly bind free cysteinyl thiols, 
inhibiting thiol-dependent enzymes.51, 53, 59 Unlike other amino acids, the reaction of 
cysteines with these rhodium complexes results in a breakdown of the carboxylate cage 
structure by thiolate replacement of the O donor ligands.52, 58 Their sensitivity to sulfur 
coordination from cysteines in biomolecular targets means rhodium(II) carboxylates can 
also act as radiosensitizers by depleting cellular thiol sources, lowering the cell’s ability 
to respond to oxidative stress.59, 60 Current research has extended the applications of 
rhodium compounds to medical imaging, radioactive isotope therapy, photodynamic 
therapy, and protein labelling, but the significant antitumor characteristics of these 
rhodium complexes remain of great interest. 59, 60 
 
Figure 5-1 Ball-and-stick representation of (Rh2(OAc)4). 
Teal represents Rh, red represents O, grey represents C, white represents H. Reproduced 
from D. L. Wong and M. J. Stillman. Copyright 2018 American Chemical Society.61  
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Dirhodium(II) tetraacetate (Rh2(OAc)4), Figure 5-1, is the simplest of the dirhodium(II) 
carboxylates. Rh2(OAc)4 is used widely as a synthetic catalyst in many organic reactions, 
a unique form of occupational exposure. It is used in many chemical synthesis reactions, 
such as catalysis of C-H, X-H insertion, and aromatic cycloaddition, with a relatively high 
solubility in aqueous solutions compared to Cu(II) acetate. Rh2(OAc)4 and related 
dirhodium complexes have demonstrated significant anti-tumor activity; Rh2(OAc)4 
administered to mice dramatically decreased the size of tumors.51-53 Tumor growth was 
inhibited by the interruption of DNA replication and protein transcription. Exhaled 14CO2 
from 14C labelled Rh2(OAc)4 indicated that the complex was decomposed within the 
organism. Urine analysis showed ~1% of the Rh was excreted, indicating that the 
remaining rhodium irreversibly bound to its target and accumulated. However, the exact 
target of Rh2(OAc)4 activity is unknown, and toxic renal side effects were high.
51-53  
Because these dirhodium(II) carboxylates are uniquely sensitive to cysteine binding, MT 
is a likely binding target. Another major cellular thiol, glutathione, was found to rapidly 
form adducts with Rh2(OAc)4 both aerobically and anaearobically.
62, 63 If cytotoxicity by 
Rh2(OAc)4 involves DNA adduct formation, or inhibition of specific enzymes, then MT 
would be acting as a pre-target interference source. Alternatively, if the cytotoxicity 
involves the depletion of cellular thiols, then MT would be the desired target. This can 
provide beneficial information for the design of future chemotherapeutics.  
5.4 Scope and Application of Results 
To prepare for the inevitable increased exposure of humans to xenobiotic metal 
complexes from many sources, it is of vital importance to understand their physiological 
chemistry. For the success of metal-based chemotherapeutics, it is imperative to 
understand drug metabolism and resistance mechanisms. The strong correlation between 
cellular thiol induction and chemoresistance requires the study of the metal binding 
pathways to the key thiol molecules, especially ubiquitous metallothioneins. In this 
Chapter, the work from Chapter 4 is extended. The systematic and rapid deconstruction of 
the tetraacetate ligands in Rh2(OAc)4, and the robust Rh2 binding by the 20 cysteines in 
apo-βαMT is reported. The metallation speciation was modelled using semi-quantitative 
electrospray ionization mass spectrometry (ESI-MS) data to obtain relative Kf values. The 
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results and their impact on the cytotoxic and environmental effects of the bioconjugation 
of MT and dirhodium complexes are discussed. 
5.5 Experimental Methods 
Preparation of Apo-MT 
Recombinant human metallothionein 1a (rh-βαMT 1a, referred when used in this study as 
“MT” unless specified otherwise) was overexpressed with an S-tag in Escherichia coli. 
The S-tag was removed and the MT purified according to previously described 
methods.64, 65 The cleaved construct has the sequence GSMGKAAAACSCATGGSCT 
CTGSCKCKECKCNSCKKSCCSCCPMSCAKCAQGCVCKGASEKCSCCAKKAAAA. 
This construct contains two mutations when compared with the human MT 1A sequence 
archived on UniProt protein database, T27N and I51V. These mutations are commonly 
found in other mammalian MTs including other human isoforms (as seen in Chapter 1, 
Figure 1-5), and are not involved in metallation reactions of the cysteinyl thiolates.66 The 
purified Cd-bound MT1a was demetallated by acidification (pH<2) and the resulting free 
Cd(II) in solution were removed by centrifugal filtration (Amicon Ultra-4 3000 Da 
MWCO). Protein concentration was calculated by remetallating a measured aliquot with 
CdSO4 and determining the Amax at the 250 nm shoulder characteristic of the LMCT band 
of Cd-S bonds (ε = 89,000 L mol-1 cm-1).67 
UV-visible absorption and circular dichroism spectroscopy 
UV-visible absorption and circular dichroism (CD) spectral data were acquired on a Cary 
UV Bio50 and JASCO J-810 Spectropolarimeter, respectively. Solutions were evacuated 
and backfilled with Ar gas prior to data collection, and measured in a sealed, 1 cm x 1 cm 
quartz cuvette.  
ESI-MS Studies  
Solutions of Rh2(OAc)4 (Sigma Aldrich) were prepared in deoxygenated, argon aerated, 
DI water. Aliquots containing known molar equivalents were added to the apo-MT 
solution immediately prior to mass spectral data acquisition using a MicroTOF II (Bruker 
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Daltonics, Toronto). All solutions were at room temperature and thoroughly deaerated 
using vacuum evacuation followed by Ar saturation. NaI was used as the calibrant. 
Spectra were collected in positive ion mode, as a function of time following mixing. The 
settings used are described in Chapter 1. The averaged spectra and data analysis were 
carried out using the Maximum Entropy application in Bruker Data Analysis 4.2 program. 
The resulting spectral data were normalized and the dominant species identified by mass.  
Cysteine Modification by p-benzoquinone and n-ethyl maleimide 
10 mM stock solutions of p-benzoquinone (pBQ) and N-ethyl maleimide (NEM) were 
dissolved in 10% v/v methanol in water and the solution vials wrapped in aluminum foil 
to protect from photochemical degradation. Aliquots of the modifiers were added to 
protein samples containing Rh2, Rh4, and Rh6MT, and mass spectral data of the resulting 
products were obtained to identify the species present. The modifier was titrated to 
excess, until the mass spectra no longer changed between additions. 
Molecular Dynamics Models of Rh2MT, Rh4MT, and Rh6MT Structures 
Molecular modelling calculations were carried out using Scigress Version 6.0.0 (Fujitsu 
Poland Ltd.). Structures, modelling parameters and sequence information were adapted 
from previously reported Cd7MT and As6MT models to build the Rh2MT models.
64, 68, 69 
In brief, the Cd(II) ions were deleted and replaced with Rh(II) prior to Molecular 
Mechanics calculations (MM3). Molecular Dynamics calculations were carried out at 300 
K for 500 ps using the dielectric constant for water of 78.5. Metal thiolate structures in 
the alpha domain were based on bridging thiol arrangements in Cd7MT. 
Methodology 
Spectroscopic and mass spectral studies provide the identity of the binding moiety and 
detailed speciation data. The mass spectral data were simulated computationally to 
determine the stepwise equilibrium constants. Cysteine modification was used initially to 
determine the metallation stoichiometry by quantifying the number of cysteines not 
involved in binding the Rh2(OAc)4. However, these results directed the research focus 
towards understanding the protein structural changes in metallation, using molecular 
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dynamics modelling and mass spectral titrations under unfolded conditions. Altogether, 
these experiments fully document the metallation process by which xenobiotic 
dirhodium(II) tetraacetate is accumulated by MT. 
5.6 Results  
5.6.1 Metallation Reactions of MT with Rh2(OAc)4: Optical 
Spectroscopic Properties 
Figure 5-2, top, shows the UV-visible absorption spectral data for the titration of apo-MT 
with increasing mole equivalents of Rh2(OAc)4 added. Significantly, the UV-visible 
absorption data show an increased absorption at ~ 300 nm, corresponding to the well-
known cysteine S→Rh LMCT band. Similar absorption is also observed with glutathione, 
cysteine, methionine, and other biological thiols.62, 63, 70-74 This LMCT band is very strong 
and the transition from the blue of the metal solution to the yellow of the protein-bound 
product can be followed readily with the naked eye.  
The CD spectra in Figure 5-2, bottom, shows the titration of increasing mol. eq. of 
Rh2(OAc)4. The apo-MT spectra is shown in blue. Unlike the UV-visible absorption 
spectra, there is no significant change in the spectra with increasing Rh2(OAc)4. 
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Figure 5-2 Spectroscopic results of the Rh2(OAc)4 into MT titration 
UV-visible absorption (top) and circular dichroism (bottom) spectra for a titration with 
increasing molar equivalents of Rh2(OAc)4. The arrow indicates the direction of 
increased [Rh2(OAc)4]. The S→Rh LMCT band increases in absorbance at ca. 300 nm. 
Reproduced from D. L. Wong and M. J. Stillman. Copyright 2018 American Chemical 
Society.61 
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Figure 5-3 Initial deconstruction of Rh2(OAc)4 by apo-MT observed with ESI – MS. 
Stepwise addition of 0.0 to 1.0 mol. eq. of Rh2(OAc)4 to apo-MT. Major species are 
indicated by dashed lines: black for apo-MT, red for Rh2MT, blue for Rh4MT and green 
for species bound to at least one complete Rh2(OAc)4 molecule. Carboxymethylated MT 
species are mass shifted by ~ 60Da and are represented with a triangle. Reproduced from 
D. L. Wong and M. J. Stillman. Copyright 2018 American Chemical Society.61 
5.6.2 Initial Deconstruction of Rh2(OAc)4 by Apo-MT: Rapid 
Displacement of the Tetraacetate Ligands 
Figure 5-3 shows a series of ESI-mass spectra as a function of increasing molar ratio of 
Rh2(OAc)4:MT (from 0 to 1 mol. eq.). The data shown in Figure 5-3 provide a snapshot 
of speciation at very low molar ratios during the early stages of apo-MT (6875 Da) 
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metallation. As previously demonstrated with cisplatin,75 the apo-MT rapidly (within the 
dead time of the instrument) engulfs the incoming Rh2(OAc)4 molecule (441.99 Da), then 
systematically shreds the ligands from the metal complex until only the Rh-Rh core is 
sequestered within its thiolate binding site. The mass spectral data show the presence of 
the incoming complete complex, and the final isolated Rh2 core bound to the MT. The 
protein species with masses of 7316, 7517, and 7758 Da are representative of Rh2(OAc)4-
MT, Rh2(Rh2(OAc)4)-MT, and (Rh2(OAc)4)2-MT, respectively. These dominant masses 
gradually diminish as the reaction inside the MT proceeds, until the masses of the final 
products of Rh2MT and Rh4MT, at 7074 and 7273 Da, respectively, dominate. The 
change in mass coincides with the mass differences between the lost acetate moieties 
from the Rh2(OAc)4 bound protein species, where each acetate group has a mass of 59.04 
Da. 
5.6.3 Accumulation of Rh2: Formation of Rh2MT, Rh4MT, and 
Rh6MT  
The formation of Rh2-metallated MT products can be described by three stepwise 
bimolecular reactions, as shown in Scheme 5-1. Each metallation event begins with 
encapsulation of the whole molecule, followed by rapid deconstruction of the ligand 
structure to the dirhodium core. The metallation continues with formation of the ligand-
stripped Rh4MT (7273 Da) and Rh6MT (7473 Da). Figure 5-4 shows a series of stepwise 
metallation reactions as from 0.0 - 2.0 mol. eq. of Rh2(OAc)4 were added to apo-MT 
under equilibrium binding conditions. The major product of the reaction is Rh4MT, which 
forms rapidly, with a small amount of Rh6MT. 
 
Scheme 5-1 Proposed bimolecular, stepwise metallation reactions for Rh2(OAc)4 binding 
to apo-MT.  
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Figure 5-4 ESI mass spectral data recorded during the titration of apo-MT with aliquots 
0.0 to 2.0 mol. eq. Rh2(OAc)4. 
The major species are indicated by dashed lines: black for apo-MT; red for Rh2MT; blue 
for Rh4MT; and green for Rh6MT. The inset bar graphs on the right of each spectra 
shows simulated mass spectral data based on the model described in Figure 5-5, using Kf 
values in Table 5-1. Carboxymethylated MT species are mass shifted by ~ 60 Da and are 
represented with a triangle and are not included in the simulation. Reproduced from D. 
L. Wong and M. J. Stillman. Copyright 2018 American Chemical Society.61 
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Figure 5-5 Experimental and simulated speciation abundance 
Experimental mass spectral speciation abundance data (A, left) and simulated data (B, 
right) calculated from the fitted relative Kf values (Table 1). Reproduced from D. L. Wong 
and M. J. Stillman. Copyright 2018 American Chemical Society.61 
5.6.4 Modeling the Reaction: Determination of Relative Binding 
Constants (Kf) 
Using the Hyperquad Simulation Speciation (HYSS)75 software, the mass spectral 
abundances associated with these reactions were modelled based on the concentrations 
and mole equivalences of the Rh2(OAc)4 added, using the equations in Scheme 5-1. The 
three relative K values (shown in Table 5-1) were calculated so that the simulated model 
matched the experimental data, Figure 5-4. The calculated abundances were used to 
simulate the mass spectra as seen in the red bar graph Figure 5-4 insets. The simulated 
mass spectra closely match the experimental MS data over the course of the titration. 
Figure 5-5A shows the experimental speciation data extracted from Figure 5-4. The 
sequence of speciation clearly follows a typical non-cooperative metallation mechanism76 
in which Rh2MT forms, followed by Rh4MT, followed by Rh6MT. The fitted results, in 
Figure 5-5B, match the experimental data closely, and provide the relative binding 
constants as shown in Table 5-1.  
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Table 5-1 Relative equilibrium binding constants for the reaction of Rh2(OAc)4 with Apo-
MT 
MT(Rh2)n Log β Log Kf 
1 4.22 4.22 
2 7.22 3.00 
3 8.89 1.67 
 
Figure 5-6 ESI -mass spectral data of modified and unmodified mixed Rh2 metallated 
species 
(A): non-modified Rh2-, Rh4-, and Rh6-MT, represented by a triangle. (B): solution in (A) 
following addition of p-BQ. (C): non-modified Rh2-, Rh4-, and Rh6-MT, represented by a 
triangle. (D): solution in C following addition of NEM. The experimental data are shown 
in bar graph representation Persistent titrations to excess and long incubation times did 
not affect the resulting spectra indicating completed reaction. Rh2MT species shown in 
red, Rh4MT species in blue, and Rh6MT species in green. Reproduced from D. L. Wong 
and M. J. Stillman. Copyright 2018 American Chemical Society.61 
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The data in Figure 5-6 show modification of MT containing Rh2MT, Rh4MT, and Rh6MT 
by both pBQ (Figure 5-6, A, B, left half) and NEM (Figure 5-6, right half). The Rh2MT, 
Rh4MT, and Rh6MT spectra measured prior to modification are shown in Figure 5-6, top 
(A and C). In B and D, these same species are present (identified by triangles) even 
though excess modifier was added. Both sets of modified species (Figure 5-6, lower) 
display a variety of Normal distributed species, as shown in Figure 5-6 in bar graph 
format. The experimental mass spectral data is shown below in Figure 5-7, but is 
represented in bar graph format in Figure 5-6 for clarity. 
 
Figure 5-7 Mass spectral data of the alkylation of Rh2-bound MT 
ESI Mass spectral data collected for a mixture containing Rh2MT, Rh4MT, and Rh6MT 
(top left and top right) and their subsequence modification by pBQ (bottom left) and NEM 
(bottom right). Reproduced from D. L. Wong and M. J. Stillman. Copyright 2018 
American Chemical Society.61 
As described by Irvine et al, cysteine accessibility can be understood by the distribution 
of cysteine modified species.77 A Normal distribution represents statistically equal 
accessibility of the modifier to all available free cysteines. This means that the unbound 
cysteines are exposed. Therefore, the breadth or spread of the distribution tells us the 
number of available cysteines, and the shape of the distribution tells us if there is 
conformation specificity or equal accessibility of the free thiols. Figure 5-6B shows the 
distribution of the modified Rh2(BQ)xMT species (red bars). The data indicate the 
presence of two species, one with x = 0-8 free cysteines, and another with x = 10-15 free 
cysteines. This means that there are two distinct Rh2MT products: one coordinating the 
Rh2 with 12 cysteines, and the other coordinating the Rh2 with 5 cysteines. This is harder 
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to distinguish at increased concentrations as the abundancies of the two distributions 
overlap each other, Figure 5-6D. The steep rise of the modified Rh4(BQ)yMT (blue) also 
displays a Normal distribution with y = 0-7 free cysteines. The formation of a modified 
Rh6(BQ)zMT species with z = 0-4 free cysteines also can be observed (green). 
There is a small discrepancy between the number of modified cysteines observed using 
pBQ and NEM. This is likely due to the reaction occurring at physiological pH, at which 
pBQ is not as effective as NEM.78 Therefore, our conclusions about the number of free 
cysteines for the metallated MT is based on the greatest number of NEM-modified 
cysteines for each Rh-bound complex. 
5.6.5 Accumulation of Rh2(OAc)4 in αMT: Evidence for Structure-
Dependent Metallation 
Figure 5-8 shows the time-dependent metallation of the single domain apo-αMT fragment 
at low pH (<2) with Rh2(OAc)4. Over the time course of the reaction (44 minutes), 
species ranging from [Rh2(OAc)4]1-MT to [Rh2(OAc)4]6-MT are observed. This is 
completely different when compared with the results from the titration carried out at pH 
7.4 with the two-domain protein (Figure 5-4). 
These data show that the unfolded, loose structure caused by the high [H+] greatly 
increases cysteine accessibility to the incoming Rh2(OAc)4 in this single domain 
fragment. In the presence of excess Rh2(OAc)4, this manifests as two distinct reaction 
pathways: i) ligand replacement by thiolates following Rh2(OAc)4 binding, as described 
for the whole protein above, and ii) proposed axial coordination of Rh2(OAc)4 by 
cysteine. These two reaction pathways are outlined in Figure 5-8, right. The acidic 
conditions minimize the nucleophilicity of the cysteinyl thiols, and allow for the lower 
Cys:metal ratios to bind with metal ratios of up to 6 x Rh2(OAc)4. Despite the observation 
of this “supermetallation,” the cysteine replacement of the tetraacetates still occurs albeit 
slower than at physiological pH. 
In Figure 5-8, the key species identified are: apo-αMT, [Rh2(OAc)4]1-αMT, 
[Rh2(OAc)4]2-αMT, [Rh2(OAc)4]3-αMT, [Rh2(OAc)4]4-αMT, [Rh2(OAc)4]5-αMT, 
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[Rh2(OAc)4]6-αMT, Rh2[Rh2(OAc)4]1-αMT, Rh2[Rh2(OAc)4]2-αMT, Rh2[Rh2(OAc)4]3-
αMT, Rh2[Rh2(OAc4]4-αMT, Rh2[Rh2(OAc)4]5-αMT, Rh2MT, and Rh4MT. 
 
Figure 5-8 ESI mass spectral data of the low pH titration of Rh2(OAc)4 into αMT 
(Left) Time-dependent mass spectral data of apo-αMT at low pH (<2), recorded over 44 
minutes following addition excess Rh2(OAc) 4. Red arrows indicate mass shift resulting 
from the loss of (OAc)4. (Right) Labels for identifiable species in the mass spectral data 
and proposed formation pathways Reproduced from D. L. Wong and M. J. Stillman. 
Copyright 2018 American Chemical Society.61 
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5.6.6 3D Models: Cysteine Accessibility throughout Metallation 
Representative structures of apo-MT, Rh2MT, Rh4MT, and Rh6MT are shown in Figure 
5-9. Energy minimized geometries using MD for apo-MT, Rh2MT, Rh4MT, and Rh6MT 
were constructed in Scigress 6.0.0 and geometry optimized using Molecular Mechanics 
(MM3) prior to Molecular Dynamics (MD) calculations at 300 K for 500 ps. These 
structures are shown in ball and stick format in Figure 5-9 and in full page format along 
with H-bond mapping in Appendix C.  
The apo-MT model, Figure 5-9A, shows the structure of the non-metallated cysteines, 
and how MT orients itself with respect to metallation. The energy minimization of apo-
MT results in a compact globular structure, in accordance with mass spectral studies at 
physiological pH.79 The cysteine residues (-SH shown with yellow spheres in Figure 5-9) 
are oriented to the exterior when metal-free, but coalesce toward the interior of the 
protein when metal-bound. In the apo-MT structure, the backbone and cysteines arrange 
themselves in a similar fashion to a helix, with cysteines facing outward. This agrees with 
results from Irvine et al. and Rigby et al. that the cysteine solvent accessibility in the apo 
form facilitates metal binding.80-82 The driving force for organized structural formation in 
mammalian metallothioneins is the metal-induced folding with each sequential M-SCYS 
chelation event.80 Once bound to a metal, these cysteines become buried within the 
protein interior, shielding them from the cellular environment. The fully bound Rh6MT 
(Figure 5-9H, “Rh2β4αMT”) shows this clearly. The configuration of the peptide back 
bone shows that MT wraps around the metal core upon binding. This effect is observed in 
the partially metallated Rh2MT and Rh4MT structures as well, in Figure 5-9. When the 
Rh2 is bound to cysteines that nominally form a single domain (Figure 5-9, Rh2βMT, 
Rh2αMTI, Rh2αMTII, Rh4αMT), the metal-bound cysteines are buried, while the remaining 
metal-free cysteine maintain their external orientation. This reflects the globular protein 
structure seen in the apo-MT model, Figure 5-9A. However, these one-domain-bound 
MTs are fluxional and capable of further subsequent metallation. In contrast, for two-
domain metal binding, like in the Rh2β2αMTI, Rh2β2αMTII, and Rh6MT, a dumb-bell-like 
structure typical of M(II) ion metallation is obtained.83 When both domains are bound, the 
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cysteine accessibility is greatly diminished. This accounts for the lower abundance of the 
Rh6MT species in the mass spectral data.  
 
Figure 5-9 Energy minimized molecular dynamics models of apo-MT, Rh2MT, Rh4MT, 
and Rh6MT. 
Rh shown enlarged in teal, cysteines shown enlarged in yellow, C in gray, O in red, N in 
blue, H in white. Structures were constructed based on Cd7MT structures from previously 
reports,10, 64, 68 using Scigress 6.0.0.84 Details of the minimization are given in the text. 
Reproduced from D. L. Wong and M. J. Stillman. Copyright 2018 American Chemical 
Society.61 
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5.7 Discussion 
5.7.1 Chronic Presence of Anthropogenic Pt, Pd, Rh (PGM’s)  
Platinum group metals have no biological role, and little is known about their long-term 
toxicity. Pd and Rh are naturally found alongside metallic Pt, therefore, their 
contamination is often mobilized by the same routes. With the use of these metals in -
catalytic converters in automobiles (to reduce volatile organic components), airborne 
PGM particulate is becoming a widespread route of exposure. Higher concentrations of 
these PGM’s are related to higher traffic density.10, 13, 23, 85 Spreading from urban areas 
and carried by the winds, fine metal particulate (< 10 nm) enter the soil, water, and food 
chain, often being converted into inorganic complexes through ingestion, inhalation, or 
absorption through damaged skin.11, 13, 16, 86-90 Bacterial, organismal, and environmental 
transformations can convert inert metal species into reactive ones. With the number of 
automotive vehicles ever increasing, the biofixation of these metals makes them more 
bioavailable than ever before. The accumulation and biological effects of subclinical 
levels of these PGM’s (in public areas like playgrounds, tramways, narrow streets) 
particularly in cities with dense populations and heavy traffic are of a concern for the 
future.10, 12, 13 
There are already several examples of anthropogenic PGMs affecting waterways and 
corresponding ecosystems near urban regions, detectable in Arctic ice cores, with 
documented metal levels increasing over several decades.88-92 Varying soil and water 
conditions, such as pH, N and S availability, and temperature and precipitation levels can 
affect metal solubility, thereby accelerating permeation through the food chain.93 
Bacterial resistance and introduction of metals into the food chain results by 
biomethylation.94 The Hg cycle, for example, causes bioaccumulation in fish and shellfish 
species, which magnifies through larger predators.95 
The cytotoxicity of these metals has been demonstrated in current and potential cancer 
metallodrugs, showing the danger of exposure in the form of their side effects. Although 
the long-term effects of sub-clinical levels of exposure are relatively unknown, it is 
concerning especially for vulnerable populations, like children.96 These soft, heavy metals 
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are more likely to be accumulated by coordination with biological thiols and exhibit long 
biological half times, increasing the risk of nephrotoxicity. While other lighter or 
physiologically essential metals are recycled or excreted through the urine rapidly, heavy 
metals like Pt, and Cd can remain in the body for decades.  
 
5.7.2 Binding Reactions of MT with Rh2(OAc)4: Explaining the 
Spectroscopic Results 
As expected, the replacement of the acetate groups with cysteine thiols resulted in a 
strong absorbance at ~ 300 nm (Figure 5-2, top). This agrees with other spectroscopic 
studies involving biological thiols (cys, GSH for e.g.62, 63, 72-74, 97, 98) and confirms the 
cysteine thiol as the binding moiety involved in the Rh2 complexation. 
In the case of the CD spectral data (Figure 5-2, bottom), it is surprising that no significant 
spectral intensities are observed during the titration of the full apo-MT. However, the lack 
of a distinct CD spectral intensity is likely due to the overlap from the presence of several 
structurally different species because the mass spectral and structural cysteine 
modification data indicate that the Rh2(OAc)4 has bound to the apo-MT. This contrast the 
results previously reported for Rh2(OAc)4 binding to the β-domain fragment, in which a 
single product is formed in a 1:1 fashion, producing a strong CD signal, as seen in 
Chapter 4.70 
5.7.3 Metallothionein: Non-Traditional Metallation and Metal 
Complex Deconstruction is Evident from the Mass Spectra 
Mass spectrometry is especially helpful in identifying biological targets.99 ESI-MS is a 
soft ionizing, high resolution, solution-phase technique that is ideally suited for tracking 
the metallation status of MT. The advantage of using ESI-MS is that it allows for 
confirmation of the presence of intermediate states in real time. These versatile properties 
have been widely exploited in Native ESI-MS,100 allowing detailed kinetic and 
equilibrium studies of the metallation of MTs.65, 70, 76, 83, 100-109 The stoichiometric and 
structural information provided by the ESI method is particularly important for MT 
because the lack of typical protein features and its high sensitivity to oxidation makes 
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MT’s protein structure difficult to observe with crystallography, NMR, or other structure 
elucidating methods. 
The conditions for cooperative and non-cooperative bimolecular metallation of Zn(II), 
Cd(II), and Cu(I) to MT have been studied with consistent stoichiometric ratios identified 
primarily using ESI-MS, including traditional metallation to form stable cluster states 
M(I)6S9, M(II)3S9 M(II)4S11.
65, 76, 83, 102-104, 110, 111 Binding coefficients can be accurately 
extracted from these data. The observed kinetic binding of Pt(II)1-7 from cisplatin was 
first determined by chromatographic methods,112 which were then enhanced by our ESI-
MS modelling methods,41 a similar methodology to that applied to this current dirhodium 
study.  
The metallation of Rh2(OAc)4 to apo-MT can be categorized as non-traditional 
metallation, because the binding of MT involves chelating Rh2(OAc)4 followed by 
disassembly of the initial metal complex by displacement of the original coordinated 
ligands. ESI-MS has been used to observe this destructive effect MT has with cisplatin, 
and Ru-based arene complexes41 This step-wise, sequential deconstruction of Rh2(OAc)4 
has been reported previously with the single apo-β-domain fragment of MT1a. Under 
those conditions, one discernible product (Rh2MT) is formed in a linear fashion.
70 In this 
present ESI-MS study, the full, two-domain protein has a higher sulfur availability (20 
cysteines), which greatly increases the rate of reaction and the number of possible 
conformers (Rh2MT, Rh4MT, Rh6MT) that can form. The ligand loss of the coordinating 
acetates and accumulation of the sequestered metal species shows that Rh2(OAc)4 does 
not survive intact when bound to MT. This emphasizes the destructive effect MTs can 
have on both chemotherapeutically related complexes and xenobiotic metals from 
environmental sources.  
The presence of metal-thiolate (Zn(II), Cd(II), Cu(I)) clusters that form in higher ratios of 
these metals make MTs resistant to trypsin digestion.105 However, it should be noted that 
As(III) binding is not considered to involve cluster formation. The As(III) bound to the 
isolated MT fragments form M(III)3S9 (α-domain), and M(III)3S9 (β-domain), and to the 
full protein forms M(III)6S18,
111 which means that the MT peptide flexibly accommodates 
a completely different style of binding than reported for the Group 12 M(II) ions. The 
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results of this Chapter show Rh2 binding also does not follow traditional cluster formation 
of Zn(II), Cd(II), and Cu(I), instead binding to MT in a rigid manner. MT is unable to 
perform its usual metal relocation, as described in Chart 5-1. Therefore, a novel MT 
binding mode is now reported for Rh2 in this study, which enforces the difference 
between the metallation of complexes and metal ions by the protein.  
 
Chart 5-1 Proposed pathway for metallation of βαMT 1a by Rh2(OAc)4 at physiological 
pH. 
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The two pathways shown apply to different configurations. Pathway A: Rh2MT binds an 
additional Rh2(OAc)4 which is deconstructed, forming Rh4MT of configuration I. No 
further metallation occurs at this point. Pathway B: Rh2MT binds an additional 
Rh2(OAc)4 which is deconstructed, forming Rh4MT involving a proposed alternate 
configuration II. This form can proceed to bind a further Rh2(OAc)4, producing Rh6MT. 
Reproduced from D. L. Wong and M. J. Stillman. Copyright 2018 American Chemical 
Society.61 
5.7.4 Structure-Dependent Metallation of Metallothioneins: Rigid 
Rh2 Binding and Comparison of Binding Constants 
The 2° and 3° structure of MT is only defined by metallation,80 as it exhibits no 2° 
structural elements or aromatic residues. A broad distribution of metallated and metal-free 
MT species exist in the cell.65, 83, 103, 104, 113-115 Despite the sensitivity of the free cysteines 
to oxidation, fluorescence labelling has demonstrated the presence of metal free apo-MT 
in roughly equal quantities to holo-Zn-MT, both in the oxidized and reduced form.116 This 
confirms that metallation of MT is a post-translational modification that can only occur 
once the protein is fully synthesized, due to the cross-linking nature of metal-cysteine 
coordination that forms the metal-thiolate clusters. To better understand the metallation 
reaction, the fully demetallated apo-MT is used as the model for the partially metallated 
MTs expected in vivo.  
Metal binding to MT is generally fluxional such that the metal ions can move from site to 
site in search of the lowest thermodynamic product (for example, the well-known change 
in Cu(I)-MT emission signal when Cu(I) is titrated into Zn-MT 1A or Zn-MT 2A).117 In 
the case of the dimeric rhodium binding, the bound cysteines form multiple metallated 
species (Chart 1). The orientation of the initial metal binding in relation to the MT 
cysteines defines how the metallation proceeds. Due to the decreased abundance of 
Rh4MT and Rh6MT, the domain location and formation of Rh2MT determines whether 
the metallation continue to Rh6MT. The two distributions for the Rh2(BQ)xMT modified 
speciation data reflect these products. The decrease in relative log Kf’s demonstrates its 
rigidity as metallation progresses (Table 5-1). Previous work with the single β domain 
fragment shows that the β-domain accommodates 1 Rh2 moeity.
70 The 11 cysteines of the 
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alpha domain can accommodate the remaining 2Rh2 if metallated efficiently (Chart 5-1, 
right pathway B). If not, the cysteines become too tangled to accommodate further metals 
(Chart 5-1, left pathway A). 
It is evident that the magnitude of log Kf’s cannot be directly compared between 
chemically different metals because of both different binding geometries, and the 
presence of competitive coordinating ligands. A comparison can only be made 
meaningfully between isomorphous metals. Due to the fluxional nature of the 20 cysteine 
thiols in MTs, metals with different oxidation states can form vastly different binding 
geometries. Just as Zn metallation of MT differs from Cd metallation, free metal ion 
accumulation in MT cannot be compared to the deconstructive process that MTs exert on 
ligated metal complexes. Complex deconstruction cannot be included in these values, as 
these are the final, observed, relative binding constants. This is important in comparing 
values, because this emphasizes the versatile nature of MT, in that there is no consistent 
metal binding site across metal families. 
5.7.5 Solvent-Cysteine Accessibility and Protein Flexibility 
throughout Metallation 
Typically, protein structural information can be obtained by analyzing the charge state 
distribution patterns in the mass spectral data. Due to the small size of MTs, this method 
is not as effective, especially to probe the apo-protein or partially metallated states. More 
recently, however, structural information about MT has been obtained through the 
reaction profiles of cysteine modifiers that take advantage of MT’s cysteine rich structure. 
p-Benzoquinone (pBQ) and N-ethyl maleimide (NEM) are organic agents capable of 
binding covalently with free thiols, as shown in Scheme 5-2. Similarly to Ellman’s 
Reagent (5,5′-dithiobis(2-nitrobenzoic acid), DTNB), this irreversible binding permits 
quantification of free thiols.77, 78, 103, 111, 118 This is observed as a predictable mass change, 
but in addition with respect to MT and its 20 cysteines, the modified speciation 
distribution can also provide information about the solvent accessibility of the cysteines.78 
This technique has been used to understand metallation of apo-MT through partially 
metallated and fully metallated Cu6MT, Cu13MT, Cu20MT, and As6MT.
65, 103 
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Scheme 5-2 Structure and reaction mechanism involved in the formation of covalent 
bonds between cysteine and modifiers pBQ (A, top) and NEM (B, bottom). Reproduced 
from D. L. Wong and M. J. Stillman. Copyright 2018 American Chemical Society.61 
In this present study, both pBQ and NEM are used in conjunction with mass spectrometry 
to quantify the number of free cysteines and to probe the surface structure and the solvent 
accessibility of the partially metallated states of Rh2MT, Rh4MT, and Rh6MT. Structural 
characteristics can be inferred from the reaction profile of modification observed in the 
mass spectral data.77 As expected, the higher metallated Rh4 and Rh6 bound MT shows 
less solvent accessibility because of the lower spread of the p(BQ)-modified species. The 
most solvent accessible species, Rh2MT, shows two distinct distributions, indicating that 
two metallated states are created. From the change in intensity for the higher metallated 
states, we can infer that only one of the observed Rh2MT species is capable of further 
metallation, as described pictorially in Chart 5-1. This rigidity is reflected again with the 
lowered abundance of Rh4MT and Rh6MT, and in the decrease of the relative log Kf 
values showing that progressive metallation is less favorable.  
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3D structures constructed using MM/MD modelling techniques from previously reported 
AsMT119, 120 and Cd-MT64, 68 metallated forms were adapted to examine the possible 
metal thiolate constructs MT may adopt when bound to dirhodium cores. The absence of 
aromatic and hydrophobic residues, and the absence of mean that the driving force for 
protein folding is the cross-linking that results from the metallation of the cysteines, 
stabilized by hydrogen bond formation. As the cysteine modification results and the MD 
structures indicate, metal-free cysteine thiolates are found to be solvent accessible,79 
while holo cysteines are buried within the protein structure. MD calculations on the holo-
Rh6MT shows no change in the conformational geometry, demonstrating the holo-MT’s 
rigid status. 
The low pH experiment shows that while the unfolded, 9 cysteine apo-αMT can bind to 
the Rh2(OAc)4, it is unable to effectively displace the coordinating ligands of the 
complex. Instead, the unfolded peptide quickly binds to 1-6 Rh2(OAc)4 species Figure 
5-8), which occupies and locks the cysteine thiolates from other reactivity. Significantly, 
the MS data recorded at pH<2 demonstrates that Rh2(OAc)4 has a strong binding affinity, 
surpassing that of Cd, which is completely demetallated from MT at this pH. These low 
physiological pH, in which the more folded MT structure can orient its cysteines to 
displace the coordinated ligands more effectively than the unfolded protein. 
The unusual malleability of MT, first reported for As(III) binding,111 is clearly an 
additional characteristic property of MT. The many species seen in the Rh2-binding mass 
spectral data imply multiple coordination possibilities for metal binding. This suggests 
that the “magic numbers” concept83 prevalent in the literature does not apply to transition 
metal complexes.  
The data reported here support the findings in Chapter 2 that the initial, intrinsically 
disordered, native MT structure at physiological pH can flexibly entrap metal complexes 
and is a necessary conformation to further react, deconstruct, and isolate the metal for 
storage. 
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5.8 Conclusions 
This Chapter reports the reaction of a xenobiotic complex with MT as a test of the 
possible chelation properties of MTs with transition metal complexes. Rh2(OAc)4, a 
robust synthetic catalyst, binds intact to the metal-free apo-MT. The tetraacetate ligands 
are rapidly removed upon binding by the folded MT at physiological pH, in a manner 
reported previously for cisplatin. The initial reaction of the apo-MT involves the 
displacement of tetraacetate groups by the cysteinyl thiolates. Where the first Rh2 binds in 
the protein, which domain, governs the remaining space in which metallation can 
continue. This intermediate state can then proceed towards two structures, one of which 
allows the metallation of a third dirhodium moiety, forming Rh6MT, the other pathway 
stops at Rh4MT. These branching pathways were determined using complementary 
techniques of cysteine modification and mass spectrometry, together providing speciation 
data for equilibrium reaction modelling.  
The increase in global exposure to anthropogenic xenobiotic metals demands updated 
understanding of the metabolic effects caused. Rh and PGMs are known to exert 
cytotoxic and nephrotoxic activity, through metabolic process that can increase the 
bioavailability. The experiments in this Thesis demonstrate the ease with which biological 
structures can greatly change the chemical activity of rhodium. A metal’s persistence in 
ever changing chemical forms emphasizes the need for long-term study and caution for 
the continued utilization of these elements for human health. 
Finally, of concern, the long term accumulation and storage of PGM’s can provoke 
chronic toxic effects. Cd-bound MT has a reported half-life in the kidneys exceeding 
twenty years.121 Due to the firm and rigid binding of Rh2(OAc)4 to MT, Rh would be 
expected to accumulate in a similarly dangerous manner. The heavy and widespread use 
of PGM’s pose a risk that cannot be ignored, as history would remind us with the use of 
lead in gasoline and paints causing widespread toxic effects. This long-term storage is 
also applicable for these xenobiotic metals. The bioaccumulation of these metals can pose 
a significant health risk in the future. 
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Chapter 6 
6 Glutathione Binding to Dirhodium(II) Tetraacetate: a 
Spectroscopic, Mass Spectral and Computational Study 
of an Anti-Tumor Compound Bound to a Model Thiol* 
6.1 Introduction 
Intracellular thiols play an important role in metabolism.1 Non-protein, sulfhydryl 
compounds aid in protection against oxidation, as well as in the safe detoxification of 
harmful or foreign agents through thioether formation.1-4 This latter property may 
substantially reduce the efficacy of drug delivery pathways and, subsequently, the success 
of a drug, which can lead to drug resistance.5-11 In particular, thiol-based resistance can be 
deleterious for metal-based chemotherapeutics, as the electron-rich thiolate favours 
binding to the soft, d-block metals commonly used in such pharmaceuticals, for example, 
Pt(II), and Au(I).10-12 
Glutathione (GSH) is a tripeptide that is required in many metabolic cycles and is vital in 
cellular defence because of its cysteine thiol (Figure 6-1A).1, 2, 6, 9, 13 Intracellular 
concentrations of GSH can reach up to 10 mM, with its regulation and synthesis tightly 
controlled.2, 3 This cysteinyl thiol provides the main ordnance through which glutathione-
based protective chemistry acts in guarding the cell against oxidative damage and 
conjugating metabolites for efflux.2, 3, 14 GSH is a common coenzyme and is also heavily 
involved in metabolic pathways such as glutathione peroxidases, reductases, and 
glutathione S-transferases.2, 6, 7, 15 
 GSH S-transferases catalyse the combination of GSH with xenobiotic compounds for 
metabolism and excretion using the highly nucleophilic cysteinyl thiolate (GS-).2 The 
predominance of GSH in the cell, coupled with its conjugation abilities, means that GSH 
is a major player in the destructive metabolism of therapeutic compounds, acting through 
conjugation as a means of drug resistance. 3, 9, 11 Metal-based therapeutic compounds that 
are vulnerable to thiol chemistry can be structurally altered, and even deactivated, 
following reaction with intracellular GSH.8, 16, 17 
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Figure 6-1 Structures described in Chapter 6 
Structures of (A) glutathione (GSH), (B) Rh2(OAc)4, (C) [Rh2(OAc)4(GS)], (D) 
methionine (Met), (E) [Rh2(OAc)4(GS)2], (F) Rh2(OAc)4(H2O), (G) Rh2(OAc)4(H2O)2, (H) 
[Rh2(OAc)5], (I) [Rh2(OAc)6], (J) Rh2(OAc)4(Met), (K) Rh2(OAc)4(Met)2, (L) 
[Rh2(OAc)4(GS)(Met)]. Colour coding: rhodium-turquoise, oxygen-red, sulfur-yellow, 
nitrogen-blue, carbon-grey, hydrogen-white. Calculations and image from A. Zhang in D. 
L. Wong et al., reproduced with permission from the Royal Society of Chemistry. 18 
Glutathione reacts with large, soft, metals such as the toxic metals Cd(II), Hg(II), Pb(II), 
and As(III).19-23 This tendency to bind soft metals also extends to the wide range of metals 
used in therapeutic complexes, for example, Ag(I), Bi(III), Pt(II) in cisplatin, and Au(I) in 
Auranofin.10, 12, 24-27 A marked increase in glutathione synthesis is often correlated with 
cisplatin resistance, such as the case in human ovarian cancers.10, 28, 29 This type of 
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protective chemistry is the basis for the co-administration of glutathione as a defence 
against renal toxicity in platinum-based chemotherapies.4, 14 There is evidence that the 
inhibition of glutathione synthesis reverses cisplatin resistance in some cancer types.30-32 
With an increase in the use of d-block metals as the key components of 
metallotherapeutic agents, it is critical to understand how this prominent defensive 
thiolate will interact with biologically-targeted metal complexes. Such interactions would 
likely reduce the efficacy of these metallodrugs. 
Dirhodium(II) carboxylates and their derivatives are an emerging class of anti-tumor 
compounds that are described as exhibiting greater potency than cisplatin in vitro,33-39 as 
described in Chapter 4 and 5. However, significantly, with respect to possible cellular 
chemistry, rhodium(II) carboxylates bind strongly to sulfur containing compounds.33, 34, 36, 
38, 40-42 Indeed, the propensity for these rhodium complexes to deplete intracellular thiols 
makes them especially useful as radiosensitizers 43, 44. Other classes of dirhodium 
carboxylates, such as the Rh2(O2CR)4 (R = Me, Et, Pr), display potent anti-tumor activity 
that stems from their ability to inhibit enzymes with sulfylhydryl groups in their active 
sites 34, 35, 45. Dirhodium(II) tetraacetate (tetrakis(μ-acetato)dirhodium(II), hereby referred 
to as Rh2(OAc)4, Figure 6-1B) is a bimetallic complex with four bridging acetate ligands 
bound in an octahedral geometry, with two empty axial sites usually coordinated by 
solvent molecules. This complex is capable of inhibiting DNA polymerase I and RNA 
polymerase, showing cytotoxic behaviour in vivo against L1210 tumors, Ehrlich ascites, 
and the sarcoma 180 and P388 tumor lines, as well as exhibiting DNA-binding in a 
manner similar to that of cisplatin 35, 36, 46, 47 and is a suitable model complex for these 
therapeutic dirhodium carboxylates. However, because of the strong affinity for thiolate 
binding to the dirhodium(II) carboxylates’ axial coordination sites, intracellular thiols like 
glutathione may prevent these rhodium-based therapeutics from reaching their intended 
target unchanged, especially with the Rh axial bioactive site remaining available. Axial 
coordination by the strongly binding thiolates will then block the intended activity. 
Spectroscopic studies of glutathione binding to dirhodium tetraacetate and related 
compounds have been reported previously by Jakimowicz et al.48 In the case of 
Jackimowicz et al., following the addition of molar equivalents of GSH to Rh2(OAc)4, the 
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authors surmised that the stoichiometric ratio, GSH:Rh2(OAc)4, for the final conjugate 
was 2:1. Unfortunately, optical spectra provide limited information, as the spectral data 
results from an averaged signal of all the chromophores present. The determination of the 
stoichiometric ratio as a function of GSH is of critical importance in the assessment of 
dirhodium complexes with therapeutic properties, because chemistry that involves 
coordination to both axial sites would effectively block the therapeutic drug. With the 
resolving power of electrospray ionization mass spectrometry (ESI-MS), one is able to 
accurately describe the products formed in reactions of Rh2(OAc)4 with thiolates and 
determine whether this potentially therapeutic agent would likely survive attack by 
biological thiols.  
This Chapter reports on the products formed following reaction of GSH with Rh2(OAc)4, 
as well as its competition with methionine-bound Rh2(OAc)4,to probe the fate of the 
rhodium complex after attack by the thiol and thioether groups, respectively. The 
reactions were studied in vitro using UV-visible and circular dichroism (CD) absorption 
spectroscopy, and electrospray-ionization mass spectrometry (ESI-MS). ESI-MS, which 
is now in this Thesis well established as an especially powerful as a technique for 
monitoring all possible intermediates formed in a reaction. Computational analysis by 
time-dependent density functional theory (TD-DFT) shows the extent of the overlap of 
both the linking acetates with the dirhodium d orbitals, and the major influence of the 
presence of water and thiolate axial ligands on all orbitals of the complex. The TD-DFT 
results explained the unexpected stoichiometric ratio of the glutathione products. These 
calculations show that the lowest energy absorption band blue-shifts with the addition of 
strong electron donors. The results described below show that GSH does attack the 
Rh2(OAc)4, but the stoichiometric ratio is 1:1 (Figure 6-1) unless there is large excess. If 
the drug complex was protected with the thioether of methionine (Figure 6-1D), the ESI-
mass spectra show that GSH would eventually displace that group. However, unlike 
previously reported reactions with the cysteine-rich, human protein, metallothionein,49 
GSH did not disassemble the complex, leaving it intact, but with one of its axial reaction 
sites blocked. These results give detailed guidance for predicting the pharmacokinetics of 
potential metallodrugs and provide a mechanism by which the strongly binding GSH may 
be inhibited. 
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6.2 Experimental Methods 
Solutions of 500 μM Rh2(OAc)4 (Sigma Aldrich) and 10 mM glutathione (Fluka) in 
deionized water were deoxygenated under vacuum and backfilled with argon gas. For the 
UV-visible (Varian Cary 50 UV-visible Spectrophotometer) and circular dichroism (CD) 
(Jasco 810 Spectropolarimeter (Jasco, New Jersey, USA)) spectroscopic measurements, 
aliquots of 0, 0.5, 1.0, 1.5, 2.0, and 2.5, mol. eq. (and additionally, 3.0, and 4.0 mol. eq. 
for the UV-visible absorption spectra) of GSH were added to an argon-backfilled quartz 
cuvette sealed with a septum cap containing the dirhodium solution, with the data 
recorded after each addition. For the first ESI-MS data collection (Figure 6-4), excess 
reduced glutathione was added to a 500 µM Rh2(OAc)4 solution in water at pH 3.0, and 
the mass spectral data were collected in positive ion mode; in the second series (Figure 
6-4), solutions with 500 μM Rh2(OAc)4 were titrated with 1.0, 1.5, and 2.5 mol. eq. 500 
μM GSH in 1 mM NH4OAc buffer at pH 7.4, recorded in both positive and negative ion 
mode. A Bruker Micro-TOF II instrument (Bruker Daltonics, Toronto, ON) operated in 
both positive and negative ion mode was used to collect the data. NaI was used as an 
external calibrant. The following settings were used: scan, m/z 50−3000; rolling average, 
2; nebulizer, 2 bar; dry gas, 80°C at a rate of 8.0 L/min; capillary, 4000 V; end plate 
offset, −500 V; capillary exit, 175 V; skimmer 1, 30.0 V; skimmer 2, 23.5 V; hexapole 
RF, 800 V.  
For the reactions with methionine followed by competition with GSH, solutions of 500 
μM Rh2(OAc)4, 10 mM DL-methionine (Sigma), and 10 mM glutathione in deionized 
water were deoxygenated under vacuum and backfilled with argon gas. The changes in 
the Rh2(OAc)4 solution were monitored following the addition of 2 mol. eq. of 
methionine using UV-visible absorption spectroscopy, followed by a subsequent addition 
of 2 mol. eq. of GSH. ESI-mass spectra were taken after each addition using the negative 
ion mode. The settings were similar to those described previously. 
Rh2(OAc)4, Rh2(OAc)4(H2O)2, [Rh2(OAc)4(GS)(H2O)]
-, and [Rh2(OAc)4(GS)2]
2-, models 
were drawn using the Scigress Modelling Software.50 GS represents the deprotonated 
glutathione moiety. Ground-state geometry optimization and TD-DFT calculations were 
performed using the Gaussian G09 program,51 using the CAM-B3LYP functional. The 6-
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31G(d,p) basis set was used for all atoms except for Rh, and the LANL2DZ basis set was 
used for Rh atoms. The TD-DFT calculations were carried out on the minimized 
geometry in single point mode, with 100 excited states calculated using the CAM-B3LYP 
functional, the 6-31G(d,p) basis set for all atoms except for Rh, and the LANL2DZ basis 
set for the Rh atoms. 
6.3 Results and Discussion 
6.3.1 UV-Visible and Circular Dichroism Spectroscopy Following 
the Colourful Reaction of Glutathione with Rh2(OAc)4 
The reaction of GSH with Rh2(OAc)4 was followed with UV-visible absorption 
spectroscopy (Figure 6-2) and CD spectroscopy (Figure 6-3). With the introduction of 
glutathione, a new absorption shoulder appears at approximately 353 nm (Figure 6-2) 
which has been assigned to a S(σ) →Rh(σ*) LMCT characteristic of sulfur coordination 
to dirhodium carboxylates.45, 48 A similar band has been previously reported for the 
spectrum of Rh2(OAc)4 coordinated to the cysteine-rich protein, metallothionein.
49 
discussed below, the assignment is better described as resulting from a mixture of 
molecular orbitals (MO) involving both the Rh-Rh MOs and the thiolate orbitals. The 
rapid change in spectral properties was observable with the naked eye, as the solution 
changed from sky blue to golden yellow as the titration progressed. This was expected as 
a result of the development of absorbance below 400 nm, which was much more intense 
than the weaker 589 nm absorption characteristic of the metal-metal-bond. The band at 
448 nm has been assigned to Rh2(π*) → Rh–O(σ*) transitions of the tetraacetate 
ligands,45, 48 which will be expanded on in the computational results below. The band at 
589 nm represents the Rh2(π*) → Rh2(σ*) transition of the metal-metal single bond, 
which persists throughout the addition of the GSH and, therefore, shows that the Rh-Rh 
single bond is still intact following thiolate coordination. Only water was used as the 
solvent for these spectroscopic studies as others, like acetonitrile, involve coordinating 
moieties that can drastically alter spectroscopic results.  
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Figure 6-2 UV-visible absorption spectra of 500 μM Rh2(OAc)4 with aliquots of reduced 
GSH added at pH 3.0 in deionized water. 
λA: S(σ) →Rh(σ*) LMCT at 353 nm. λB: Rh2(π*) → Rh–O(σ*) at 448 nm. λC: Rh2(π*) → 
Rh2(σ*) at 589 nm. The arrows show the direction of change in absorbance with an 
increasing amount of GSH present. Reproduced from D. L. Wong et al., reproduced with 
permission from the Royal Society of Chemistry. 18 
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Figure 6-3 CD spectral results of glutathione reacting with Rh2(OAc)4 
Circular dichroism spectra of 500 μM Rh2(OAc)4 following addition of 0, 0.5, 1.0, 1.5, 
2.0, and 2.5 mol. eq. aliquots of 10 mM reduced GSH added. The arrows show the 
direction of change in absorbance with increasing amount of GSH present. GSH does not 
absorb in the region shown. Reproduced from D. L. Wong et al., reproduced with 
permission from the Royal Society of Chemistry. 18. 
The CD spectra shows that Rh2(OAc)4 is achiral, as expected (black line, Figure 6-3). 
However, with the introduction of GSH, two new bands appear, a maximum at 298 nm 
(marked as λ1) and a minimum at 339 nm (marked as λ2), with a crossover point between 
325 and 330 nm. The development of the strong CD spectrum with the coordination of 
GSH indicates that a chiral structure is formed upon binding GSH to the dirhodium 
complex. The arrows show the change in chiral signal over the course of the titration. 
Similar CD spectral changes have been reported previously for reactions of GSH with 
Cu(I) and Cd(II).52 There was little to no CD intensity under the metal-metal-bond band 
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at 589 nm. This was not unexpected, as the transition dipoles obtained from the 
computational results below are located away from the chirality introduced by the GSH. 
6.3.2 Analysis by Electrospray Ionization Mass Spectrometry 
An inherent property of mass spectrometry is the creation of charged species for their 
detection. All the masses in the spectra correspond to the charged species. 
Spectra taken at pH 3.0 of Rh2(OAc)4 with excess reduced glutathione show the presence 
of mono- and di-glutathione adducts (Figure 6-4). The ESI-mass spectral data shows that 
the reaction creates a mixture of species: (i) glutathione polymers (at 615.1, 922.2 (A), 
and 1229.3 (C) m/z, Figure 6-4); and (ii) deprotonated glutathione coordination of the 
Rh2(OAc)4 forming [(GS)Rh2(OAc)4], [(GS)2Rh2(OAc)4], and [GS)3Rh2(OAc)4] at below 
1% relative intensity (at 749.9 (star, Figure 6-4), 1056.0 (star, Figure 6-4), and 1364.1 
m/z (D, Figure 6-4)). The two most prominent conjugates are those of a single 
deprotonated glutathione-bound complex, [GS-Rh2(OAc)4] (Figure 6-1C), and that of a 
double deprotonated di-glutathione-bound complex, [(GS)2-Rh2(OAc)4] (Figure 6-1E). 
With the accuracy of the ESI-MS experiment, it is observed that the masses of these two 
new complexes differ from the sum of the individual components by one and two protons, 
respectively, indicating that a proton is lost to form the binding moiety. Coupled with the 
optical spectroscopic data, we identify the cysteine sulfur as being the donor atom from 
the GSH that is involved. The GS- binds to the vacant axial position of Rh2(OAc)4 that is 
generally coordinated by solvent, as is confirmed by similar studies concerning dirhodium 
complexes.38, 40  
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Figure 6-4 Low pH reaction of Rh2(OAc)4 with GSH 
ESI – mass spectra of 500 μM. Rh2(OAc)4 with excess reduced glutathione added, at pH 
3.0 in deionized water. Taken in the positive ion mode. The circles identify GSH-related 
complexes, where A = (GSH)3 at 922.2 m/z , C = (GSH)4 at 1229.3 m/z and the stars 
indicate Rh2(OAc)4,-related complexes, where B = (GS)[Rh2(OAc)4]2 at 1191.8 m/z, D = 
(GS)3Rh2(OAc)4 at 1364.1 m/z and E = (GS)2-[Rh2(OAc)4]2 at 1498.9 m/z. (Note that in 
the positive ion mode the complexes will be oxidized in the ionization process so the 
masses correspond to the complexes with correct charges, but are observed as the 
monocation). Reproduced from D. L. Wong et al., reproduced with permission from the 
Royal Society of Chemistry. 18. 
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Figure 6-5 Reaction of Rh2(OAc)4 with GSH at physiological pH 
ESI-Mass spectra of 500 μM Rh2(OAc)4 with 2.5 mol. eq. 500 μM GSH added, in 1 mM 
NH4OAc buffer at pH 7.4, recorded in both positive (left) and negative (right) ion mode. 
The insets show detail of the mono-adduct glutathione-rhodium complex region at near 
750 m/z for both polarities. The individual peaks are assigned in the tables. (Note that in 
the positive ion mode the complexes will be oxidized in the ionisation process so the 
masses correspond to the complexes with correct charges, but are observed as the 
monocation.) Reproduced from D. L. Wong et al., reproduced with permission from the 
Royal Society of Chemistry. 18 
To test the possibility of conjugation under a more physiologically relevant environment, 
the reaction was carried out using 500 μM Rh2(OAc)4 with 2.5 mol. eq. GSH added in 1 
mM NH4OAc at pH 7.4, Figure 6-5. Under these conditions, glutathione remains largely 
unbound at 308.1 m/z in the positive ion mode (further denoted as “+ mode”), and 306.1 
m/z in the negative ion mode (further denoted as “- mode”). The main Rh2(OAc)4 species 
observed are the mono-aquated products (Figure 6-1F) at 459.8 m/z (+ mode), or 458.8 
m/z in the negative ion mode, where the bis-aquated (Figure 6-1G), mono-acetate (Figure 
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6-1H) and bis-acetate coordinated species (Figure 6-1I) are also observed at 476.8, 500.8, 
and 559.5 m/z. At a relative intensity of under 10%, the glutathione mono-adduct product 
is observable at 749.9 m/z (+ mode), and 747.9 m/z (- mode), corresponding to a complex 
involving a deprotonated glutathione and the Rh2(OAc)4. Very little di-glutathione adduct 
product was observed, at 1056.4 m/z (+ mode) and 1053.0 m/z (- mode), both at less than 
1% relative abundance, with virtually none of the possible tri-adduct detected. 
These quantitative results provide evidence for the exact products made in solution, and 
their relative abundancies viewed in both positive and negative ion mode. It is clear that 
the strong absorption band reported by Jakimowicz et al. should not be assigned to a 2:1 
GSH: Rh2(OAc)4 stoichiometry, rather the product formed in that study was likely 1:1. 
The computational results below provide an interpretation of the appearance of the strong 
absorption below 400 nm following coordination with thiolates. 
At this point, it has been established that GSH binds as a deprotonated peptide to the 
Rh2(OAc)4 axial positions, forming the mono-adduct at 749.9 m/z (+ mode). The 
combination of mass spectral data and the absorption and CD spectra suggest that the 
tetraacetate linkers are intact and that the Rh-Rh single bond persists. To address the 
structures of the proposed products, the structure of the singly-bound, and doubly-bound 
glutathione-Rh2(OAc)4 complexes were constructed in the Scigress Modelling Software 
and their geometries optimized prior to molecular orbital (MO) calculations using TD-
DFT methods, described below. 
6.3.3 Competition by Glutathione for the Axially-Coordinated 
Methionine in Rh2(OAc)4(Met) 
In Chapter 4 and 5, the studies with metallothionein suggested axial coordination of the 
dirhodium core by the cysteinyl thiolates was the initiating reaction prior to complex 
deconstruction, because the additional cysteines in the protein bound in the place of the 
O-donors of the tetraacetate ligands.49 As discussed above, cellular resistance can be 
associated with thiol coordination of the active sites of metallodrugs. Blocking these axial 
positions of the metallodrug with weak nucleophiles should introduce a defense against 
cellular resistance due to steric effects impeding the attack by strong nucleophiles. The 
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question arises how best to protect the complex against fast attack by such agents as 
metallothionein and GSH. The use of a weaker binding ligand, such as the thioether of 
methionine, may provide this protection. The reaction of methionine and related thioether 
complexes with Rh2(OAc)4 has been reported by Pneumatikakis et al. and others 
38, 42, 53. 
This Chapter explores the reaction when glutathione is added after methionine is bound to 
the Rh2(OAc)4. Scheme 6-1 summarizes the series of possible reactions that were used to 
investigate the potential protection offered by methionine (Met) against competition by 
GSH. First, when Met is added to the dirhodium complex. Using absorption spectra and 
ESI-mass spectral data, the products formed can be determined: either a single Met binds 
(Scheme 6-1, Equation 1, also Figure 6-1J) or two Met bind (Scheme 6-1, Equation 2a, 
also Figure 6-1K). Next, GSH is added, and again, Scheme 6-1 shows the possible 
outcomes: either displacement of one Met bound (Scheme 6-1, Equation 2b, also Figure 
6-1L), addition to the 2nd axial position (Scheme 6-1, Equation 3), or complete 
occupation of both axial positions (Scheme 6-1, Equation 4). The question then is, does 
Met offer any protection against axial ligation and therefore deactivation by strongly 
nucleophilic biological thiols, such as GSH and metallothionein, before the drug can 
reach its eventual target?  
 
Scheme 6-1 Reaction equations depicting possible outcomes of glutathione added to 
methionine-bound Rh2(OAc)4.  
The structures of each species described here in Scheme 6-1 Reaction equations depicting 
possible outcomes of glutathione added to methionine-bound Rh2(OAc)4.are shown in 
Figure 6-1. The reactions all depict axial ligation of the dirhodium core. The GSH 
coordinated cores will be monoanions or dianions in solution but following the 
ioniosation process the mass spectral data show only monocations and monoanions 
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representing the redox nature of the ionisation process. Reproduced from reference 18 
with permission from the Royal Society of Chemistry. 
 
Figure 6-6 UV-visible absorption spectral changes following the reaction of an aqueous 
solution of 500 μM Rh2(OAc)4 with 2 mol. eq. of methionine (Met) following 20 minutes 
of mixing. 2 mol. eq. of glutathione was then added and the spectrum monitored. 
The absorption spectra (left) can be separated into three sections: A) black line, the 
initial blue solution; B) with 2 mol. eq. Met followed for 20 minutes, red, green, and blue 
lines; the red and green lines are obscured by the 20 minute blue line as the reaction was 
fast. C) after addition of 2 mol. eq. GSH, followed for 180 min, cyan, pink, yellow, green, 
brown lines. ESI-mass spectra of the initial methionine bound solution (right, top) and 
following glutathione addition (right, bottom) were recorded at 20 minutes and 60 
minutes after mixing, respectively, in negative ion mode. Notable peaks: Met1(Rh2(OAc)4) 
589.9 m/z; (Met)2(Rh2(OAc)4 738.9 m/z (GS)(Rh2(OAc)4) 747.8 m/z; (GS)2(Rh2(OAc)4) 
1054.9 m/z. There was no evidence for (Met)(GSH)Rh2(OAc)4 in the expected region of 
890-895 m/z. Reproduced from D. L. Wong et al., reproduced with permission from the 
Royal Society of Chemistry. 18 
Figure 6-6 shows the absorption and ESI-mass spectra recorded for the reactions outlined 
in Scheme 6-1. The absorption spectrum follows the same trends as described above. The 
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starting spectrum of the Rh2(OAc)4 in Figure 6-4(A) is the same as in Figure 6-1. The 
addition of 2 mol. eq. of Met results in a slight, but distinct blue-shift in the wavelength 
maximum of the Rh2(π*) → Rh2(σ*) metal-metal bond band from 589 to 570 nm, 
indicating as before, that while Met has bound to the complex, the Rh-Rh bond is still 
intact. The most significant change is the intensification of the band at 350 nm associated 
with the thioether coordination 40 (Figure 6-6B). The reaction is fast and there is no 
change after 20 minutes following mixing (B). Now the Met coordination is challenged 
by addition of 2 mol. eq. of GSH, which results in a slow change in the optical spectrum, 
with a significant increase in absorbance in the 353 nm region representing the 
competition of glutathione for the axial position occupied by the methionine (Figure 
6-6C). There is a slight red shift in the 580 nm region that confirms the Rh-Rh bond is 
still present.  
Negative ion mode ESI-mass spectra are very important in providing identification of the 
species present at each step (Figure 6-6, inset, top). Following the addition of the Met, the 
solution measured in the absorption as “B”, is primarily (Met)1(Rh2(OAc)4) at 589.9 m/z 
as shown in Scheme 6-1, equation 1, with a very small fraction of (Met)2(Rh2(OAc)4 at 
738.9 m/z formed in equation 2a. Following GSH addition (lines “C” in the absorption 
spectra), the negative ion ESI-mass spectrum (Figure 6-6, inset, bottom) shows the 
presence of [(GS)1(Rh2(OAc)4)] at 747.8 m/z formed in Scheme 6-1, equation 2b, and 
also [(GS)2(Rh2(OAc)4)] at 1054.9 m/z formed in Scheme 6-1, equation 4. The reactions 
with GSH were slow, as indicated in the absorption spectra measured over 3 hours, and 
still possibly not at completion when the mass spectra were measured.  
These results conclude that indeed Met does offer some protection because the 
displacement reaction is slow, and the binding by the strongly nucleophilic GS- is 
impeded. However, from a pharmacokinetic point-of-view, the exact rates in vivo would 
need to be determined. 
153 
 
6.3.4 DFT Calculations Provide Insight into the Stability of the 
GSH Complexes 
An accurate X-ray structure of the Rh2(OAc)4(H2O)2 was reported by Cotton et al. in 
1971, showing specifically, for this paper, the location of the two water molecules on the 
z-axis defined by the Rh-Rh bond.54 The Rh-Rh bond length calculated here for 
Rh2(OAc)4(H2O)2 is 2.390 Å, which compares well with the reported value of 2.386 Å.
54 
For the results described above, we wanted to examine the electronic structure of the 
complex in solution and when axially coordinated by GSH. There were three specific 
question: (i) how extensive is the stabilizing role of the acetate linkers (ii) what is the 
extent of the disturbance to the Rh-Rh 4d-based MO structure of the core caused by 
coordination of the glutathione thiolate ligand, and (iii) can the dramatic colour change 
from blue to yellow immediately after addition of the thiolates be explained from the 
calculated absorption spectrum using time dependent-DFT (TD-DFT) methods? A charge 
of -1 and -2 was entered in the Gaussian input file for [Rh(OAc)4(GS)(H2O)]
- and 
[Rh(OAc)4(GS)2]
2-, respectively, because the GS thiolate brings in a negative charge 
when it coordinates to the neutral dirhodium core. 
i) The electronic structure of Rh2(OAc)4 and Rh2(OAc)4(H2O)2 to determine the 
effect of axial coordination by the water solvent 
Axial coordination of the Rh2 core has been the subject of much study
38, 40, 42, 44, 45, 48, 53, 55-
58 since the electronic structure for the metal-metal bonded species suggested a single 
bond, that would leave 5pz or the 4dz
2 as available, empty orbitals. The electronic 
structure leading to the Rh-Rh bond and its bond order, are reflected in the absorption 
spectrum. Polarized crystal spectra of Martin et al.59 (1979, revised slightly by Miskowski 
et al. in 1984)60 provided key information in the assignment; first of the lowest energy, 
visible region band to the π* to σ* transition, followed at higher energies to mixtures of 
Rh-based MOs to the σ* orbital and also ligand to Rh-Rh core transitions. A more recent 
report by Futera et al. in 2011,61 reported the electron occupancies based on DFT 
calculations. For completeness in our discussion of the GSH to the axial Rh(II) bond 
formation, we have included DFT results for the axial ligand-free core Figure 6-7, and the 
H2O ligated core in Figure 6-8.  
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Figure 6-7 MO energies and isoelectric density surfaces for the MOs that contribute to 
the visible-near UV absorption spectra for [Rh2(OAc)4], from DFT geometry optimization 
calculations.  
Yellow and red surfaces represent unoccupied MOs, blue and green surfaces represent 
occupied MOs. The Rh-Rh core MOs are identified where clear. The isoelectric surfaces 
are displayed in two orientations: (left) looking down the Rh-Rh bond so exposing the x/y 
plane and (right) looking down the x/y plane at the horizontally aligned Rh-Rh bond. 
Both orientations are easiest to see starting with the σ* orbital at the top of the stack of 
orbitals. An expanded version is available in Appendix D. Calculations and image from 
A. Zhang in D. L. Wong et al., reproduced with permission from the Royal Society of 
Chemistry. 18 
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Figure 6-7 shows the DFT results for the dirhodium core with just the acetate linkages. 
The MO order follows the expected sequence with the exception of the increased energy 
of the δ* MO (79). The gas phase calculation shows that δ* lies just above the π* MOs 
(77 and 78). We have labelled the well-known MOs with 4d origin (the occupied: σ (70), 
π (74, 75), δ (76), π* (77, 78), and δ* (79) and the lowest unoccupied MO, σ* (80)). The 
isoelectric surface images provide the spatial distribution of these orbitals, showing two 
orientations. On the left, the view is looking down the Rh-Rh bond, so this is the x/y 
direction. On the right, the viewing direction is perpendicular to the Rh-Rh bond, which is 
aligned horizontally to show the axial ligands and acetate linker MOs. Expanded views of 
all the MO surfaces are presented in Appendix D. 
In aqueous solution the axial positions are coordinated by water (as in the X-ray 
structures of Cotton et al. (1971)54) and this represents the species expected for optical 
and ESI-MS measurements. The MO energies and surfaces are shown in Figure 6-8. The 
coordination of the two water molecules increases the electron density of the two rhodium 
atoms, raising the energy of all the MOs in this region. Particularly, the σ MO (86) now 
lies above the δ (85) and π (83 & 84). In addition, the energy of the σ* MO (90) is raised 
roughly 1 eV with respect to that orbital without the ligands (Figure 6-7, MO 80). As seen 
below (Figure 6-12), the lowest energy absorption band is blue-shifted from the 800 nm 
of the anhydrous Rh2(OAc)4 to 600 nm for the dihydrate, because the π* to σ* energy gap 
increases. Except for the rise in σ (86), the ordering does not change, with the occupied δ 
(85) and δ* (89) being located above the respective π and π* MOs (83, 84, and 87, 88). 
The surfaces again provide interesting contrasts in the electron distribution for the linking 
acetates, the two waters, and the two Rh atoms. Symmetry rules mean that the water MOs 
are only involved in significant overlap with the z-axis σ and σ* MOs (86 & 90).  
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Figure 6-8 MO energies and isoelectric density surfaces for the MOs that contribute to 
the visible-near UV absorption spectra for [Rh2(OAc)4(H2O)2] from DFT geometry 
optimization calculations.  
Yellow and red surfaces represent unoccupied MOs, blue and green surfaces represent 
occupied MOs. The Rh-Rh core MOs are identified where clear. The isoelectric surfaces 
are displayed in two orientations: (left) looking down the Rh-Rh bond so exposing the x/y 
plane and (right) looking down the x/y plane at the horizontally aligned Rh-Rh bond. 
Both orientations are easiest to see starting with the σ* orbital at the top of the stack of 
orbitals. An expanded version is available in Appendix D. Calculations and image from 
A. Zhang in D. L. Wong et al., reproduced with permission from the Royal Society of 
Chemistry. 18 
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ii) The electronic structure when thiol is coordinated: [Rh2(OAc)4(GS)(H2O)]- 
and [Rh2(OAc)4(GS)2]2- 
The ESI-MS data in Figure 6-5 show the presence of both the mono- and di-GS2- 
complexes, although the di-GS2- product is in extremely low abundance. Figure 6-9 and 
Figure 6-10 show the interaction between the GS- MOs and the dirhodium MOs. Figure 
6-11 shows the expanded view of the σ*, σ, and π* MOs for [Rh2(OAc)4(GS)(H2O)]
- and 
[Rh2(OAc)4(GS)2]
2-. The MO structure for the mono-adduct (Figure 6-9) shows a 
significant rise in the energy of all the MOs compared to the bisaquated structure (Figure 
6-10). This is due to the increased density on the Rh atoms from the axial coordination of 
the thiolate ligand. This time, because of the lack of axial symmetry, the σ (164) and one 
of the π* (165) MOs rise in energy, now above the π* (163) and δ* (162). The surfaces 
show that the three residues of the tripeptide, GS-, interact strongly with many of the Rh-
Rh MOs, and not with the tetraacetate MOs. For example, of the highest lying occupied 
MOs, only π* (163), δ* (162), and δ (155) do not have significant contribution from the 
GS- MOs. MOs 159, 160, and 156 are located mainly on the GS-. The extensive overlap 
of the GS- density with the Rh-Rh core MOs (Figure 6-11) accounts for the retention of 
the GS- coordination of the Rh2(OAc)4 complex in the ESI-mass spectrometer under the 
dehydrating conditions of the MS vacuum (Figure 6-5). Figure 6-10 shows the results of 
the calculations for [Rh2(OAc)4(GS)2]
2-. The large donation of density from the two 
anionic glutathiones in [Rh2(OAc)4(GS)2]
2- raises the energy of the Rh-Rh σ MO (241) 
above π (240). With two GS- there is significant overlap of the MOs of the tripeptide with 
all the Rh-Rh core MOs (Figure 6-11), shuffling the energy stack considerably. MOs 242-
232 are located on the two GS- ligands. Despite searching down to MO 220, an MO with 
symmetry characteristics of the δ (like MO 155 in Figure 6-10) were not found. The 
surfaces provide much more detail concerning the overlap of electron density than text 
can do justice to, so we direct the reader to Appendix D. The H2O in 
[Rh2(OAc)4(GS)(H2O)]
- does not coordinate to the dirhodium, instead it hydrogen bonds 
to the acetate linkers, seen in Figure 6-9. 
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Figure 6-9 MO energies and isoelectric density surfaces for the MOs that contribute to 
the visible-near UV absorption spectra for [Rh2(OAc)4(GS)(H2O)]
- from DFT geometry 
optimization calculations. 
Yellow and red surfaces represent unoccupied MOs, blue and green surfaces represent 
occupied MOs. The Rh-Rh core MOs are identified where clear. The isoelectric surfaces 
are displayed in two orientations: (left) looking down the Rh-Rh bond so exposing the x/y 
plane and (right) looking down the x/y plane at the horizontally aligned Rh-Rh bond. 
Both orientations are easiest to see starting with the σ* orbital at the top of the stack of 
orbitals. An expanded version is available in Appendix D. Calculations and image from 
A. Zhang in D. L. Wong et al., reproduced with permission from the Royal Society of 
Chemistry. 18 
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Figure 6-10 MO energies and isoelectric density surfaces for the MOs that contribute to 
the visible-near UV absorption spectra for [Rh2(OAc)4(GS)2]
2- from DFT geometry 
optimization calculations. 
Yellow and red surfaces represent unoccupied MOs, blue and green surfaces represent 
occupied MOs. The Rh-Rh core MOs are identified where clear. The isoelectric surfaces 
are displayed in two orientations: (left) looking down the Rh-Rh bond so exposing the x/y 
plane and (right) looking down the x/y plane at the horizontally aligned Rh-Rh bond. 
Both orientations are easiest to see starting with the σ* orbital at the top of the stack of 
orbitals. An expanded version is available in Appendix D Calculations and image from A. 
Zhang in D. L. Wong et al., reproduced with permission from the Royal Society of 
Chemistry. 18 
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Figure 6-11 Electron density surface representation of the highest occupied and lowest 
unoccupied orbitals for [Rh2(OAc)4(GS)(H2O)]
- and [Rh2(OAc)4(GS)2]
2-.  
These surfaces show the extensive overlap of the axially coordinated GS- with the σ and π 
MOs of the Rh-Rh bond. An expanded version is available in Appendix D. Calculations 
and image from A. Zhang in D. L. Wong et al., reproduced with permission from the 
Royal Society of Chemistry. 18 
iii) Calculated absorption spectra for [Rh2(OAc)4], [Rh2(OAc)4(H2O)2], 
[Rh2(OAc)4(GS)(H2O)]- , and [Rh2(OAc)4(GS)2]2-  
Figure 6-12A shows the calculated absorption spectra, labelled with the Excited States 
(ES) that show significant oscillator strength (a list of the excited states are available in 
Appendix D). Figure 6-12B shows the molecular orbital contributions to each excited 
state for [Rh2(OAc)4(H2O)2], [Rh2(OAc)4(GS)(H2O)]
-. 
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Figure 6-12 Calculated absorption and orbital contributions to the excited states from 
TD-DFT calculations for Rh2(OAc)4 and the complex coordinated by water and GS
1- 
A) Calculated absorption spectra for [Rh2(OAc)4], [Rh2(OAc)4(H2O)2], 
[Rh2(OAc)4(H2O)(GS)]
-, and [Rh2(OAc)4(GS)2]
2-. The labels “ES1,” etc. identify the 
Excited States for which the oscillator strength for the transition from ES0 is greater than 
0.001. The excited states calculated from TD-DFT are tabulated in Appendix D. (B) 
Orbital participation in the excited states above 230nm with oscillator strengths >0.001 
for [Rh2(OAc)4(H2O)2] and [Rh2(OAc)4(H2O)(GS)]
-. The red arrow represents the 
transition with the highest contribution. The detailed contributions are shown in Table S1 
in Appendix D. The MOs of the Rh2 core are shown in the two boxes. Calculations and 
image from A. Zhang in D. L. Wong et al., reproduced with permission from the Royal 
Society of Chemistry. 18 
TD-DFT calculations were carried out for the four complexes described above, however, 
as the only two that are described in the experimental optical data for are the bisaquated 
and the mono-adducted GS-, only those results are described here. The full results for the 
calculations between 900 and 200 nm are shown in Appendix D, with the resulting 
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spectral data shown in Figure 6-12. The data in Figure 6-2 identify two visible region 
bands for the bisaquated complex, at 589 and 448 nm before intense absorbance below 
300 nm giving these solutions a sky blue colour. The calculations for the bisaquated 
predict bands at 549 and 537 nm, and 397 and 389 nm, with a much more energetic and 
intense band at 238 nm. The relative intensities and band energies are reproduced very 
closely by the calculations. The calculation for the bisaquated complex (Figure 6-8) 
shows that the visible region bands arise from pairs of transitions that add contributions 
from each of the Rh 4d orbital set. Symmetry labels are added to allow the mixing to be 
seen clearly. The δ*MO does not contribute significantly to any absorption. The predicted 
absorption is essentially purely the Rh core offset by the electron density from the two 
waters. 
6.3.5 Origins of the Electronic Absorption Spectrum  
[Rh2(OAc)4(H2O)2]  
The bisaquated dirhodium tetraacetate is a sky blue colour in solution with the lowest 
energy band at 589 nm, Figure 6-2. The TD-DFT results (Figure 6-12) assign this band to 
a mixture of transitions from the π* and σ (86, 87, & 88) to the σ* (90) and MO 91, but 
not from the δ* (89) because of application of selection rules. However, the major 
contribution to the oscillator strength is from π* (88) to σ* (90). The theoretical 
absorption spectrum (Figure 6-12A) shows the presence of three distinct absorption bands 
(labelled ES1/2, ES3/4, ES5) that arise from pairs of transitions involving all the 
dirhodium MOs as shown in Figure 6-12B. The predominant transition remain π* to σ* 
for the visible region bands. The lack of strong absorption between 500 and 300 nm 
accounts for the blue colour. The ES3/4 can be seen in the absorption spectrum at 448 nm 
(Figure 6-2). These four transitions all involve a significant contribution from the acetate-
Rh MOs. However, ES5 is strongly connected with a σ (86) to σ* (90) transition, which 
involves the two coordinated waters and not the acetates.  
[Rh2(OAc)4(GS-)(H2O)]-  
Addition of thiols results in a yellow colouration (Figure 6-2) arising from the increase in 
absorption at 353 nm. The calculated results for the mono-thiolate (Figure 6-12A and B) 
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show the presence of new transitions in the visible and near-UV regions. The calculations 
again place the lowest energy transition near 600 nm, as seen in the experimental 
spectrum, but now introduce a series of bands, mostly very weak, but with the most 
intense new band being at 326 nm (ES5). These bands result from charge transfer from 
GS--dominated MOs to the σ* (166) Rh2 core MO. By plotting the theoretical spectrum 
with realistic band widths, the origins of the shoulder in Figure 6-2 as the GSH is added 
are seen. The CD spectrum Figure 6-3, indicates the asymmetry introduced by the chiral 
GS- binding to the Rh2 core between 250 and 370 nm, a region associated in the 
calculations with bands at 321 and 326 nm. 
The theoretical electronic absorption spectrum of [Rh2(OAc)4(GS)2]2-  
The calculation for the di-GS- shows an increase in the charge-transfer transition below 
400 nm (Figure 6-12, ES3-8) and the blue-shift of the lowest energy transition near 530 
nm (ES1) is associated with stronger contributions from both coordinated glutathiones.  
Table 6-1 summarizes the computational results for the Rh-Rh bond length, the energies 
of the σ, σ*, and π* MOs for the four complexes. As more electron donating groups are 
added, these MOs increase in energy, and the Rh-Rh bond length increases. With the 
increase of electron density on the rhodium, the Rh-Rh single bond is weakened. In 
addition, the data show that as a result of the interaction between the axial ligands and the 
Rh-Rh MOs, the axial ligands become more involved in the structure of the complex. 
Table 6-1 Computational parameters derived from TD-DFT calculations. Calculations 
from A. Zhang in D. L. Wong et al., reproduced with permission from the Royal Society of 
Chemistry. 18 
Complex 
Rh-Rh bond 
length /Å 
E(σ) /eV E(σ*) /eV E(π*) /eV 
  Rh2(OAc)4 2.370 -10.104 -1.902 -8.126 
[Rh2(OAc)4(H2O)2] 2.390 -8.349 -0.291 -7.411 
[Rh2(OAc)4(GS)(H2O)]- 2.464 -4.006 2.013 -3.637 
[Rh2(OAc)4(GS)2]2- 2.471 -0.895 4.691 -1.447 
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6.4 Conclusions 
Glutathione is well known as a strongly coordinating thiol that exists in high cellular 
concentration. It is upregulated in homeostatic response to soft and potentially toxic 
metals. In the results described above, glutathione binds to Rh2(OAc)4, forming primarily 
the mono-adduct with retention of the single Rh-Rh bond. This means that glutathione 
binds axially and does not disrupt the intended, therapeutically-important, structure, but 
does block one of the axial sites. In the cellular milieu, this may mean that dirhodium 
carboxylates can survive and retain their anti-cancer activity. The computational results 
provide insight into the extensive overlap of the glutathione molecular orbitals with the 
Rh2(OAc)4 core orbitals, leading to interpretation of the strength of the glutathione 
cysteine thiolate-rhodium bond. The calculations also allow an understanding of the 
optical spectral properties, showing how the introduction of axial ligands introduce new, 
strong absorption in the 300-400 nm region, and blue-shifting the lowest energy band at 
500-600 nm. The presence of the axial ligand results in significant charge transfer in each 
of the optical transitions. The calculated MO energies for the four species studied show 
that the presence of the axial ligand is to destabilize all orbitals as a result of the 
introduction of electron density onto the rhodium core. Significantly, the relative energy 
of the Rh σ is raised with respect to δ and π. Despite the extensive overlap of the 
glutathione orbitals with the Rh MO, the acetate linker MOs remain largely unaffected, 
which accounts for the observation that the acetates are retained following axial 
coordination with GSH.  
The results from the previous Chapters show that the cysteine-rich metallothionein 
protein not only binds Rh2(OAc)4, but sequentially deconstructs the complex by replacing 
the four carboxylate ligands with the metallothionein cysteine thiolates.49 In this case, the 
Rh2(OAc)4 would be deactivated. Metallothionein has long been associated with a 
detoxification role, and this reaction with Rh2(OAc)4 is just one example of this property. 
However, glutathione is present in at least 100 times greater concentration in the 
cytoplasm than metallothionein. This suggests, based on the results presented here, that a 
major feature in the design for these therapeutic rhodium carboxylates should be the 
incorporation of weakly coordinated sulfur at the axial position of the dirhodium core. If 
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such groups were included in the overall design, the results presented above suggest that 
the complex could remain intact longer in the cell and be somewhat protected against 
rapid metabolic deconstruction.  
Metallodrugs offer a future of tunable therapeutic complexes that will be applicable to a 
large number of diseased states; well-known examples include Platinol (Pt), Ridaura 
(Au), and Trisenox (As).62 For the drug to be effective, the delivered form of the metal 
complex must be as designed. Pro-drugs are designed to change, following metabolism, 
into the active therapeutic agent, in which case the metabolic pathways must be well 
known. In other cases, it is assumed that the metallocomplex will be unchanged following 
passage into the cell. The plasma and cellular cytoplasm contain coordinating 
biomolecules that will bind tightly to these xenobiotic metals that form the therapeutic 
complex, changing the complex's properties. If this change significantly alters their 
therapeutic activity, then this drug has no value, and may result in higher toxicity. 
Understanding the potential coordination chemistry that can take place in either the 
plasma or the cytoplasm is important in the design and subsequent application of these 
drugs. The data confirm the view that the dirhodium(II) tetraacetate could easily be 
targeted by the intracellular thiols like glutathione, but could be protected by weak axial 
ligands commonly present in the cellular milieu, and still be able to bind to their intended 
biological targets. 
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Chapter 7 
7  Conclusions: Xenobiotic Metals in Therapeutic 
Agents as Models for Toxicity* 
As a result of the Internet and the technological age, decades worth of electronic metal 
waste have been produced at a rate higher than can be sustainably dealt with. From this 
waste, xenobiotic metals are being introduced into the ecosystem. Already, metallic 
particulates of Pt, Pd, Os, Rh, and Ir are evident in the environment from their use in 
catalytic converters in the automotive industry.1-4 With the new age of smart devices, a 
host of exotic xenobiotic consumer waste will become a global concern. 
Metallotherapeutics leverage the properties of xenobiotic metals in the treatment of 
cancers and tumors, and, in addition, anti-inflammatory, or anti-microbial agents in other 
medical treatments. However, metallotherapeutics directly expose humans to these 
xenobiotic metals, and this risk must be considered when determining the 
pharmacokinetics of these drugs. Often these treatments are intravenously administered, 
and this means that the metallo-drug will encounter a host of adduct-forming proteins in 
the blood plasma (e.g. albumin).  
With its 20 cysteine thiols, metallothionein (MT) is a small protein with a powerful Lewis 
basicity that makes it highly reactive towards metal ions. Additionally, isoforms with 
single amino acid mutations may assist in the binding of metals using modes other than 
homoleptic cysteine coordination. This type of flexible bonding could also be considered 
as an example of non-traditional binding when discussing the metallation of MTs.  
In the research described in this Thesis, I have postulated that these potentially toxic 
metal complexes could be intercepted by MT. Because of its flexible structure, it is well 
known that MT does not have specific, well-defined metal binding sites, unlike typical 
metalloproteins. Thus, MT is able to accommodate the specific coordination demands of 
many different metals, but the protein itself is not innocent in its coordination when these 
metals bind as complexes. This is because the thiolate ligands are such strong sigma 
donors, that they displace the original metal-bound ligands. In this way, one might say 
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that MT “digests” the complex. The experimental data reported in this Thesis provide a 
number of major novel findings. Clearly, the first is that metallocomplexes are not 
immune to coordination by this ubiquitous protein, and their bound form may be 
subsequently modified. Secondly, MT does not (as noted above) exert its coordination 
through the traditional binding site model of metalloproteins, rather the structures formed 
depend entirely on the conformation of the 20 cysteines and the incoming complex. 
Thirdly, the apoprotein is a folded structure that is highly fluxional and dependent on the 
surrounding solution environment. The flexibility of the backbone allows MT to 
effectively ensnare incoming metal complexes, encapsulating them within the protein 
core. 
7.1 Exotic Metals as Medicines 
This Thesis has introduced the reader to the double-edged sword that xenobiotic metals 
represent to humans. Some of this class of metals can be used therapeutically and, in that 
sense, they are beneficial. On the other hand, exposure from metal waste pollution is 
toxic, and, therefore, detrimental. However, if metallothionein becomes involved in the 
pharmacokinetic pathways of any of these routes of exposure, new metabolic pathways 
may result that may be more or less beneficial or detrimental. This mechanistic dilemma 
leaves many unanswered questions concerning the relative value of the beneficial use of 
xenobiotic metals in consumer goods, which must be reflected in the challenge of safe 
and sustainable heavy metal recovery. Before revisiting the conclusions drawn from the 
specific experiments reported in this Thesis, I will first introduce brief examples of d-
block metals currently in therapeutic and diagnostic use, to put into context the specific 
studies I have reported on cisplatin and dirhodium(II) tetraacetate. The examples of the 
exotic metals described below are: Technetium, Rhenium, Platinum, Ruthenium, 
Rhodium, and Gold. 
Technetium  
99mTc, with its emission of 140.5 keV γ-rays and biological half-life of 6 hours,5 makes 
this synthetic metal a versatile imaging agent.6 The groundbreaking research by Morelock 
and Tolman on utilizing MT as a radiolabel drug delivery mechanism showed that the 
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stable decay product, 99TcO3+ bound readily to MT. Significantly, coordination 
determined using extended X-ray absorption fine structure (EXAFS) showed the Tc was 
bound to both N/O ligand donors as well as the cysteine thiols.7 99mTc has been used to 
effectively image many organs, the first being the liver.8 These types of diagnostic agents 
used in medicine are likely encapsulated by MT for up take in all tissues.  
Rhenium 
With similar properties to 99Tc, 186Re and 188Re have also been utilized for the 
radiopharmaceutical imaging of cancerous liver tissue.9 
The binding reaction of Re to MT has been investigated by Palacios et al. in the form of 
[facRe(CO)3] and these Re moiety-containing complexes were observed to bind 
significantly slower compared to the analogous reaction with [facTc(CO)3].
10 The same 
study showed that of the four human isoforms of MT, the most Cu-philic, MT3, reacted 
most readily with the Re complex. This was likely due to the presence of a histidine 
residue in MT3, that is not present in the other isoforms. 
Platinum 
Platinum and its anti-cancerous effects introduced the world to metal based cancer 
therapeutics. Its original anticancer activity was discovered by Rosenberg et al.,11 and it is 
now a flourishing billion dollar industry with a variety of analogs of refined activity, 
examples are shown in Figure 7-1.12 Since its discovery and subsequent use, it has been 
found that many cancer types have developed resistance following prolonged treatment.13, 
14 A number of these platinum resistant cancer types display an increased expression in 
nuclear MT, correlated to platinum treatment.15-17 
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Figure 7-1 Cisplatin and its subsequently developed analogs. 
MT reacts readily with cisplatin,18-20 more so than its transplatin analog.21 With cisplatin, 
the ammine ligands are removed by the cysteine thiolates of MT,22 but transplatin retains 
its ammines.21 There are a variety of newly developed analogs of cisplatin designed to 
increase selectivity by adopting ligand structures that are more stable at biological levels. 
These are currently in use as effective treatments of a variety of cancer types.12 An 
example of a novel therapeutic, is platinum(II) 9-aminoacridine, a structure resistant to 
MT1a reactivity.23 The downside of these platinum based anti-cancer treatments are their 
side effects (nephrotoxicity, neurotoxicity, nausea) and their limited selectivity. As a 
175 
 
 
result, researchers are currently surveying non-platinum metal complexes for similar 
anticancer therapeutic activity. 
Ruthenium 
Ruthenium complexes are studied for their low toxicity and antimetastatic behavior, with 
many displaying strong anti-tumor activity. The most promising examples of these Ru 
complexes are shown in Figure 7-2. Imidazolium trans-
imidazoledimethylsulfoxidetetrachloro-ruthenate (NAMI-A) is a stable Ru(III) prodrug 
that is converted to its active Ru(II) state upon entering the reducing environment of the 
cancerous cell. Trans-tetrachlorobis(indazole)ruthenate(III) (KP1019) imparts its activity 
by binding with the iron transport protein transferrin,24 interfering with iron uptake of the 
nutritionally-starved cancer cells. RAPTA agents are Ru(II) arene piano stool compounds 
that carry a 1,3,5-triaza-7-phosphaadamantane (PTA) ligand. They are a family of potent 
cytotoxics that significantly reduce metastatic activity.25 The organometallic, arene 
structure proves to be a robust chemical architecture withstanding thiolate attack, and 
continues to show promise with Rh and Os analogs in selective anti-tumor activity.26 
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Figure 7-2 Structures of Ru(II) complexes NAMI-A (Left), KP1019 (Right), and 
RAPTA-C (bottom). 
Rhodium 
Rhodium was considered as an alternative to Ruthenium because it is more inert 
biologically. It is also promising as a radiosensitizer, for direct enzyme inhibition, and 
photodynamic therapy. Rh3+ complexes exhibit therapeutic effects by inhibiting beta 
amyloid aggregation, kinase inhibition, and DNA intercalation.27 
Dirhodium carboxylate anti-tumor activity has been known since the 1970’s,28-31 but due 
to the serious nephrotoxic side effects, they are not currently used. However, the 
construction of these bimetallics can be finely tuned with their ligand decoration, and 
these complexes has been the subject of much research.27, 32-40 
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Gold 
Au(I) salts have been used for decades to relieve the chronic side effects of rheumatoid 
arthritis, in a multi-action approach known as chrysotherapy.41 Chrysotherapeutic effects 
include anti-inflammatory and antimicrobial response, inhibition of T-cell proliferation 
and enzyme inhibition.42 The Au(I) complexes are known to interact with MTs, and are 
deactivated upon binding. This includes the well-known therapeutic agent, 
aurothiomalate.43 
Some Au(III) complexes show activity against cisplatin-resistant cells,44 demonstrating 
promising alternatives for non-platinum therapeutics. These include the tetrapyrrole 
Au(III) porphyrin,42 Au(III) corrole complexes,45 and multi-dentate N donor ligands,46 
and as such, these new structural designs are focused on improving their durability as 
cytotoxic agents.  
7.2 MT Metabolism of Metal-based Drugs 
After introducing examples of metal-based drugs above, and the known interactions of 
these metals with MT, I now return to the conclusions drawn from the experiments 
performed in this Thesis. 
Chapter 3: Human MT Metallation with Cisplatin 
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Figure 7-3 Graphical abstract for the breakdown of cisplatin by MT using ESI-MS. 
Reproduced from D. L. Wong and M. J. Stillman, with permission from the Royal Society 
of Chemistry. 22 
In vitro reactions involving cisplatin and transplatin binding to mammalian MTs were 
studied previously using HPLC and NMR spectroscopy. ESI-MS was used to provide 
quantitative detail of the effects of transmetallation of Zn-MT by Pt(II), but there were no 
details concerning the initial metal displacement reaction.21, 47 Chapter 3 describes the 
initial binding and dissection of cisplatin when bound to MT1A utilizing ESI-MS to 
quantify the mechanism for these primary ligand substitution reactions, Figure 7-3. 
Hagrman et al. showed that there were multiple phases to the cisplatin-MT reaction, but 
the first phase occurred far too rapidly to be observed using LC methods.48 With the high 
resolution and time resolving power of the ESI TOF MS, it was possible to measure the 
rates of the first 4 metallation reactions, k1-4, and to propose a detailed mechanism for the 
interaction between cisplatin and MT.22 
Chapters 4 and 5: Human MT Metallation with Dirhodium(II) Tetraacetate 
 
Figure 7-4 Graphical abstract depicting the encapsulation of a Rh-Rh core by the β-MT 
domain. 
Reproduced from D. L. Wong and M. J. Stillman, with permission from the Royal Society 
of Chemistry. 49 
The biological uptake of Rh and its related platinum group metals has gained interest with 
the reports of metal particles in soil and freshwater species near routes of heavy traffic.1, 
50-52 This increase in the presence of such biologically exotic metals has been linked to the 
advent of platinum-based catalytic converters in automobiles to reduce noxious 
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emissions. However, these metal-based catalysts are not completely stable; thermal 
decomposition and mechanical sintering results in these metal particulates being released 
into the environment.  
A way to study the possible physiological effects of toxic rhodium exposure from this 
pollution is to examine the use of rhodium-based platinum alternatives in chemotherapy. 
The work described in Chapter 4, and 5 proves that MT can play an active role in the 
metabolic destruction of dirhodium metallocomplexes; a result that had not been reported 
in the literature previously.49, 53 The sequestration of a dirhodium(II) tetraacetate by MT 
results in the removal of the acetate ligands, leaving the Rh-Rh core intact. Chapter 4 
described the reaction with the 9 cysteine, β-domain fragment, which easily 
accommodates one and only one Rh2 core. In Chapter 5, the reaction with the full, 20 
cysteine, two domain protein is more complex, with multiple metal binding 
conformations possible due to the elegant flexibility of MT. Rh uptake by MT is fixed at 
a Rhn:MT ratio, where n = multiples of 2. MT-to-MT metal-transfer equilibration would 
result in odd-numbered stoichiometries, which were not observed. The resulting 
encapsulated Rh-Rh core was visualized as being embedded in the MT structure using 
molecular dynamics. Rh2(OAc)4 is easily taken up by MT and the resulting product in 
vivo may exhibit nephrotoxic effects similar to Cd-MT54, 55 due to its comparable size. 
Chapter 6: Strength of the Cysteine Thiolate Metal Coordination- Studies with 
Glutathione 
 
Figure 7-5 Graphical abstract emphasizing the harmony of the methods used to explain 
the properties of the metal-thiolate bond. 
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Calculations and image from A. Zhang in Wong et al., reproduced with permission from 
the Royal Society of Chemistry. 56 
Reactions with glutathione provide a model system from which we can understand the 
reaction of the dirhodium complex with MT. Glutathione on its own does not dismantle 
the tetraacetate cage under our anaerobic conditions. However, the GSH clearly did bind 
to the dirhodium complex, based on the changes in the optical spectrum, and this 
prompted a computational investigation into the strength of the resulting metal-thiolate 
bond.  
Strong electron donation from the thiolates of the cysteines raises the energy of the Rh-Rh 
bond MO, weakening the Rh-Rh single bond. This was observed from the increase in the 
calculated bond lengths with the coordination of the glutathione. The effect of acetate 
replacement with multiple glutathione molecules would be of interest in order to 
understand the hyperchelative effect of MT, and the change in energy that results from 
the stepwise replacement of the acetate ligands. 
7.3 A New Biological Role for MT  
Active Disassembly and Binding Metals of Complexes 
In the work described in Chapters 3, 4, 5, and 6, I have introduced the dilemma of 
beneficial and detrimental pathways for which metallothionein may be implicated. In the 
six decades of research since its discovery, the reactions of metallothioneins with metal 
ions have been well documented and, in this Thesis, we have defined these as traditional 
reactions (for e.g. Zn(II) and Cd(II),57 see Scheller et al. for a comprehensive list).58 
However, in the context of these xenobiotic metals, I have described the metallation as 
non-traditional. Reactions of coordination complexes with MT are far more complicated. 
Metallothionein is a multidentate hyperchelator, which in its action, envelopes and 
systematically exchanges its ligands in an irreversible fashion, deconstructing the 
incoming metal complexes using its 20 electrophilic cysteine thiolates.  
Historically, MT was considered to bind Zn(II) and Cd(II) into well-defined clustered 
structures. The reactions reported at the time were analyzed based on the assumption that 
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metallation always involved complete cluster formation and metal saturation, even with 
mixed-metal products. However, Yang, Maret and Vallee, through the analysis of cellular 
content, identified and confirmed the in vivo presence of partially-metallated 
metallothionein (5 Zn(II) instead of 7) and postulated that there would be free thiols based 
on the assumption that incomplete clusters formed.59 With recent data, particularly with 
the advent of ESI-MS studies, including those shown in this Thesis, it is now clear that 
the partially-metallated metallothioneins may not require cluster formation, instead the 5 
Zn(II) referred to above have been shown to bind with terminal thiolates. We now 
understand the metallation mechanism and chelating behavior of MT and its isoforms 
better than before. This new recognition that partially metallated metallothioneins do not 
require cluster formation leads to the description of the non-traditional binding of 
xenobiotic metals that have been described here. 
As we approach the future with computers and electronics becoming deeply integrated 
into daily life, the possibility of chronic exposure to xenobiotic metal waste increases. 
The issue is that the combined controlled and uncontrolled (legal and illegal) extraction, 
purification, recycling and reclamation results in the incorporation of these metals into the 
food chain. At this point, the studies described in this Thesis suggests that non-traditional 
binding to metallothionein will occur. Metallothioneins in all Life will be required to 
adapt as a result. 
In cancer, the abhorrent growth and replication of diseased cells causes an overdrive in 
protein expression, of which cellular thiols like MT are heavily implicated. The studies 
described in this Thesis suggest that the exacerbation of this metal scavenging by the 
increased amount of cellular MT will greatly hinder the efficacy of metal-based 
anticancer drugs.  
We have now completed the description of the aggressive attack of therapeutic 
metallocomplexes by this cellular metal gatekeeper, metallothionein (MT). The 
metallation of de novo MT would be the first response in the inherent cellular defense 
against xenobiotic metals. Therefore, in closing, and as a final comment on the 
chemistries described in this Thesis, I conclude that the epic method by which MT 
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eviscerates metal complexes uniquely allows MT to adopt novel, and unprecedented 
structural properties to defend the cell against these intruding xenobiotic complexes. 
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Appendix A: Observed Rate Constants for Experiments 
Performed in Chapter 2 
 
Figure Constant Conditions Variable 
Conditions 
Kobs (10
6s-1) Standard 
Deviation 
pH Titration 4 M GdmCl 
2.5 eq. Cd (II) 
10 ˚C 
pH 5 215.48 3.127 (1.45%) 
pH 6 317.95 2.842 (0.89%) 
pH 7 422.40 5.084 (1.20%) 
pH 7.5 918.93 8.412 (0.92%) 
pH 8 2150.00 41.75 (1.94%) 
 
Cd Titration pH 5 
0 M GdmCl 
10 ˚C 
1 eq 830.89 21.57 (2.60%) 
2.5 eq 353.97 3.797 (1.07%) 
5 eq 182.60 1.252 (0.69%) 
 
pH 5 
4 M GdmCl 
10 ˚C 
1 eq 404.28 7.262 (1.80%) 
2.5 eq 215.48 3.127 (1.45%) 
5 eq 147.17 1.313 (0.89%) 
 
pH 8 
0 M GdmCl 
10 ˚C 
1 eq 7198.20 265.4 (3.69%) 
2 eq 4690.10 72.29 (1.54%) 
2.5 eq 3633.30 78.59 (2.16%) 
3 eq 1953.90 19.02 (0.97%) 
4 eq 1459.70 10.27 (0.70%) 
5 eq 2318.80 11.29 (0.49%) 
 
pH 8 
4 M GdmCl 
1 eq 1238.10 9.705 (0.78%) 
2.5 eq 2150.00 41.75 (1.94%) 
189 
 
 
10 ˚C 5 eq 878.86 14.15 (1.61%) 
 
GdmCl Titration pH 5 
2.5 eq. Cd (II) 
10 ˚C 
0 M 353.97 3.797 (1.07%) 
1 M 265.67 1.827 (0.69%) 
2 M 252.91 1.58 (0.62%) 
4 M 215.48 3.127 (1.45%) 
 
Temperature 
Dependence  
pH 5 
0 M GdmCl 
2.5 eq. Cd (II) 
10.1 ˚C 353.97 3.797 (1.07%) 
15.3 ˚C 407.14 4.142 (1.02%) 
18.1 ˚C 468.10 7.597 (1.62%) 
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Appendix B: Known Kinetic and Equilibrium Binding 
Constants for MTs 
Table 2. Reports of kinetic data for the metallation of individual metallothioneins 
Metal Organism
** 
Isoform Fragment/
Protein 
Stoichiometry Technique Rate constants  
k [M-1 s-1] 
Reference 
As human20 MT1a α As3MT ESI-MS k1 5.5 
k2 6.3 
k3 3.9 
1 
human20 MT1a β As3MT ESI-MS k1 3.6 
k2 2.0 
k3 0.6 
1 
human20 MT1a βα As6MT ESI-MS k1 25 
k2 24 
k3 19 
k4 14 
k5 8.7 
k6 3.7  
2 
Bi rabbit MT2 βα Bi7MT UV-visible 
absorption, 1H 
NMR 
k1 5.8 × 10-3 
(Cd 
displacement) 
k2 1.0 × 10−4 
(Cd 
displacement) 
k1 7.2 × 10−3 
(Zn 
displacement) 
k2 5.9 × 10−5 
(Zn 
displacement) 
3 
Cd human20 MT1a α Cd4MT Stopped flow 
spectrophotometry 
k1-4 60.4 
(native) 
k1-4 3.32 
(denatured) 
4 
horse 
kidney20 
MT βα Cd7MT Absorption 
spectroscopy 
2.7 x 10-6  
(Demetallatio
n by EDTA) 
5 
rabbit20  MT2 βα Cd7MT Stopped flow 
spectrophotometry 
pH 4.1     
60±10 
pH 4.6     
140±30 
pH 5.1     
280±50 
pH 5.4     
350±100 
6 
rabbit20  MT2 α Cd4MT Stopped flow 
spectrophotometry 
pH 4.6     
170±60 
pH 5.1     
350±100 
pH 5.4     
460±200 
6 
Zn rabbit20 MT2 βα Zn7MT Stopped flow 
spectrophotometry 
pH 4.6     
10±1  
pH 5.2     
15±1 
6 
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pH 5.8     
28±2 
pH 6.3     
43±7 
pH 6.6     
100±15 
pH 7.2     
300±100  
rabbit20  MT2 α Zn4MT Stopped flow 
spectrophotometry 
pH 6.6     
90±10  
pH 7.2     
230±100 
pH 7.5     
690±300 
6 
Pt rabbit20 MT βα Pt7MT Atomic absorption 
spectroscopy, UV 
absorption, HPLC  
0.14 (to apo-
MT) 
0.75 to 
Cd/Zn-MT 
0.53 to 
Cd7MT 
0.65 to 
Zn7MT 
7 
Zn horse 
kidney20 
MT βα Zn7MT Absorption Demetallation 
by EDTA 
k1 fast 
k2 14.2x10-4 
k3 2.0x10-4 
5 
** superscript shows the number of cysteines in the peptide  
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Table 3. Reports of binding constant data for the metallation of individual human metallothioneins 
Metal Isoform Fragment/P
rotein 
Stoichiometry Technique*** Binding constant 
value (logK) 
Reference 
Cu MT2 βα Cu10MT ESI-MS, pH 7.5 K       14.6 8 
MT1a βα Cu20MT ESI-MS1 
pH 7.4 
K1      15.5 
K2      15.0 
K3      14.6 
K4      19.3 
K5      14.6 
K6      18.9 
K7      12.9 
K8      13.1 
K9      13.7 
K10     15.5 
K11     10.7 
K12     11.2 
K13     12.9 
K14     9.5 
K15     9.5 
K16     8.6 
K17     8.1 
K18     7.0 
K19     6.1 
K20     5.0 
9 
Pb MT3 βα Pb7MT ITC, pH 6.0 K1-2   11.7 
K3-4   10.2 
K4-7     8.7 
10 
Zn MT2 βα Zn7MT Fluoresence 
spectroscopy2 
pH 7.4 
K1-4    11.8  
K5      10.45  
K6      9.95 
K7      7.7 
11 
 
MT3 βα Zn7MT ITC, pH 6.0 K1-4    10.8 
K5     10.5 
K6      9.9 
K7      7.7 
10 
MT1a βα Zn7MT ESI-MS3 K1      12.35 
K2      12.47 
K3      12.52 
K4      12.37 
K5      12.21 
K6      12.05 
K7      11.80 
12 
**superscript shows the number of cysteines in the peptide 
 
***Explanations: 
1 determined by analysis of the pH dependent titration data 
2 binding strength was determined using competitors and fluorogenic dye 
3 binding constant values were determined through competition of zinc binding to carbonic anhydrase 
 
1. T. T. Ngu and M. J. Stillman, Arsenic binding to human metallothionein, J. Am. 
Chem. Soc., 2006, 128, 12473-12483. 
2. T. T. Ngu, A. Easton and M. J. Stillman, Kinetic analysis of arsenic− metalation 
of human metallothionein: significance of the two-domain structure, J. Am. Chem. 
Soc., 2008, 130, 17016-17028. 
193 
 
 
3. H. Sun, H. Li, I. Harvey and P. J. Sadler, Interactions of bismuth complexes with 
metallothionein (II), J. Biol. Chem., 1999, 274, 29094-29101. 
4. G. W. Irvine, K. E. Duncan, M. Gullons and M. J. Stillman, Metalation kinetics of 
the human α‐metallothionein 1a fragment is dependent on the fluxional structure 
of the apo‐protein, Chem. Eur. J., 2015, 21, 1269-1279. 
5. T.-Y. Li, A. J. Kraker, C. F. Shaw and D. H. Petering, Ligand substitution 
reactions of metallothioneins with EDTA and apo-carbonic anhydrase, Proc. Natl. 
Acad. Sci. U.S.A., 1980, 77, 6334-6338. 
6. J. Ejnik, J. Robinson, J. Zhu, H. Försterling, C. F. Shaw III and D. H. Petering, 
Folding pathway of apo-metallothionein induced by Zn2+, Cd2+ and Co2+, J. Inorg. 
Biochem., 2002, 88, 144-152. 
7. D. Hagrman, J. Goodisman, J. C. Dabrowiak and A.-K. Souid, Kinetic study on 
the reaction of cisplatin with metallothionein, Drug Metab. Dispos., 2003, 31, 
916-923. 
8. L. Banci, I. Bertini, S. Ciofi-Baffoni, T. Kozyreva, K. Zovo and P. Palumaa, 
Affinity gradients drive copper to cellular destinations, Nature, 2010, 465, 645. 
9. J. S. Scheller, G. W. Irvine, D. L. Wong, A. Hartwig and M. J. Stillman, Stepwise 
copper (I) binding to metallothionein: a mixed cooperative and non-cooperative 
mechanism for all 20 copper ions, Metallomics, 2017, 9, 447-462. 
10. M. Carpenter, A. S. Shah, S. DeSilva, A. Gleaton, A. Su, B. Goundie, M. Croteau, 
M. Stevenson, D. Wilcox and R. Austin, Thermodynamics of Pb (II) and Zn (II) 
binding to MT-3, a neurologically important metallothionein, Metallomics, 2016, 
8, 605-617. 
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Appendix C: Supplementary Structures and Energies for Rh2 
bound MT 
 
Fig S. 4. Top: Apo-MT MD result. Cysteine S shown in yellow. Bottom: Potential Energy 
trajectory over time. Reproduced from reference.1 Copyright 2018 American Chemical 
Society. 
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Fig S. 5. Apo-MT MD result. Cysteine S shown in yellow. H bond interactions are 
indicated in blue. Reproduced from reference.1 Copyright 2018 American Chemical 
Society. 
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Fig S. 6. Top: Rh2MT MD result. Cysteine S shown in yellow. Rh shown in teal. Bottom: 
Potential Energy trajectory over time Reproduced from reference.1 Copyright 2018 
American Chemical Society. 
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Fig S. 7. Rh2MT MD result with Rh2 in the β-domain. Cysteine S shown in yellow. Rh 
shown in teal. H bond interactions are indicated in blue. Reproduced from reference.1 
Copyright 2018 American Chemical Society. 
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Fig S. 8. Top: Rh2MT MD result with Rh2 in a conformation in the α-domain. Cysteine S 
shown in yellow. Rh shown in teal. Reproduced from reference.1 Copyright 2018 
American Chemical Society. 
199 
 
 
 
 
Fig S. 9. Rh2MT MD result with Rh2 in a conformation in the α-domain Cysteine S 
shown in yellow. Rh shown in teal. H bond interactions are indicated in blue. Reproduced 
from reference.1 Copyright 2018 American Chemical Society. 
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Fig S. 10. Top: Rh2MT MD result with Rh2 in an alternate conformation in the α-domain. 
Cysteine S shown in yellow. Rh shown in teal. Bottom: Potential Energy trajectory over 
time. Reproduced from reference.1 Copyright 2018 American Chemical Society. 
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Fig S. 11. Rh2MT MD result with Rh2 in an alternate conformation in the α-domain. 
Cysteine S shown in yellow. Rh shown in teal. H bond interactions are indicated in blue. 
Reproduced from reference.1 Copyright 2018 American Chemical Society. 
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Fig S. 12. Top: Rh4MT MD result with Rh2 in the β-domain and Rh2 in a conformation in 
the α-domain. Cysteine S shown in yellow. Rh shown in teal. Bottom: Potential Energy 
trajectory over time. Reproduced from reference.1 Copyright 2018 American Chemical 
Society. 
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Fig S. 13. Rh4MT MD result with Rh2 in the β-domain and Rh2 in a conformation in the 
α-domain. Cysteine S shown in yellow. Rh shown in teal. H bond interactions are 
indicated in blue. Reproduced from reference.1 Copyright 2018 American Chemical 
Society. 
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Fig S. 14. Top: Rh4MT MD result with Rh2 in the β-domain and Rh2 in an alternate 
conformation in the α-domain. Cysteine S shown in yellow. Rh shown in teal. Bottom: 
Potential Energy trajectory over time. Reproduced from reference.1 Copyright 2018 
American Chemical Society. 
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Fig S. 15. Rh4MT MD result with Rh2 in the β-domain and Rh2 in an alternate 
conformation in the α-domain. Cysteine S shown in yellow. Rh shown in teal. H bond 
interactions are indicated in blue. Reproduced from reference.1 Copyright 2018 American 
Chemical Society. 
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Fig S. 16. Top: Rh4MT MD result with Rh4 in the α-domain. Cysteine S shown in yellow. 
Rh shown in teal. Bottom: Potential Energy trajectory over time. Reproduced from 
reference.1 Copyright 2018 American Chemical Society. 
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Fig S. 17. Rh4MT MD result with Rh4 in the α-domain. Cysteine S shown in yellow. Rh 
shown in teal. H bond interactions are indicated in blue. Reproduced from reference.1 
Copyright 2018 American Chemical Society. 
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Fig S. 18. Top: Rh6MT MD result with Rh2 in the β-domain and Rh4 in the α-domain. 
Cysteine S shown in yellow. Rh shown in teal. Bottom: Potential Energy trajectory over 
time. Reproduced from reference.1 Copyright 2018 American Chemical Society. 
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Fig S. 19. Rh6MT MD result with Rh2 in the β-domain and Rh4 in the α-domain. Cysteine 
S shown in yellow. Rh shown in teal. H bond interactions are indicated in blue. 
Reproduced from reference.1 Copyright 2018 American Chemical Society. 
1. D. L. Wong and M. J. Stillman, Metallothionein: An Aggressive Scavenger—The 
Metabolism of Rhodium (II) Tetraacetate (Rh2 (CH3CO2) 4), ACS Omega, 2018, 3, 
16314-16327. 
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Appendix D: Surfaces and Orbital Energies for GSH bound 
to Rh2(OAc)4 
  
Fig S1. Expanded views of Rh2(OAc)4 molecular orbital surfaces, part 1/2. Calculations 
and image from A. Zhang in reference, 1 reproduced with permission from the Royal 
Society of Chemistry. 
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Fig S2. Expanded views of Rh2(OAc)4 molecular orbital surfaces, part 2/2. Calculations 
and image from A. Zhang in reference, 1 reproduced with permission from the Royal 
Society of Chemistry. 
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Fig S3. Expanded views of Rh2(OAc)4(H2O)2 molecular orbital surfaces, part 1/2. 
Calculations and image from A. Zhang in reference, 1 reproduced with permission from 
the Royal Society of Chemistry. 
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Fig S4. Expanded views of Rh2(OAc)4(H2O)2 molecular orbital surfaces, part 2/2. 
Calculations and image from A. Zhang in reference, 1 reproduced with permission from 
the Royal Society of Chemistry. 
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Fig S5. Expanded views of [Rh2(OAc)4(GS)(H2O)]
- molecular orbital surfaces, part 1/2. 
Calculations and image from A. Zhang in reference, 1 reproduced with permission from 
the Royal Society of Chemistry. 
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Fig S6. Expanded views of [Rh2(OAc)4(GS)(H2O)]
- molecular orbital surfaces, part 2/2. 
Calculations and image from A. Zhang in reference, 1 reproduced with permission from 
the Royal Society of Chemistry. 
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Fig S7. Expanded views of [Rh2(OAc)4(GS)2]
2- molecular orbital surfaces, part 1/2. 
Calculations and image from A. Zhang in reference, 1 reproduced with permission from 
the Royal Society of Chemistry. 
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Fig S8. Expanded views of [Rh2(OAc)4(GS)2]
2- molecular orbital surfaces, part 2/2. 
Calculations and image from A. Zhang in reference, 1 reproduced with permission from 
the Royal Society of Chemistry. 
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Table S1. Transition contributions for excited states (ES) with oscillator strength (f) 
greater than 0.001. Calculations from A. Zhang in reference, 1 reproduced with 
permission from the Royal Society of Chemistry 
Rh2(OAc)4 
ES Transition Contribution Energy [eV 
(nm)] 
f 
1 72 → 80 
78 → 80 
0.12995 
0.67953 
1.5418 (804.16) 0.0037 
2 71 → 80 
77 → 80 
0.13086 
0.67956 
1.5426 (803.75) 
 
0.0037 
14 72 → 80 
78 → 80 
0.68665 
-0.12489 
4.7555 (260.72) 
 
0.0229 
15 71 → 80 
77 → 80 
0.68635 
-0.12557 
4.7676 (260.06) 0.232 
16 69 → 80 0.69654 5.1009 (243.06) 0.0140 
17 68 → 80 0.69633 5.1094 (242.66) 0.0142 
20 62 → 81 
63 → 80 
66 → 82 
70 → 80 
79 → 87 
79 → 88 
0.14182 
-0.14773 
-0.12428 
0.61243 
-0.11805 
0.14491 
5.3426 (232.07) 0.0643 
Rh2(OAc)42H2O 
ES Transition Contribution Energy [eV 
(nm)] 
f 
1 86 → 90 
87 → 91 
88 → 90 
0.10876 
0.17148 
0.65326 
2.2561 (549.55) 0.0034 
2 80 → 90 
87 → 90 
0.10439 
0.65256 
2.3078 (537.23) 0.0027 
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88 → 91 0.19584 
6 76 → 92 
84 → 92 
87 → 90 
88 → 91 
-0.11427 
-0.20679 
-0.22219 
0.61712 
3.1246 (396.80) 0.0018 
7 74 → 92 
83 → 92 
87 → 91 
88 → 90 
-0.12927 
0.20788 
0.62609 
-0.19353 
3.1860 (389.15) 0.0019 
15 72 → 91 
75 → 92 
86 → 90 
88 → 90 
89 → 99 
0.13910 
-0.11732 
0.61760 
-0.10257 
0.20974 
5.2099 (237.98) 0.1489 
[Rh2(OAc)41GS]- 
ES Transition Contribution Energy [eV 
(nm)] 
f 
1 153 →166 
161 →166 
165 →166 
165 →167 
-0.12239 
-0.30150 
0.57168 
-0.11791 
2.0002 (619.85) 0.0013 
2 153 →167 
161 →167 
161 →169 
163 →166 
163 →167 
165 →167 
-0.12419 
-0.20202 
0.10319 
0.44851 
0.12743 
0.35148 
2.3540 (526.69) 0.0029 
4 153 →167 
161 →167             
162 →169 
-0.13409 
-0.15160 
0.14879 
2.5712 (482.20) 0.0013 
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163 →166 
163 →167 
163 →169 
165 →166 
165 →167 
-0.37276 
-0.12279 
0.14540 
0.13916 
0.43725 
6 161 →166 
161 →169 
162 →169 
163 →166 
163 →167 
163 →169 
165 →166 
165 →169 
0.23994 
0.32872 
-0.10429 
0.10738 
-0.24660 
0.34638 
0.20374 
-0.13194 
2.7976 (443.18) 0.0016 
13 153 →167 
154 →166 
156 →166 
161 →167 
163 →166 
164 →166 
165 →167 
0.19539 
-0.10185 
-0.16372 
0.42275 
0.12060 
0.26718 
0.31264 
3.8002 (326.26) 0.0704 
14 153 →167 
161 →167 
164 →166 
165 →167 
-0.10584 
-0.24010 
0.58547 
-0.15724 
3.8639 (320.88) 0.3938 
15 138 →166 
152 →166 
154 →166 
156 →166 
157 →166 
160 →166 
161 →167 
0.13137        
0.22820 
0.23745 
0.46218 
0.12203 
-0.10821 
0.15066 
4.0651 (305.00) 0.0569 
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163 →166 
164 →166 
-0.10670 
0.19565 
[Rh2(OAc)42GS]2- 
ES Transition Contribution Energy [eV 
(nm)] 
f 
1 232 → 245 
235 → 242 
235 → 244 
236 → 242 
236 → 244 
239 → 242 
239 → 244 
240 → 242 
240 → 244 
-0.12926 
0.13289 
-0.14224 
0.42475 
-0.21641 
-0.21184 
0.15268 
0.29186 
-0.11257 
2.3396 (529.93) 0.0029 
2 234 → 245 
235 → 242 
235 → 244 
236 → 244 
238 → 242 
238 → 244 
239 → 242 
240 → 242 
240 → 244 
-0.12280 
0.31121 
0.16534 
-0.17550 
0.28945 
0.22085 
-0.23043 
-0.19450 
-0.20986 
2.3866 (519.50) 0.0021 
9 232 → 245 
233 → 244 
234 → 244 
235 → 244 
235 → 245 
236 → 242 
236 → 244 
0.12454 
0.14644 
-0.14958 
0.17043 
0.22699 
0.15648 
0.33913 
2.9522 (419.98) 0.0035 
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1. D. L. Wong, A. Zhang, A. S. Faponle, S. P. de Visser and M. J. Stillman, 
Glutathione binding to dirhodium tetraacetate: a spectroscopic, mass spectral and 
computational study of an anti-tumour compound, Metallomics, 2017, 9, 501-516. 
 
236 → 245 
238 → 245 
239 → 242 
239 → 244 
240 → 245 
241 → 244 
-0.15082 
0.25701 
-0.11774 
-0.13665 
-0.10547 
-0.11128 
12 241 → 242 0.67072 3.4198 (362.55) 0.7178 
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Appendix E: Copyright Permissions 
In Chapter 1 and 7, all figures were made by Ms. Daisy Wong and are unpublished 
elsewhere, except for Figure 1-10 which was used with permission from the American 
Chemical Society from the article “Kinetic Analysis of Arsenic-Metalation of Human 
Metallothionein: Significance of the Two-Domain Structure” by Ngu et al. and their 
permission requirements have been followed as described below. 
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The figures used in Chapters 2, 3, 4, and 6 were created by Ms. Daisy Wong and 
published in Royal Society Journals, and their permission requirements have been 
followed as described below. 
 
The images used in Chapter 6 are open for public use under the American Chemical 
Society AuthorChoice License: 
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